Myristoyl CoA:Protein N-Myristoyl Transferase: A Target for a Novel Antimalarial Drug by Meier, Franziska & Meier, Franziska
1 | P a g e  
 
 
 
 
 
 
 
 
Myristoyl CoA:Protein N-Myristoyl Transferase:  
A Target for a Novel Antimalarial Drug 
 
 
Franziska Meier 
 
 
 
 
 
 
 
A thesis submitted in fulfilment of the requirements for  
the degree of Doctor of Philosophy and  
the Diploma of Imperial College London 
 
 
Department of Chemistry, Imperial College London, South Kensington Campus, SW7 2AZ 
June 2009  
2 | P a g e  
 
 
 3 | P a g e  
 
Abstract 
Malaria, an illness caused by protozoan parasites of the genus Plasmodium, 
continues to be a key global health issue; around 40% of the world’s population are 
at risk and more than one million people are killed each year according to the World 
Health Organisation (WHO). It is transmitted via bites of infected female mosquitoes 
(Anopheles) and its severest form, falciparum malaria, can lead to death if left 
untreated. Effective malarial treatment is complex due to drug resistance and 
socioeconomic issues in many of the most affected areas. 
An enzyme from the parasite, myristoyl CoA:protein N-myristoyl transferase 
(NMT), has been identified as a potential target for antimalarial drugs. N-Myristoyl 
transferase, which catalyses the co-translational transfer of myristic acid to an 
N-terminal glycine of certain substrate proteins, has been shown to be essential for 
various pathogens. This thesis demonstrates the design, synthesis and analysis of 
potential inhibitors of Plasmodium falciparum NMT. 
Approximately 50 inhibitors with systematic variations based on a benzothiazole 
scaffold have been synthesised. It is known that these benzothiazoles compete with 
binding of peptide substrate within the NMT enzyme binding cleft. Differences 
between the peptide binding pockets of P. falciparum and human NMTs were 
exploited to design effective and selective new antimalarial treatments. The level of 
inhibition was measured using SPA that monitors the transfer of 3H-labelled 
myristoyl CoA to the N-terminus of a polypeptide substrate. A plot of enzyme 
activity as a function of inhibitor concentration gave inhibition curves from which 
IC50-values were derived. 
In vitro tests resulted in four hits with improved activity in the low micromolar 
region against P. falciparum NMT compared to the lead compound. Nevertheless, 
the inhibitors were not exceptionally selective over Homo sapiens NMT with an IC50 
in the low micromolar region also. Selections of the most promising inhibitors have 
been tested in vivo and considerable reductions in parasitemia were noted. 
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Nomenclature and symbolism for amino acids and peptides were adopted from the 
recommendations of the IUPAC-IUB Joint Commission on Biochemical 
Nomenclature (IUPAC-IUB Commission on Biochemical Nomenclature 1972). The 
systematic nomenclature of benzothiazole derivatives starts counting on the N-atom 
and continues in clockwise direction (Figure I-1). The absolute and relative 
stereochemistry was defined as follows. Block-shaped bonds were used for 
racemates and wedge-shapes were used to define each stereocentre of single 
enantiomers. 
 
 
Figure I-1: Numbering of a benzothiazole 
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II INTRODUCTION 
 
II.1 Malaria – An Introduction 
II.1.1 Prologue 
One of the leading causes of morbidity and mortality in the developing world is 
malaria. Around 3.3 billion people in 109 countries and territories throughout Africa, 
South East Asia, India, and South America were at risk at the end of 2006 (WHO 
2008). This parasitic disease is caused by micro-organisms of the genus Plasmodium 
that are transmitted to human hosts via female mosquito (Anopheles) vectors. 
Malaria caused by Plasmodium falciparum is the most lethal with more than one 
million deaths each year (WHO and UNICEF 2005). Furthermore, due to synergy 
with other infections and illnesses such as HIV/AIDS, malaria contributes to an even 
higher death toll. Effective treatment is challenging due to the complexity of the life 
cycle, increasing drug resistance, mosquito-favouring changes in climate, and lack of 
socioeconomic development in the most affected areas. A comprehensive strategy to 
deal with malaria is indispensable, not only to diminish incidence but also to prevent 
re-emergence. 
 
II.1.2 Global Distribution 
WHO in conjunction with local authorities developed the “Global Malaria Control 
Strategy”. Funds, largely government subsidized, are being made available to 
malaria interventions which incorporate artemisinin-based combination therapy 
(ACT, (Bosman and Mendis 2007)), improvements of health infrastructure and 
prevention strategies, such as long-lasting insecticidal nets (LLIN), indoor residual 
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spraying of insecticide (IRS) and intermittent preventive treatment in pregnancy 
(IPT) (WHO 2008). These ongoing efforts in disease management have reduced the 
number of reported regions that are at risk of malaria transmission from 
140 countries and territories (1950s) to 107 endemic areas (Figure II-1) (WHO and 
UNICEF 2005). Persistent intervention strategies in countries at risk may promote 
further decline. Targets were set to “ensure a reduction in the burden of malaria of at 
least 50% by 2010 and by 75% by 2015”. This had been interpreted to mean a 
reduction in malaria morbidity as well as mortality (WHO 2008). World 
Antimalarial Resistance Network (WARN) has been initiated as a public resource to 
link open access global databases containing clinical, in vitro, molecular and 
pharmacological data to guide research into antimalarial treatment (Sibley, Barnes et 
al. 2008). 
 
 
 
Figure II-1: Global distribution of malaria transmission risk 
The Malaria Report 2005 states over three billion people are at risk of malaria transmission (WHO 
and UNICEF 2005). The figure shows, with different intensities of colour green, in which region of 
the world the risk is highest. 
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II.1.3 The Complex Life Cycle of the Parasite 
The discovery of the parasitic agent of malaria was in 1880 when Laveran found 
Plasmodium to infect red blood cells in humans (Ross 1902; Laveran 1907). Decades 
later research groups established its transmission via mosquitoes of the genus 
Anopheles to humans (Bruce-Chwatt 1988). Figure II-2 shows a female mosquito 
(A) and infected red blood cells consumed by Plasmodium (B). 
Anopheles gambiae is the most efficient malaria vector which lives exclusively on 
the African continent. The population is difficult to control; effective methods such 
as indoor residual spraying of insecticide (IRS), insecticide impregnated bed-nets 
(ITN) and sterile insect technology (SIT) 1 are being applied to reduce the possibility 
of transmission of malaria (Atkinson 2005; Baton and Ranford-Cartwright 2005; 
Catteruccia 2005; WHO and UNICEF 2005; WHO 2008). 
There are over 100 known species of Plasmodium; however, only four appear to 
infect human hosts (P. vivax, P. ovale, P. falciparum, and P. malariae). A scheme of 
the life cycle is illustrated in Figure II-3. It is very complex and comprises an 
exogenous sexual phase in the mosquito vector (Baton and Ranford-Cartwright 
2005) and an endogenous asexual phase in the vertebrate host. 
The infectious stage begins with release of sporozoites in the salivary glands of the 
mosquito that are subsequently transmitted to the human host. After the 
exo-erythrocytic cycle (development in the liver) schizonts invade erythrocytes 
where they mature (erythrocytic cycle) and degrade iron and haemoglobin as a 
source of amino acids for their metabolism. This may lead to cell rupture, releasing 
waste of the parasite and cell debris that cause some clinical symptoms of malaria 
such as the periodical “chill and fever” (Wiesner, Ortmann et al. 2003). A more 
detailed description of the erythrocytic cycle is discussed in Chapter VI.1 (p. 170). 
Falciparum malaria can be fatal due to sequestration. The parasite produces specific 
proteins that embed on the cell membrane of an infected erythrocyte. The infected 
red blood cells thus adhere to microvascular endothelium (cytoadherence) in 
capillaries and venules of vital organs such as the brain (Berendt, Ferguson et al. 
                                                 
1
 SIT is an alternative technology to chemical insecticides, whereby sterile male insects are released to 
suppress or eradicate entire populations through sterile mating. The paper by Atkinson 2005 
summarises improved methods such as genetic engineering for sexing mosquitoes which was carried 
out by Catteruccia 2005. 
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1994; Wiesner, Ortmann et al. 2003). They interfere with the microcirculatory flow 
thus reducing oxygen and substrate supplies (White and Ho 1992). The combination 
of cytoadherence and rosetting (erythrocyte adhesion) can cause severe malaria. It 
may result in anaemia, renal failure, placental dysfunction, spleen enlargement, 
cerebral malaria, coma and death if left untreated. Furthermore, the immune system 
of the host is weakened to other illnesses such as bacterial infections. However, there 
are genetic changes that have occurred over time to resist malaria naturally 
(Marquardt, Demaree et al. 2000). Sickle cells, for example, have evolved due to low 
oxygen tension which results in sickling. Needle-like crystal formations of 
haemoglobin destroy the parasites mechanically. Nevertheless anaemia is fatal.  
There are many opportunities for interception. Pre-erythrocytic vaccination examines 
the prevention of the invasion of hepatocytes by sporozoites. Erythrocytic 
vaccination targets surface proteins, responsible for binding to erythrocytes. Other 
strategies look into preventing fertilisation in the mosquito or blocking sequestration 
of parasite-infected erythrocytes (Waters 2006). 
The inhibitor development of this project targets the erythrocytic cycle of 
Plasmodium falciparum. The potency of inhibitors can be tested by means of 
analysing reinvasion and maturation of parasites after incubation of infected 
erythrocytes for a complete life cycle of P. falciparum (Bowyer 2006). The parasite 
may reinvade red blood cells (Baton and Ranford-Cartwright 2005) to initiate the 
next phase in the malarial cycle or mature into gametocytes (Talman, Domarle et al. 
2004) which are ingested by the mosquito where the life cycle closes. 
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(A)   (B)  
Figure II-2: Feeding female Anopheles and Plasmodium infected erythrocytes  
When an infected female Anopheles takes a blood meal (A, (http://sill-www.army.mil, 04/2006)) the 
parasite gets transferred to the human host where it matures over several cycles, first in hepatocytes 
followed by erythrocytes (B, (www.nationalgeographic.com, 12/2008)), only to be taken up again by 
mosquitoes during feeding. 
 
 
 
 
Figure II-3: Overview of the life cycles of Plasmodium spp. 
An overview of the life cycles of Plasmodium spp. is displayed. It consists of the sporogenic cycle in 
the mosquito vector and the exo-erythrocytic and intra-erythrocytic cycle in the human host (adapted 
from (Schlitzer 2008)). The sporogenic cycle is the sexual life cycle of the parasite where the 
gametocytes mature to sporozoites. These are then passed on to the human host where the asexual 
development occurs. 
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II.1.4 Antimalarial Drugs 
There are various prophylactic and therapeutic agents available against malaria 
(shown in Figure II-5), each targeting different pathways of Plasmodium spp. 
(Wiesner, Ortmann et al. 2003; Schlitzer 2008). 
Figure II-5A shows a selection of quinolines which belong historically to the oldest 
antimalarial drugs and have been taken for many centuries. It is suggested, 
quinolines reside in food vacuoles of the parasite where they accumulate and inhibit 
haem polymerisation, which in turn leads to cell death due to toxicity (Warhurst 
1981; Slater and Cerami 1992). Quinine 1, extracted from chinchona bark, and its 
derivative chloroquine 2 have been employed in malaria eradication campaigns in 
the 1950s and 60s, yet effectiveness has declined rapidly and Plasmodium 
falciparum populations are widely resistant against 2 (see Figure II-4). 
To combat chloroquine-resistant areas, antifolates were strategically employed (see 
Figure II-5B). The inexpensively produced drugs are competitive inhibitors that 
target the folate pathway of Plasmodium spp. (Hyde 2005), in particular 
dihydropteroate synthase (DHPS, (Triglia and Cowman 1994)) and dihydrofolate 
reductase (DHFR (Bzik, Li et al. 1987)). The products of the folate pathway are 
essential for DNA synthesis and the metabolism of certain amino acids. 
Combinations of DHPS and DHFR inhibitors act synergistically to increase efficacy 
against the malaria parasite with Fansidar®, a combination of sulfadoxine 4 and 
pyrimethamine 5, being very successful for decades. However, point mutations of 
dhps and dhfr genes in Plasmodium falciparum have led to increased resistance 
(Plowe, Kublin et al. 1998; Sibley, Hyde et al. 2001). Different combination 
therapies which are based on pyrimidines and triazin structures are currently under 
investigation such as dapsone 6 – chlorproguanil 7 and atovaquone 8 – proguanil 9 
(Malarone™). Reviews for further reading include “Overview of the past and present 
antifolates with regards to affect Plasmodium falciparum” (Nzila 2006) as well as 
“Mechanisms of resistance of malaria parasites to antifolates” (Gregson and Plowe 
2005). 
Figure II-4 gives an outline of existing drug resistances in the malaria parasite 
revealing that traditional drugs such as chloroquine, sulfadoxine – pyrimethamine 
and mefloquine 3 (Lariam®) are no longer effective. At present, main treatments 
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against malaria involve artemisinin 10 and its analogues shown in Figure II-5C 
(WHO and UNICEF 2005). 10 is a herbal natural product from the sweet wormwood 
(Artemisia annua) which was isolated in 1972 and since then numerous derivatives 
have been synthesised (Haynes 2001). The endoperoxide bridge in artimisinins is the 
active functionality. Currently prescribed are artemisinin derivatives in sequential 
combination, known as ACT, with assorted drugs such as pyronaridine 12 –
 artesunate 11 (PANDA, Pyramax®) and dihydroartemisinin 13 – piperaquine 14 
(Eurartesim®) which are in Phase III (MMV 2006; MMV 2007; WHO 2008). ACT is 
aimed to delay or prevent emergence of resistance with multiple components. The 
active compounds target the same stage of the parasite but with individual modes of 
inhibition. For example, an artemisinin derivative affecting the mitochondrial 
electron transport combined with an antifolate reagent targeting the folate 
metabolism, both effective in the asexual blood stage, would be considered a good 
combination. (Baird 2005). Nevertheless, persistent increase of drug resistance 
makes ongoing inhibitor development indispensable.  
 
 
Figure II-4: Drug resistance in P. falciparum from studies in sentinel sites, up to 2004 
Common prescribed medicine with active reagents such as chloroquine ( ), 
sulfadoxine-pyrimethamine (  ), or mefloquine (  ) are widely inactive against Plasmodium falciparum 
(WHO and UNICEF 2005). 
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(A)  
 
(B)  
 
(C)  
Figure II-5: Common active reagents in antimalarial drugs 
There are several classes of antimalarials on the market. They can be classified under quinolines (A), 
antifolates (B) and artemisinins (C). 
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II.2 Myristoyl CoA:Protein N-Myristoyl Transferase – An Overview 
II.2.1 Introduction 
Myristoyl CoA:protein N-myristoyl transferase (NMT, EC 2.3.1.97)2 is a monomeric 
enzyme which is ubiquitous in eukaryotes. It involves the irreversible 
co-translational transfer of myristate to an N-terminal glycine of particular peptides 
via formation of an amide bond (Wilcox 1987; Deichaite 1988). 
The first isolation of NMT (from Saccharomyces cerevisiae) was carried out in 1987 
(Towler, Adams et al. 1987) and since then the enzyme has been identified and 
characterised in organisms including fungi (Candida albicans, Cryptococcus 
neoformans (Wiegand, Carr et al. 1992; Lodge, Johnson et al. 1994)), parasitic 
protozoa (Leishmania major, Trypanosoma brucei, Plasmodium falciparum 
(Gunaratne, Sajid et al. 2000; Price, Menon et al. 2003)) and mammals (Homo 
sapiens (Duronio, Reed et al. 1992)). Given that between 0.5% and 1.7% of the 
proteome may undergo N-myristoylation depending on the organism (Maurer-Stroh, 
Eisenhaber et al. 2002; Boisson, Giglione et al. 2003; Boisson and Meinnel 2003), 
NMT is a key drug target. Experiments established that NMT is essential for the 
viability of certain protozoa such as yeast (Duronio, Towler et al. 1989) and other 
fungal micro-organisms (Weinberg, McWherter et al. 1995; Lodge, Jackson-
Machelski et al. 1998). It has been suggested, NMT represents a potential drug target 
in the malarial intra-erythrocytic cycle (Gunaratne, Sajid et al. 2000; Gelb, Van 
Voorhis et al. 2003). Research is currently being carried out by Dr R Tewari 
(Institute of Genetics, University of Nottingham) in cooperation with Dr E W Tate 
(Department of Chemistry, Imperial College London) to verify whether NMT plays a 
crucial role in the survival of Plasmodium falciparum as well. It is already shown 
that inhibition of NMT in Plasmodium falciparum can lead to parasitic death 
(Bowyer 2006). 
NMT is quite specific for myristoyl CoA, suggesting that the specific fatty acid 
moiety, chain length and consequently flexibility provide structural features for 
myristoylated proteins critical for correct orientation within the membrane and thus 
enabling interactions with essential substrates (James and Olsen 1990). Myristoyl 
                                                 
2
 2 (transferase), 3 (transferase including acyltransferase), 1 (acyltransferases transferring groups 
other than amino-acyl groups), 97 (acyltransferases transferring groups other than amino-acyl groups) 
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CoA (Figure II-6B) is biosynthesised from myristic acid (Figure II-6A) and CoA-SH 
through acyl CoA synthetase. Myristic acid is a rare 14-carbon saturated fatty acid 
(C14:0) and only represents 1–3% of fatty acids in eukaryotic systems (Khandwala 
and Kasper 1971). The activated thioester can then react easily with nucleophiles 
such as an amine moiety of N-terminal Gly peptides (Figure II-6C). 
Potential substrates have been identified as ADP-ribosylation factor 1 (ARF1). ARF 
proteins, structurally and functionally conserved with an approximate size of 21 kDa, 
belong to the family of regulatory GTP-binding proteins and have been shown to 
play vital roles, such as aiding membrane trafficking (Boman and Kahn 1995). They 
can be divided into ARF and ARF-like (ARL) proteins, all of which may be 
myristoylated. The ARF family have been conserved throughout evolution and can 
be found in all eukaryotes, of which for example Pfarf1 has been fully characterised 
(Stafford, Stockley et al. 1996). ARF is known to undergo N-terminal 
N-myristoylation in the presence of NMT (Kahn, Randazzo et al. 1992; Price 2005). 
 
(A)   
 
(B)  
(C)  
Figure II-6: From myristic acid to myristoylated substrates 
Myristic acid (A), a rare saturated fatty acid, is generated during fatty acid synthesis. The reaction 
with coenzyme A creates myristoyl CoA (B). The thioester moiety is susceptible for nucleophiles such 
as 1° amines (C). 
 
N-Myristoylation in vivo is an early co-translational event, although some targets, 
notably in the apoptotic pathway, are myristoylated post-translationally after 
cleavage by an endoprotease. NMT interacts with elongated polypeptides just after 
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protein synthesis begins, but after removal of N-terminal methionine by methionine 
aminopeptidase. This was demonstrated by myristoylation of nascent polypeptides 
whilst still attached to tRNA (Wilcox 1987). Other experiments investigated the 
instance of N-myristoylation in a cell-free environment creating a translation-
myristoylation system with the ability to synchronise protein synthesis by delayed 
addition of specific initiation inhibitors (Deichaite 1988).  
Lipid modifications such as myristoylation are not only vital for attachment of 
proteins to the plasma membrane. Myristoylated proteins target a wide range of 
subcellular localisations throughout the cell such as lipid rafts (Resh 1999; Simons 
and Toomre 2000; Maurer-Stroh, Gouda et al. 2004). The impact of 
N-myristoylation will be explained in further detail later in this chapter. 
N-Myristoylation has also been exploited for in vitro and in vivo bioorthogonal 
N-terminal labelling of recombinant proteins. Recently, Heal et al. described a 
method of labelling myristoyl CoA with an azide or alkyne tag to capture labelled 
myristoylated proteins with secondary tags using the Staudinger–Bertozzi reaction. 
This method could be used to further uncover the myristoylated proteome (Hang, 
Geutjes et al. 2007; Heal, Wickramsinghe et al. 2008; Heal, Wickramsinghe et al. 
2008; Kostiuk, Corvi et al. 2008; Martin, Vilas et al. 2008). 
 
II.2.2 Structure and Catalytic Mechanism 
N-Myristoyl transferase has been well documented for Saccharomyces cerevisiae. 
Data on ScNMT range from isolation, expression and purification (Towler, Adams et 
al. 1987), to crystallisation studies (Figure II-7 (Bhatnagar, Fütterer et al. 1998; 
Farazi, Waksman et al. 2001; Wu, Tao et al. 2007)) and viability assays (Duronio, 
Towler et al. 1989).  
The ScNMT protein fold (pseudo two-fold symmetry) consists of a large saddle 
shaped -sheet with several -helices at its side (Bhatnagar, Futterer et al. 1999). 
Similarities were observed in the crystal structure data of Candida albicans NMT 
(Weston, Camble et al. 1998) and Leishmania major NMT (Qiu, Hutchinson et al. 
To be published), with a mixed / fold and an internal two-fold symmetry. The 
N-terminal domain forms the myristoyl CoA binding site, whereas the C-terminal 
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domain forms the majority of the peptide binding site and also interacts with the 
N-terminal domain (Bhatnagar, Futterer et al. 1999).  
Studies on S. cerevisiae NMT resulted in identification of the Bi Bi reaction 
mechanism as the catalytic mode of action (Rudnick, McWherter et al. 1991; 
Bhatnagar, Jackson-Machelski et al. 1994; Yang, Shapiro et al. 2005), illustrated in 
Figure II-8. Myristoyl CoA enters the N-terminal domain of NMT and thereby 
induces a conformational change in the disordered Ab loop exposing the peptidic 
binding site. This allows the C-terminus to aid the polypeptide substrate in binding. 
At the time this mechanism was reported, NMT was the only enzyme where the 
C-terminus was known to exhibit a catalytic role (Bhatnagar, Futterer et al. 1999), 
although other enzymes have been reported since (Fuchs, Xiao et al. 2008). The 
N-terminal Gly of the substrate carries a positive charged due to the acidic 
environment in the cell, and deprotonation is achieved by the C-terminal carboxylate 
of the enzyme (Leu455) generating a nucleophilic amine.  
The thioester moiety of myristoyl CoA is accommodated in an oxyanion hole formed 
by backbone amides Phe170 and Leu171. The hydrogen bond-carbonyl group 
interactions result in stronger polarisation facilitating nucleophilic attacks by the 
amine. Gly1 of the peptide substrate is aligned with the CoA thioester by hydrogen 
bonding with Asn169 and Thr205 in the C-terminal domain. In a nucleophilic 
addition-elimination reaction, the amine attacks the carbonyl of the thioester to form 
a tetrahedral intermediate that is stabilised by the oxyanion hole. Free CoA is then 
eliminated from the ternary complex, and the structure induced on binding is relaxed, 
resulting in the release of the myristoylated product (Bhatnagar, Futterer et al. 1999; 
Farazi, Waksman et al. 2001). 
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(A)
(B)
(C)
Figure II-7: Co-crystal structure of ScNMT
The ternary complex 
(non-hydrolysable myristoyl CoA
blue respectively (pdb file 2nmt, 
C-terminus is highlighted in red and shows the interaction 
figure was generated in PyMOL™ (0.99rc6, DeLano Scientific LLC, 
from published pdb files. 
 
   
  
 
of ScNMT (A) is illustrated with bound S-(2
, B) and a peptide substrate (SC-58272, C) coloured in yellow and 
(Bhatnagar, Fütterer et al. 1998). The enzyme is shaded in grey. The 
within the peptide binding 
http://pymol.sourceforge.net/
32 | P a g e  
 
-oxo)pentadecyl CoA 
pocket. The 
) 
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Figure II-8: The proposed Bi Bi reaction mechanism of N-myristoylation in detail 
The detailed mechanism of N-myristoylation is shown in this figure, adapted from (Bhatnagar, Futterer et al. 1999). 
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II.2.3 Impact of N-Myristoylation 
Myristoylation is a ubiquitous protein modification that has been subject of many 
reviews (Schultz, Henderson et al. 1988; Towler 1988; James and Olsen 1990; 
Boutin 1997; Farazi, Waksman et al. 2001; Nalivaeva and Turner 2001; Bowyer, 
Tate et al. 2008). The transfer of myristate to substrate proteins increases their 
affinity for membranes. Only N-terminal glycines of particular polypeptides are 
myristoylated. The second main type of protein fatty acylation is S-palmitoylation 
(Bhatnagar and Gordon 1997). Unlike myristoylation, palmitoylation is reversible. 
Palmitate (C16:0) is attached to the thiol moiety of variably located cysteine 
residues. S-Palmitoylated proteins can be found solely on the plasma membrane 
compared to a much wider distribution of N-myristoylated proteins, which are not 
only present on the plasma membrane but also in other subcellular compartments 
such as the cytosol, ER and nucleus (James and Olsen 1990).  
The hydrophobic N-terminal myristate group of an N-myristoylated protein embeds 
in the phospholipid bilayer of the membrane forming an anchor that promotes 
reversible protein–membrane binding (Peitzsch and McLaughlin 1993; McIlhinney 
and McGlone 1996; Maurer-Stroh, Eisenhaber et al. 2002).  
N-Myristoylation alone has been shown to be insufficient for persistent membrane-
binding; secondary interactions such as protein–protein interactions, further 
lipidation, or attractive electrostatic forces are required to stabilise the protein–
membrane interaction (Shahinian and Silvius 1995; Murray, Ben-Tal et al. 1997).  
Figure II-9 displays various combinations of N-terminal lipid modifications to assist 
in the association of proteins to the membrane (McCabe and Berthiaume 1999; Resh 
1999; Maurer-Stroh, Gouda et al. 2004). There are five major classes which have 
been defined to co-occur commonly with myristoyl anchors and thus contribute to 
subcellular localisation and membrane attachment: Class I – palmitoylatable 
cysteine, Class II – amino terminal cluster of positive charges, Class III – PIP2-
specific binding domain, Class IV – transmembrane segments, Class V – protein–
protein interactions (Maurer-Stroh, Gouda et al. 2004).  
This necessity for further membrane associations for stabilisation can be exploited as 
switches, as destabilisation may cause the release of proteins from the membrane 
(Nalivaeva and Turner 2001). For example, in an electrostatic switch protein 
II INTRODUCTION 
35 | P a g e  
 
phosphorylation adjacent to the membrane increases the local negative charge and 
thus repels the membrane, inducing dissociation, e.g. phosphorylation of 
Ser-residues in MARCKS (McLaughlin and Aderem 1995). Conformational 
switches are also regulated by ligand binding that can either uncover or bury the acyl 
chain, e.g. reversible membrane binding of ADP-ribosylation factor (Boman and 
Kahn 1995) or the calcium-myristoyl protein switch (Zozulya and Stryer 1992; 
Ames 1996). 
 
Figure II-9: Scheme of membrane–myristoylated protein interactions 
This is a schematic representation of the membrane attachment of proteins with a myristoyl anchor 
(dark gray, space-filling atomic representation) in combination with different co-occurring 
membrane-attachment factors. 
Class I, plus palmitoyl anchor (also dark gray, space-filling); Class II, plus cluster of positive 
charges (dark blue, space-filling); Class III, plus PIP2-specific binding domain (PIP2 in space-filling, 
alkyl tails in cyan); Class IV, plus transmembrane segments; Class V, plus a domain for specific 
protein-membrane protein interactions. White space-filling molecules in the model membrane 
represent cholesterol and symbolise targeting to specialised compartments (Maurer-Stroh, Gouda et 
al. 2004). 
 
II.2.4 Inhibitory Targets of N-Myristoyl Transferase 
NMT belongs to the group of transferases which catalyse the irreversible transfer of 
a C14:0 saturated fatty acid to N-terminal Gly of assorted proteins. N-myristoyl 
transferase possesses two binding pockets and hence two potential targets for drug 
development, one for myristoyl CoA and one for peptide substrates. Efforts have 
gone into analysis of the N-myristoylome to investigate substrate sequence motifs 
(Maurer-Stroh, Eisenhaber et al. 2002; Maurer-Stroh, Eisenhaber et al. 2002; Heal, 
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Wickramsinghe et al. 2008). The first direct analysis for a higher eukaryote was 
carried out in 2003 (Boisson, Giglione et al. 2003). 
A phylogenetic analysis may give insight into similarities and divergences of NMT 
across species to aid rational drug design (Johnson, Bhatnagar et al. 1994). Figure 
II-10 illustrates both N- and C-terminal domains of NMT for various organisms, 
wherein three major separate clusters were identified: metazoan (H. sapiens), plants 
and fungi (C. albicans) ((Eisenhaber, Eisenhaber et al.) 2006). The N-terminal 
domain forms the myristoyl CoA binding site, whereas the C-terminal domain forms 
the majority of the peptide binding site and also interacts with the N-terminal domain 
(Bhatnagar, Futterer et al. 1999). Examination of P. falciparum NMT and H. sapiens 
NMT, highlighted by a black box, shows more similarities within the N-terminus 
(Figure II-10A) compared to the C-terminal (Figure II-10B) binding domain. 
In conclusion, selective inhibition against the target parasitic NMT over human 
NMT may be achieved via the peptide binding site as it retains quite distinct 
differences compared to the myristoyl CoA binding domain that has many features in 
common (Rocque, McWherter et al. 1993).  
 
II.2.4.1 N-Myristoyl Transferase in Humans and Parasites 
II.2.4.1.1 N-Myristoyl Transferase in Humans 
In the early 1990s, researchers isolated a single cDNA encoding for human NMT 
(Duronio, Reed et al. 1992; Glover, Hartman et al. 1997). It contains 416 AA and has 
found to be 44% identical to ScNMT. This enzyme was labelled HsNMT1 as there 
was biochemical evidence of several distinct NMTs in vivo (Boutin 1997). And 
indeed by the end of the decade a second human N-myristoyl transferase was 
discovered (Giang and Cravatt 1998); both myristoylate commonly-studied peptide 
substrates have comparable but distinguishable relative selectivity. HsNMT2 is 
65 kDa in size whereas for HsNMT1 there are four splice isoforms ranging in size 
from 49 kDa to 68 kDa (Giang and Cravatt 1998). Comparative studies between 
HsNMT1 and HsNMT2 revealed only 76–77% sequence identity (Appendix, Figure 
VIII-1A), suggesting two divergent families of N-myristoyl transferases.  
Specific inhibition of either human NMT may lead to selective myristoylation, 
which in turn may be beneficial for in vivo regulation and pharmaceutical targeting 
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of NMT (Giang and Cravatt 1998; Maurer-Stroh, Eisenhaber et al. 2002). 
Crystallographic analysis of the human apoenzyme has been attempted but remain 
unpublished (3.00 Å, pdb file 1rtx (Yang To be published)). 
Kinetic studies of human NMT have been carried out and it has been shown that the 
established Bi Bi reaction mechanism for ScNMT is retained in the N-myristoylation 
of peptides by human NMT (Rocque, McWherter et al. 1993). This information 
together with divergent properties of the peptide binding pocket among different 
eukaryotic systems makes NMT a potentially valuable drug target. 
N-Myristoylation of p60src, located to the inner surface of the membrane, has found 
to be essential as only myristoylation enables interactions with the membrane, 
enabling p60scr to carry out site-specific functions such as cell transformations 
(Glover, Goddard et al. 1988). Experiments with synthetic peptides based on the 
N-terminal sequence of p60scr established that the first nine residues were essential 
for enzyme specificity (Glover, Goddard et al. 1988). Inhibition assays against 
human NMT were carried out with peptide substrates based on the N-terminus of 
p60scr peptide: GSSKSKPKDP (10mer, (Giang and Cravatt 1998)) and 
GSSKSKPKDPSQRRRY (16mer, (McIlhinney, Patel et al. 1994)) for example. 
 
II.2.4.1.2 N-Myristoyl Transferase in Leishmania spp. 
N-Myristoyl transferase is also a target for protozoan parasitic diseases. 
Leishmaniasis, a tropical illness transmitted by sand flies, is caused by 
Leishmania spp. and has been under investigation by collaborators at York 
University, UK. They reported peptide substrates other than ARL-proteins (Price 
2005) to be myristoylated: hydrophilic acylated surface proteins (HASP, (Denny, 
Gokool et al. 2000)). They are only expressed in infectious parasite stages and need 
to be myristoylated for exact localisation to the plasma membrane (Flinn, Rangara et 
al. 1994; Pimenta, Dasilva et al. 1994). Synthetic peptide substrates may be based on 
HASPA, HASPB or ARL (Panethymitaki, Bowyer et al. 2006). Recent 
developments in successful co-crystallisation of Leishmania major NMT (1.49 Å, 
pdb file 3h5z (Qiu, Hutchinson et al. To be published)) with myristoyl CoA and 
Leishmania donovani NMT with a myristoyl CoA analogue (unpublished data) open 
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up possibilities of docking studies to analyse enzyme-inhibitor interactions, as 
already has been done for Candida albicans NMT (Ruge, Korting et al. 2005). 
 
II.2.4.1.3 N-Myristoyl Transferase in Trypanosoma spp. 
Sleeping sickness, caused by Trypanosoma spp., represents an additional target 
disease for drug development against N-myristoyl transferase. Collaborators at 
Dundee University, UK, are currently working at this at a large screening facility for 
drug discovery. The peptide substrates employed in assays may be based on the 
N-terminal sequence of CAP5.5, GCGGSKVK (Hertz-Fowler, Ersfeld et al. 2001; 
Panethymitaki, Bowyer et al. 2006). 
 
II.2.4.1.4 N-Myristoyl Transferase in Plasmodium spp. 
We have identified myristoyl CoA:protein N-myristoyl transferase as a potential 
target for novel antimalarial drugs against Plasmodium falciparum. The gene coding 
for PfNMT was cloned in 2000 (Gunaratne, Sajid et al. 2000). It is a single copy 
gene encoding a protein comprised of 410 AA; the corresponding mRNA is 
expressed in asexual blood stages making NMT a potential target in the intra-
erythrocytic cycle. However, there is no co-crystal structure published up to date 
which would chiefly facilitate enhancement of potency and selectivity for PfNMT 
over human NMT. 
The divergent peptide binding site may be exploited for drug development. 
Examples of peptide substrates are based on ARF proteins as they are readily 
myristoylated in Plasmodium spp.: GLYNSRLFNRLFQKK (15mer, (Stafford, 
Stockley et al. 1996)), GLYVSRLF (8mer, (Gunaratne, Sajid et al. 2000)) and 
GLYVSRLFNRLFQKK (15mer, (Bowyer, Gunaratne et al. 2007)). Key 
characteristics include an N-terminal Gly, large hydrophobic residues at position 2, 
neutral residues in 3 and 4 and Ser at position 5. Lys is also common in position 6, 
and basic residues are favourable in positions 7 and 8 (Rudnick, McWherter et al. 
1991; Duronio, Reed et al. 1992; Sikorski, Devadas et al. 1997). 
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II.3 Rational Drug Design 
II.3.1 Piggy-Back Approach 
N-Myristoyl transferase is a key drug target and N-myristoylation is essential for 
various pathogens (Duronio, Towler et al. 1989; Weinberg, McWherter et al. 1995; 
Lodge, Jackson-Machelski et al. 1998). Attachment of the long hydrophobic 
myristate group to substrate proteins increases affinity for binding to the membrane, 
followed by secondary interactions with proteins to fully stabilise the embedded 
myristoylated protein anchor in the membrane, to then be able to interact with 
various proteins important for the function of the organism. Inhibition of 
N-myristoylation may have a harmful effect on the parasite. High similarities in 
homology studies of NMTs of organisms that have shown to require NMT for 
survival, propose a lethal effect on Plasmodium spp. Furthermore, apart from a 
highly conserved myristoyl CoA binding site across many organisms the peptidic 
binding cavity is quite divergent, in particular with respect to the human species, 
making it an ideal target site for drug development. Large research programmes 
developed selective inhibitors against N-myristoyl transferase for fungi (Candida 
albicans (Pfizer, unpublished work; (Rocque, McWherter et al. 1993; Yamazaki, 
Kaneko et al. 2005)) and parasitic protozoa (Leishmania major, Trypanosoma brucei 
(Panethymitaki, Bowyer et al. 2006)). To enable accelerated progress in drug 
development for malaria, the information of superior drug compounds for CaNMT is 
applied to the Plasmodium falciparum organism in the so-called piggy-back 
approach, whereby an established inhibitor for an enzyme is optimised for a new 
target organism (Gelb, Van Voorhis et al. 2003). This drug development aid is only 
applicable if the systems are homologous. Sequence alignment between NMT of 
Candida albicans and Plasmodium falciparum reveal moderately high similarities 
(Figure II-11). Amino acids that have been revealed as important for inhibition 
against CaNMT and thus may play a role in PfNMT are highlighted in Figure II-11. 
12 out of 14 AA are identical, except F341 which is a Ser in PfNMT and Y351 
which is a Phe in PfNMT. The latter change still enables CH-% stacking interactions, 
whereas serine may form hydrogen bonds with the inhibitor molecule. 
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Figure II-11: Sequence alignments of CaNMT and PfNMT 
The sequences of various NMT proteins have been aligned with the program MultAlign (Version 
5.4.1.(Corpet 1988)). The colour code is as follows: Red = exact match, blue = AA of similar 
properties, black = no match, with a consensus level of 90% high and 50% low. The consensus 
symbols are as follows: ! = any of IV, $ = any of LM, % = any of FY and # = any of NDQEBZ. 
The highlighted amino acids are likely to undergo interactions with binding substrates in the active 
site. 12 out of 14 AA are identical, except F341 which is a Ser in PfNMT and Y351 which is a Phe in 
PfNMT.  
 
II.3.2 Drug Development against CaNMT 
High-throughput screening against Candida albicans NMT revealed numerous hits 
leading Roche to develop non-peptidic inhibitors based on a benzofuran scaffold 
(Figure II-12). 15 was a positive hit in a large HTS by Roche. Optimised further to 
16, it was more potent against CaNMT and ~5 000-fold selective over human NMT 
(Masubuchi, Kawasaki et al. 2001). Further development led to 17 (Ebiike, 
Masubuchi et al. 2002) and 18 (Kawasaki, Masubuchi et al. 2003) with an IC50 
(CaNMT) of 0.39 nM and 1 000 000-fold selectivity over human NMT. 
Crystallographic analysis revealed various binding with amino acids from the 
peptide binding pocket, enabling refinement for further drug development. 
Crystallographic studies have been carried out within Roche, to gain more 
information about the conformation of the peptide binding pocket in CaNMT to 
increase the potency of inhibitors (Sogabe, Masubuchi et al. 2002). Figure II-13 
illustrates three bound inhibitors (19, 20, 21) from the benzofuran series 
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co-crystallised with CaNMT. This knowledge enables 3D-QSAR, docking and MEP 
studies to analyse enzyme-inhibitor interactions in more depth (Hasegawa, Morikami 
et al. 2003; Purushottamachar and Kulkarni 2003). 
Figure II-14 demonstrates key interactions of benzofuran-based inhibitor 22 with 
surrounding AA in the peptidic binding pocket of CaNMT (Hasegawa, Morikami et 
al. 2003). The first of four major interactions is a charge-charge interaction between 
the carboxylate of Leu451 and the 2° amine functionality. Hydrogen bonding occurs 
between the hydroxyl group of Tyr119 and the N-atom of the pyridine residue of the 
inhibitor, the 2° amine group of His227 and the benzofuran core, and the primary 
amine group of Asn192 interacts with both the oxygen of the ether moiety and the 
fluorine atom, whereby F-H the strongest hydrogen bond is and also orientated 
linearly. Surrounding Tyrosine-groups (Tyr225, Tyr354) interact with the %-system 
of the benzofuran core. Van der Waals forces such as hydrophobic interactions also 
fix the position of the inhibitor molecule in the binding cavity. Zihong Yu under the 
supervision of Prof R J Leatherbarrow (Department of Chemistry, Imperial College 
London) is currently optimising benzofuran inhibitors based on the published work 
by Roche with the aim of generating potent antimalarial compounds. 
 
 
Figure II-12: Development of antifungal inhibitor based on benzofuran scaffold 
The figure shows the development of non-peptidic inhibitors by Roche starting with a positive hit from 
high-throughput screening (15). Step-by-step progression of compound optimisation afforded an 
inhibitor (18) with an IC50 of 0.39 nM against CaNMT and 1 000 000 selectivity over human NMT 
(Masubuchi, Kawasaki et al. 2001; Ebiike, Masubuchi et al. 2002; Kawasaki, Masubuchi et al. 2003).  
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Figure II-13: Bound conformation of non-peptidic inhibitors in CaNMT 
Crystallographic studies succeeded in the production co-crystals of benzofuran-based inhibitors with 
CaNMT (Sogabe, Masubuchi et al. 2002). Three inhibitors were separately co-crystallised with 
CaNMT to investigate the inhibitory effects of various R-groups with different chemical properties to 
investigate the peptide binding pocket more thoroughly. 
 
 
 
 
Figure II-14: Key interactions of active benzofuran-based inhibitor 22 and CaNMT 
Detailed interactions of amino acids in the peptide binding pocket with inhibitor 22 were investigated, 
adapted from (Hasegawa, Morikami et al. 2003). Ionic interactions and H-bond donor/acceptor 
interactions can be seen clearly. 
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II.3.3 Benzothiazole Series 
Drug design for the peptide binding site has led to peptidomimetic and non-peptidic 
inhibitors (Georgopapadakou 2002). Peptidomimetic inhibitor optimisation against 
CaNMT began from the derived N-terminal ARF sequence GLYASKLS; whereby 
the competitive octapeptide inhibitor ALYASKLS-NH2 was developed. Mutagenesis 
experiments suggest that residues 1, 5 and 6 are valuable for binding (McWherter, 
Rocque et al. 1997). Further studies indicate, reduction of peptide bonds may 
increase in vivo activity (Devadas 1998). De-peptidisation, while maintaining the 
conformation of Ser and Lys at position 5 and 6, led to an effective non-peptidic 
inhibitor (23, SC-58272, Figure II-16) against Candida albicans NMT 
(IC50 = 56 nM) (Bhatnagar, Fütterer et al. 1998). 
Pfizer dedicated their antifungal research towards NMT inhibitors bearing a 
benzothiazole scaffold in search for broad-spectrum antifungal treatments. Intense 
developments including co-crystallisation trials yielded inhibitors specific towards 
Candida albicans (24-30, Figure II-16, Pfizer, unpublished work). The introduction 
of a dimethylamide group at C6-position of the benzothiazole ring, as well as an 
aromatic group attached at the free amine, enhance the binding properties in CaNMT 
significantly. The IC50-value of the lead compound is in the low nanomolar region, 
IC50 (CaNMT) = 13 nM (29, Figure II-16, Pfizer, unpublished work). 
Figure II-17, Figure II-18 and Figure II-19 illustrate co-crystal structures of 
inhibitors in CaNMT. Figure II-17 demonstrates the penetration of the benzothiazole 
scaffold of 26 into the peptide binding pocket where it is able to form interactions 
with surrounding AA in contrast to peptidomimetic inhibitor 23. Important 
interactions are indicated in Figure II-18 and include Asn392 for interactions with 
the oxygen atom of the dimethylamide, Leu451CO2H for interactions with the amine 
and Thr211 for other polar interactions. The expansion of the compound with an 
aromatic group attached to the free amine seems to open up a new pocket for 
additional binding via the conformational change of Tyr210 (Figure II-19), reducing 
IC50-values to the low nanomolar region.  
Research and further development of benzothiazole-based antifungal inhibitors have 
been suspended as the lead compounds are unable to target NMT of fungal 
pathogens other than Candida albicans and Candida tropicalis. Pfizer has agreed to 
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collaborate with Imperial College London to test compounds for activity in 
Plasmodium falciparum (Bowyer 2006; Bowyer, Gunaratne et al. 2007; Bowyer, 
Tate et al. 2008). These compounds will be referred to as “Pfizer series”. Initial 
screens using in vitro tests of enzyme activity as well as in vivo tests with 
P. falciparum infected erythrocytes with antifungal inhibitors have shown positive 
results (Bowyer 2006). A series of specific benzothiazole compounds was identified 
that inhibit PfNMT in the micromolar range, with an IC50 of 30 ± 3 µM for the best 
compound (Figure II-15 (Bowyer, Gunaratne et al. 2007)). 
 
 
Figure II-15: Lead compound, 31 
Out of the benzothiazole-based compounds UK-370,509 inhibited best against PfNMT with an IC50 of 
30 ± 3 µM. 
 
Recently, computer modelling has been performed utilising published crystal 
structure data of fungal NMTs to create 3D-models of PfNMT by homology 
modelling methods (Sheng, Ji et al. 2009). The homology score for CaNMT–PfNMT 
was calculated as 43.0% and ScNMT–PfNMT 46.8%. The 3D-model of PfNMT 
showed common features with the fungal NMTs such as a large -sheet with several 
-helices at the side and the internal pseudo two-fold symmetry. 
The active site was found to have four characteristic pockets: two hydrophobic 
pockets, one hydrogen bonding pocket, one positively and one negatively charged 
hydrogen bonding pocket (Figure II-20A). Two key residues for activity were 
located; the first is Leu410, the C-terminal carboxylate, situated in the S4 negatively 
charged hydrogen bonding site and the second are Leu163 and Leu91 in the S2 
hydrogen bonding pocket which form the oxyanion hole with their backbone amides 
to accommodate myristoyl CoA and subsequently polarise the thioester moiety. 
Lead compound UK-370,509 (Figure II-20C) was docked into the active site using 
flexible molecular docking methods (Figure II-20B). The main interactions of the 
inhibitor with surrounding amino acids were hydrophobic and hydrogen bonding in 
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nature. The oxygen of the amide was proposed to form two hydrogen bonds with 
Lys25 (S5 pocket) and Tyr211 (S4 pocket). The interaction with Lys25 is specific 
for PfNMT and not found in human NMT, thus is proposed to be vital for selectivity. 
Loss of this hydrogen bond was suggested to result in lower inhibition. A third 
hydrogen bond is suggested between Tyr107 (S2 pocket) and the secondary amine. 
Perhaps more controversially, the model proposes that the secondary amine does not 
interact with the C-terminus as initially suggested in Figure II-18 or Figure II-14. 
Hydrophobic interactions are thought to occur in the S1 and S3 pockets and involve 
the aromatic ring of the benzothiazole and the cyclohexyl unit. Proposed key 
residues are highlighted in Figure II-20B. 
 
Japanese researchers have independently carried out further investigations to 
produce more potent and selective inhibitors against CaNMT. Employing solid phase 
synthesis, they developed a very potent inhibitor against CaNMT with an IC50-value 
in the picomolar region (30, FTR1335, Figure II-16, (Yamazaki, Kaneko et al. 
2005)). 
 
 
II.4 Project Aims 
The work presented in this thesis documents the development of effective inhibitors, 
whereby differences in the peptide binding pockets of PfNMT and human NMT 
were exploited to produce more selective and potent inhibitors, to lead to efficient 
novel antimalarial treatments.  
 
• Synthesis of benzothiazole-based lead compound of the “Pfizer series” 
• Optimisation of the lead compound for potency against PfNMT 
• Improvement of inhibitors for selectivity against PfNMT over human NMT 
• Test for activity of compounds in established in vitro and in vivo assays (with 
prior expression of PfNMT and human NMT for in vitro assay) 
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Figure II-16: Optimisation process of antifungal compounds 
Another inhibitor development process is pictured. Starting from peptide-based inhibitors, Pfizer 
research developed into benzothiazole-based inhibitors (23–30) with an activity against CaNMT in 
the low nanomolar region. However, further research by Yamazaki et al. produced an even more 
potent inhibitor, 30 (Pfizer, unpublished results; (McWherter, Rocque et al. 1997; Bhatnagar, 
Fütterer et al. 1998; Yamazaki, Kaneko et al. 2005; Bowyer 2006)).112112 
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Figure II-17: Co-crystal structure of two inhibitors and CaNMT  
A peptide mimetic (23, SC-58272, brown-coloured) and a non-peptidic molecule (21, UK-370,485, 
green-coloured) have been co-crystallised in CaNMT (Pfizer, unpublished data, undisclosed info). 
 
 
Figure II-18: In depth view of inhibitor binding interactions 
A closer examination of interactions with surrounding amino acids from peptide binding pocket of 
CaNMT with non-peptidic compound (21, UK-370,485, green-coloured) can be seen (Pfizer, 
unpublished data, undisclosed information). 
  
Figure II-19: Comparison of two different benzothiazole compounds 
On comparison of two structurally closely related compounds (light green- and dark green-coloured) 
a change in the orientation of nearby amino acids of the peptide binding pocket was noticed (Pfizer, 
unpublished data, undisclosed information). 
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(A)  
(B)  
 
(C)  
 
Figure II-20: Homology modelling for PfNMT 
3D-Models of PfNMT were constructed on the basis of published data of fungal NMTs using 
homology modelling. The surface, showing the active site of PfNMT, is displayed in A. B shows the 
docking information of compound UK-370,509 (C) in the active site of PfNMT (Sheng, Ji et al. 2009). 
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III NMT EXPRESSION, ISOLATION & ANALYSIS 
 
III.1 Introduction 
The expression and purification procedures of N-myristoyl transferase for the in vitro 
assay from organisms Plasmodium falciparum (PfNMT), Homo sapiens (HsNMT1 
and HsNMT2), Candida albicans (CaNMT) and Leishmania major (LmNMT) is 
described in this chapter. Various physical properties of these NMTs, exploited for 
efficient purification procedures, are listed in Table III-1.  
 
Table III-1: Overview of physical properties for NMT of various organisms 
The table lists molecular weight and formula for NMT of different species as well as the extinction 
coefficient, , which was predicted with ProtParam tool at a wavelength of 280 nm 
(http://www.expasy.org/tools/protparam.html). The isoelectric point, pI, was obtained through 
calculations with Vector NTI Advance™ software (Invitrogen). 
Enzyme N-terminal 
Tag 
Molecular Formula Mr 
[kDa] 
Extinction 
Coefficient, , 
× 103[M-1 cm-
1] 
Reference 
(FASTA 
Sequence) 
pI  
PfNMT His6 tag C2344H3610N620O678S17 52 81 Table VIII-2 8.40 
HsNMT1 His6 tag C2550H3979N687O738S23* 57* 71* P30419 7.74* 
HsNMT2 His6 tag C2552H4009N691O750S19* 57* 69* O60551 9.54* 
CaNMT — C2362H3630N598O693S12* 52* 78* P30418 6.06* 
LmNMT His6 tag C2211H3367N579O622S16* 49* 74* AAG38102 6.28* 
* 
calculated from FASTA sequence 
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III.2 Material & Methods 
III.2.1 Chemicals and Reagents 
Solvents and reagents of the highest available standard were obtained from 
commercial sources (BDH, Fisher Scientific, GE Healthcare formerly known as 
Amersham Biosciences, HyClone, Invitrogen, Merck, Millipore, Sigma-Aldrich). 
Escherichia coli BL21(DE3) strains were obtained from Stratagene and 
E. coli DH5™ strains from Novagen. 
 
III.2.1.1 Solutions – Media 
Ultrapure laboratory grade water (filtered, deionised, sterilised) was obtained from 
in-house Elix® and MilliQ® water purification systems. All solutions were prepared 
in ultrapure laboratory grade water and filter sterilised through a 0.22 µm GSWP 
filter (nitrocellulose membrane, Millipore). 
Media were prepared, sterilised and stored according to the manufacturer and 
standard published protocols (Sambrook and Russel 2001). Media were handled in 
sterile conditions under an open flame. The composition of media is stated below. 
LB: Lysogeny broth (Bertani 2004) (LB broth (Miller), Merck, Fisher Scientific) 
was prepared according to the manufacturer, sterilised by means of autoclaving and 
stored at RT. LB contains 1% (w/v) tryptone, 0.5% (w/v) yeast extract and 1% (w/v) 
NaCl in distilled water. LB-agar: Lysogeny broth-agar (LB-agar (Miller), Merck) 
was prepared according to the manufacturer, sterilised by means of autoclaving and 
stored at RT. It consists of LB supplemented with 1.2% (w/v) agar.  
SOC medium: Super optimal broth with catabolite repression (Hanahan 1983) (SOC 
medium, Sigma) was used to maximise the transformation efficiency of competent 
cells by improving the molecular uptake whilst stabilising the cells. The solution 
contains 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 8.6 mM NaCl, 2.5 mM KCl, 
20 mM MgSO4 and 20 mM glucose in distilled water. It was stored at 4 °C. 
Antibiotic stock: Stocks of ampicillin (sodium salt, Sigma) were prepared on the day 
of handling in distilled water and stored at 4 °C. Ampicillin stock was used at a 
working concentration of 50 mg mL-1. LB-amp: Lysogeny broth-ampicillin was 
prepared in a 1:1 000 dilution (1 mL 50 mg mL-1 ampicillin stock in 1 L LB). 
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III.2.1.2 Bacterial Strains and Plasmids 
Three expression vectors were used in the overexpression of various recombinant 
proteins, two from the pET vector series for Homo sapiens NMT and 
Candida albicans NMT and pTrc vector for Plasmodium falciparum, NMT (Table 
III-2). The pET system is often used for cloning and expression of recombinant 
proteins in E. coli. The plasmids carry a T7 RNA polymerase which can be induced 
by IPTG to selectively promote target gene expression. All vectors were stored in 
glycerol stocks at -20 °C. 
The pET-11c vector is ampicillin resistant, encodes a T7 lac promoter, carries an 
N-terminal T7 tag sequence and a BamH1 cloning site (Table III-2A). The plasmid, 
a gift from Pfizer PLC, was utilised to overexpress CaNMT. 
The pTrcHisA vector with PfNMT insert was obtained from Dr A A Holder 
(National Medical Research Institute, London, UK) and used for overexpression of 
P. falciparum NMT (Table III-2B). The insert is a synthetic gene, codon-optimised 
for optimum expression in E. coli (Bowyer, Gunaratne et al. 2007). 
pET-15b vector is also ampicillin resistant, contains a T7 lac promoter, bears an 
N-terminal His6 tag followed by a thrombin site and three cloning sites (Table 
III-2C). The plasmid was obtained from Dr S Elroy (University of Dundee, UK) and 
used for the overexpression of HsNMT1 and HsNMT2. 
E. coli strains used for overproduction of proteins were DH5™ and BL21(DE3). A 
full genotype can be found in the Appendix (Table VIII-1). 
DH5™ was used for plasmid maintenance and BL21(DE3), the general purpose 
expression host, for overexpression of the recombinant proteins. They were stored at 
-80 °C. 
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Table III-2: Plasmid vectors 
The table lists primary expression vectors used in the course of this project along with relevant 
details, (A) pET-11c, (B) pTrcHisA, (C) pET-15b. Sequences were numbered by the pRB322 
convention. (Source: Novagene, Vectorpedia, www.addgene.org, 14.07.2008) 
Insert (Plasmid 
Name) 
Vector 
System 
Source of DNA Comments 
Candida albicans 
NMT (CaNMT) 
 
pET-11c a kind gift from Pfizer PLC, UK No tag 
Plasmodium 
falciparum NMT 
(PfNMT) 
 
pTrcHisA a kind gift from Dr A A Holder, National 
Institute for Medical Research, UK 
N-terminal 
His6 tag 
Homo sapiens NMT1 
(HsNMT1) 
 
pET-15b a kind gift from Dr S McElroy, Drug 
Discovery Unit, University of Dundee, 
UK 
N-terminal 
His6 tag 
Homo sapiens NMT2 
(HsNMT2) 
pET-15b a kind gift from Dr S McElroy, Drug 
Discovery Unit, University of Dundee, 
UK 
N-terminal 
His6 tag 
 
(A)    (B)    (C) 
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III.2.2 Methods and Equipment 
Unless otherwise stated, all chromatography media and columns were purchased 
from GE Healthcare. Protein purification was carried out using FPLC on an Äkta 
System, Unicorn Version 4.11 (GE Healthcare) Software. 
The pH of the buffered solutions was measured at room temperature with a pH meter 
(Hanna instruments 8519). Calibration was performed with ‘colour key’ buffer 
solution from BDH (red – pH 4.0 ± 0.02 at 20 °C, yellow – pH 7.0 ± 0.02 at 20 °C). 
The pH adjustments were made with a suitable acid or base, e.g. HCl, NaOH, NH3. 
Buffered solutions used throughout the project are catalogued in Table III-4. 
Incubation was carried out at 37 °C (Innova 4400 Incubation Shaker or LTE IP60 
incubator), 15 °C (Innova 4430 Incubation Shaker), or at 4 °C (Roto-Shake Genie, 
Scientific Industries, Inc.). 
The centrifuge for speeds up to 20 000g was performed with Sorvall RC 5C Plus, 
Kendro Laboratory Products and SS-34 Rotor. For 4 000g the Centrifuge 5810 R, 
Eppendorff or Jouan BR4 or Jouan A14 were used. 
OD measurements and quantitative analysis of enzymes were analysed on a 
Biowave II WPA UV detector at 600 nm and 280 nm respectively. 
Sonication was performed with Bandelin Sonoplus at 30% power output. 
 
III.2.2.1 Manipulation of Bacteria 
III.2.2.1.1 Preparation of Agar-Amp Plates 
Agar stock was melted carefully in the microwave with several 5 s heat pulses until 
clear. After it cooled down to ~37 °C, 50 mg mL-1 freshly prepared ampicillin was 
added in a ratio of 1:500 (160 µL 50 mg mL-1 ampicillin in 80 mL agar). 20 mL of 
antibiotic rich agar was poured in a Petri dish, cooled down to room temperature and 
stored upside down at 4 °C. 
III.2.2.1.2 Growth of Subcultures 
Bacteria were streaked on agar plates with the appropriate antibiotic selection, 
incubated overnight at 37 °C and stored at 4 °C. 50–100 mL LB-media were 
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inoculated with one colony from the agar plate. The liquid cultures were incubated 
overnight in a 1 L flask at 37 °C with shaking at 220 rpm. 
III.2.2.1.3 Transformation of Bacteria 
1 µL of DNA and 20 µL of cells were mixed and incubated on ice for 30 min. The 
cells were then heat shocked at 42 °C for 30 s, followed by a further incubation 
period on ice for 2 min. 250 µL of SOC medium was added after which the mixture 
was incubated in a shaker at 37 °C for 1 h. A portion of cell suspension was diluted 
1:1 with fresh SOC medium (100 µL cells + 100 µL SOC) and then streaked on an 
agar-amp plate and incubated overnight at 37 °C. 
 
III.2.2.2 Protein Manipulation 
III.2.2.2.1 Polyacrylamide Gel Electrophoresis (PAGE) of Proteins and Staining 
Protein samples were analysed by method of SDS-PAGE (X-Cell Sure Lock™, 
BioRad Power Pac Basic) which separates proteins according to size. For qualitative 
analysis of fractions after purification procedures, 5 µL was loaded in each well.  
2–5 µg were loaded for quantitative analysis of pure protein. The protein was mixed 
with Sample Buffer (4 × NuPAGE LDS Sample Buffer, Invitrogen) and diluted with 
H2O to a final volume of 20 µL. 1 µL -mercaptoethanol was added. The samples 
were thoroughly mixed and boiled at 100 °C for 5 min prior to loading. 5 µL protein 
marker (SeeBlue® Pre-Stained Standard, Invitrogen) was loaded in the outer lanes 
and 21 µL samples in subsequent lanes. NuPAGE MOPS SDS Running Buffer 
(Invitrogen) or NuPAGE MES SDS Running Buffer (Invitrogen) was used with 
NuPAGE 12% Bis-Tris gels (precast, Invitrogen or for self-made see (Table III-3). 
Electrophoresis was carried out at 195 V. 
For visualisation of proteins, gels were soaked in Coomassie Blue (Brilliant Blue G 
solution, Sigma) for 1 h and destained by soaking in Destaining Solution (25% (v/v) 
MeOH, 5% (v/v) CH3COOH) overnight. 
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Table III-3: Recipe for two 12% Bis-Tris gels 
The discontinuous SDS-PAGE method by Laemmli (Laemmli 1970; Sambrook and Russel 2001) 
exploits prior separation in a stacking gel (4%, top section of gel) before separation according to size 
in the resolving gel (12%, bottom section of gel). The composition of Bis-Tris gels is listed. 
 Resolving Gel (12%) [mL] Stacking Gel (4%) [mL] 
30% Acrylamide 6 0.667 
1.25 M Bis-Tris (pH 6.5) 4.300 1.428 
H2O 4.550 2.880 
10% APS 0.150 0.050 
TEMED 0.006 0.004 
 
III.2.2.2.2 Immunoblotting 
To visualise specific proteins, namely His6-tagged proteins which can be visualised 
with anti-His HRP antibody plus its substrate by means of enhanced 
chemoluminescence (ECL), the gel was subjected to a Western Blot following 
electrophoresis. 
Blotting filter paper (2 × 2.5 mm, Invitrogen) and nitrocellulose membrane (0.2 µm, 
GE Healthcare) were thoroughly soaked in Towbin Buffer (Table III-4D) for 
semi-dry blotting. They were then stacked on top of each other in the following order 
(from bottom to top): anode, blotting paper, membrane, gel, blotting paper, and 
cathode. A voltage of 20 V was applied over 27 min. After transfer of protein to the 
membrane, it was immersed in 10 mL 5% BSA in TBS-T (Table III-4D) at 4 °C 
overnight to block any non-specific binding sites. The membrane was then rinsed 
with TBS-T (10 mL, 3 × 5 min), incubated in a 1:4 000 antibody solution (10 mL 
TBS-T, 2.5 µL 4 mg mL-1 Anti-His HRP (HisProbe™-HRP, Thermo Scientific)) at 
room temperature and washed again with TBS-T (10 mL, 3 × 10 min). His6-tagged 
proteins were visualised by first covering the membrane with the detection solutions 
in a ratio of 1:40 (1 mL Solution A (ECL™ Plus substrate solution containing 
Tris Buffer) and 25 µL Solution B (acridan solution in dioxane and ethanol, both 
from ECL™ Plus Western Blotting Detection Reagents, GE Healthcare)), and placed 
it protein side up on the tray to expose it to light. Chemiluminescence was detected 
with Fujifilm LAS-3000. 
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III.2.2.2.3 Protein Concentration Determination 
Protein concentration of purified enzyme was determined with Lambert-Beer Law 
(see Equation III-1). The length of the cuvette was 1 cm. Absorbance was measured 
at 280 nm. The extinction coefficient, &, was predicted with ProtParam tool 
(http://www.expasy.org/tools/protparam.html).  
Protein concentration of impure samples was determined with the Bradford Assay 
(Bradford 1976). It was carried out with BioRad Protein Assay according to the 
manufacturer. BSA was used as a protein model to generate a standard curve of 
absorbance at 595 nm against the concentration from which the absolute protein 
concentration was determined. 
Equation III-1: Lambert-Beer Law     
 
III.2.2.2.4 Buffer Exchange and Concentration 
Buffer exchange and concentration were carried out in Vivaspin5 or 20 
(5 000 MWCO, 5 or 20 mL capacity, Sartorius Stedim Biotech) as appropriate. 
Samples were subjected to five cycles of concentration and re-suspension to ensure 
complete buffer exchange. 
Purified protein was dialysed into storage buffer (SPA buffer, Table III-4A), 
concentrated and stored at -20 °C. 
With regards to the possibility of aggregation, in early stage purification steps 
dialysis was performed using dialysis cassettes. The protein was injected into the 
chamber of the dialysis cassette (Slide-A-Lyzer Dialysis Cassette, 3 500 MWCO,  
3–12 mL capacity, Pierce) and dialysed into the appropriate buffer (3 × 2 L) for 1 h 
at 4 °C. 
 
III.2.3 Preparation and Purification of PfNMT (Small Scale) 
III.2.3.1 Overexpression of Plasmodium falciparum NMT 
The construct PfNMT-pTrcHisA was transformed into BL21(DE3) expression cell 
lines. A single colony of transformed cells was used to inoculate 5 mL LB-amp in a 
100 mL flask. After overnight incubation in a shaker at 37 °C, the cells from the 
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cloudy starter culture were harvested by centrifugation (4 000g, 15 min, 25 °C). The 
supernatant was discarded whereas the pellet was re-suspended in 2.5 mL fresh 
LB-amp. 
The cells were diluted further with fresh LB-amp (1:40 dilution, 2.5 mL cells per 
90 mL LB) in a 1 L flask and incubated in a shaker at 37 °C to mid-log phase 
(OD600 nm = 0.6). The culture was then split into falcon tubes (9 × 10 mL), 
appropriate amount of freshly prepared IPTG was added (see below) and incubated 
in a shaker at various temperatures (19 °C, 31 °C, 37 °C). 5 mL cells were harvested 
after 5 h and 19 h by centrifugation (4 000g, 30 min, 4 °C). The pellet was then 
re-suspended in PBS (HyQ PBS 0.0067 M, HyClone). After centrifugation (4 000g, 
60 min, 4 °C) the pellet was snap frozen with N2 (l) and stored at -80 °C. 
 
Final Concentration of IPTG Quantity Added to Culture 
1.0 mM 10 µL of 1 M IPTG stock in 10 mL culture (1:1 000 dilution) 
0.1 mM 10 µL of 0.1 M IPTG stock in 10 mL culture (1:1 000 dilution) 
0.01 mM 10 µL of 0.01 M IPTG stock in 10 mL culture (1:1 000 dilution) 
 
III.2.3.2 Sample Preparation 
The pellet was thawed on ice in 1 mL of cold Lysis Buffer (Table III-4A). The 
solution was vortexed until smooth. After 30 min incubation on ice, Triton X-100™ 
(Sigma) was added to a final concentration of 1% (10 µL 10% stock in 1 mL). The 
mixture was sonicated (10 × 3 s at 30% power with 3 s rest on ice), centrifuged 
(17 000g, 10 min, 4 °C), snap frozen with N2 (l) and stored at -20 °C. 
 
III.2.4 Preparation and Purification of PfNMT (Large Scale) 
III.2.4.1 Overexpression of Plasmodium falciparum NMT 
The construct PfNMT-pTrcHisA was transformed into BL21(DE3) expression cell 
lines. A single colony of transformed cells was used to inoculate 25 mL LB-amp in a 
100 mL flask. After overnight incubation in a shaker at 37 °C, the cells from the 
cloudy starter culture were harvested by centrifugation (4 000g, 15 min, 25 °C). The 
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supernatant was discarded whereas the pellet was re-suspended in 25 mL fresh 
LB-amp. 
The cells were diluted further with fresh LB-amp (1:40 dilution, 25 mL cells per 1 L 
LB) and incubated in a shaker at 37 °C to mid-log phase (OD600 nm = 0.6). Typically 
4 × 1 L culture was grown in 2 L flasks. Protein expression was induced by freshly 
prepared IPTG (Sigma) with a final concentration of 0.1 mM (1:10 000 dilution, 
100 µL 1 M IPTG in 1 L LB-amp). Cells were harvested after incubation in a shaker 
for 5 h at 30 °C by centrifugation (4 000g, 30 min, 4 °C). The pellet was 
re-suspended in PBS (HyQ PBS 0.0067 M, HyClone). After centrifugation (4 000g, 
60 min, 4 °C), the pellet was snap frozen with N2 (l) and stored at -80 °C. 
 
III.2.4.2 Purification of Plasmodium falciparum NMT 
The pellet was thawed on ice. 20 mL of cold Lysis Buffer (see Table III-4A) was 
added as well as a protease inhibitor cocktail tablet (complete, EDTA-free, Roche). 
The solution was vortexed at regular intervals until smooth. Lysozyme (from hen 
egg white, Fluka) was added to a final concentration of 1 mg mL-1 (30 mg in 30 mL). 
After 30 min incubation on ice, Triton X-100™ (Sigma) was added to a final 
concentration of 1% (3.2 mL 10% stock for 32 mL). The mixture was sonicated 
(8 × 30 s at 30% power with 30 s rest on ice). DNAaseI (Roche) was added to the 
viscous solution and incubated on ice for further 30 min. The now smooth mixture 
was centrifuged (18 000g, 45 min, 4 °C), the lysate (soluble fraction) filtered to 
remove debris (insoluble fraction) and subjected to three purification steps. 
III.2.4.2.1 Immobilised Metal Affinity Chromatography (IMAC) 
The His6-tagged protein was captured by immobilised Ni2+ (HisTrap™ HP, 1 mL, 
pre-packed Ni Sepharose™ High Performance, dynamic binding capacity 40 mg 
His6-tagged protein / mL medium) according to the protocol of the manufacturer 
using an ÄKTAFPLC system (flow rate, 1 mL min-1; pressure limit, 0.7 MPa). The 
lysate was loaded via a 50 mL superloop on IMAC Buffer A (see Table III-4A) 
equilibrated column. After 20 CV column wash, PfNMT was eluted by increasing 
the concentration of imidazole with IMAC Buffer B (see Table III-4A) from 20 mM 
to 1 M. The gradient employed was 0–50% in 10 CV, 50–100% in 5 CV, and 100% 
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for 2 CV. The fractions were analysed by SPA and SDS-PAGE, whereby active 
fractions were pooled, concentrated, filtered to remove debris and further purified. 
III.2.4.2.2 Size Exclusion Chromatography (SEC) 
The column (HiPrep™ 16/60 Sephacryl™ S-100) was used according to the protocol 
of the manufacturer on an ÄKTAFPLC system (flow rate, 0.5 mL min-1; pressure limit, 
0.5 MPa). Using a 2 mL loop, the concentrated fractions were loaded on the column. 
It was previously equilibrated with SEC Buffer (see Table III-4A). The fractions 
were analysed first by SPA, followed by analysis of the active fractions by 
SDS-PAGE. They were then pooled, concentrated, dialysed into IEX Buffer A (see 
Table III-4A), filtered to remove debris and further purified. 
III.2.4.2.3 Ion Exchange Chromatography (IEX) 
The final step of cation exchange chromatography was carried out using a 
Resource™ S column (6 mL, methyl sulfonate strong cation) according to the 
protocol of the manufacturer on an ÄKTAFPLC system (flow rate, 1.0 mL min-1; 
pressure limit, 1.5 MPa). Using a 2 mL loop, the concentrated fractions were loaded 
on the column. It was previously equilibrated with IEX Buffer A (see Table III-4A). 
After 20 CV column wash, PfNMT was eluted by increasing the concentration of salt 
with IEX Buffer B (see Table III-4A) from 25 mM to 1 M. The gradient employed 
was 0–15% in 20 CV, 15–60% in 10 CV, 60–100% in 15 CV, and 100% for 2 CV. 
The fractions were analysed first by SPA, followed by analysis of the active fractions 
by SDS-PAGE. They were then pooled, concentrated, dialysed into SPA Buffer (see 
Table III-4A), filtered to remove debris, aliquoted and stored at -20 °C. 
 
III.2.5 Preparation and Purification of Homo sapiens NMT1 and NMT2 
III.2.5.1 Overexpression of Homo sapiens NMT1 and NMT2 
Before the construct HsNMT1-pET-15b/HsNMT2-pET-15b was transformed into 
BL21(DE3) expression cell lines, the DNA was bulked up in a Miniprep. The 
plasmid HsNMT1-pET-15b/HsNMT2-pET-15b was transformed into DH5™ 
expression cell lines. 
1 µL of DNA and 20 µL of cells were mixed and incubated on ice for 30 min. The 
cells were then heat-shocked at 40 °C for 30 s, followed by a further incubation 
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period on ice for 2 min. 500 µL of SOC medium was added after which the mixture 
was incubated in a shaker at 37 °C for 1 h. A portion of cell suspension was diluted 
1:3 with fresh SOC medium (50 µL cells + 100 µL SOC) and then streaked on an 
agar-amp plate and incubated overnight at 37 °C. 
A single colony of transformed cells was used to inoculate 10 mL LB-amp. After 
overnight incubation in a shaker at 37 °C, the cells from the cloudy starter culture 
were harvested by centrifugation (4 000g, 15 min, 25 °C). The supernatant was 
discarded whereas the pellet was re-suspended in 10 mL fresh LB-amp. The bench 
protocol QIAprep Spin Miniprep Kit (Qiagen) was followed to isolate the plasmid 
DNA from the culture. 
1 µL of amplified pure DNA and 20 µL of BL21(DE3) cells were mixed and 
incubated on ice for 30 min. The cells were then heat-shocked at 42 °C for 30 s, 
followed by a further incubation period on ice for 2 min. 250 µL of SOC medium 
was added after which the mixture was incubated in a shaker at 37 °C for 1 h. A 
portion of cell suspension was diluted 1:1 with fresh SOC medium (100 µL cells + 
100 µL SOC) and then streaked on an agar-amp plate and incubated overnight at 
37 °C. 
A single colony of transformed cells was used to inoculate 10 mL LB-amp. After 
overnight incubation in a shaker at 37 °C, the cells from the cloudy starter culture 
were harvested by centrifugation (4 000g, 20 min, 25 °C). The supernatant was 
discarded whereas the pellet was re-suspended in 10 mL fresh LB-amp. 
The cells were diluted further with fresh LB-amp (1:100 dilution, 10 mL cells per 
1 L LB) and incubated in a shaker at 37 °C to mid-log phase (OD600 nm = 0.6). 
Protein expression was induced by freshly prepared IPTG (Sigma) with a final 
concentration of 0.05 mM (1:20 000 dilution, 50 µL 1 M IPTG in 1 L LB-amp). 
Cells were harvested after incubation in a shaker for 19 h at 15 °C by centrifugation 
(4 000g, 30 min, 4 °C). The pellet was re-suspended in PBS (HyQ PBS 0.0067 M, 
HyClone). After centrifugation (4 000g, 60 min, 4 °C), the pellet was snap frozen 
with N2 (l) and stored at -80 °C. 
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III.2.5.2 Purification of Homo sapiens NMT1 and NMT2 
The pellet was thawed on ice in 20 mL of cold Lysis Buffer (see Table III-4B). The 
solution was vortexed at regular intervals until smooth. The mixture was sonicated 
(8 × 30 s at 30% power with 30 s rest on ice). DNAaseI (Roche) was added to the 
viscous solution and incubated on ice for further 30 min. The now smooth mixture 
was centrifuged (15 000g, 30 min, 4 °C), the lysate (soluble fraction) filtered to 
remove debris (insoluble fraction) and subjected to two purification steps. 
III.2.5.2.1 Immobilised Metal Affinity Chromatography (IMAC) 
The His6-tagged protein was captured by immobilised Ni2+ (Ni-NTA agarose resin, 
Qiagen, dynamic binding capacity 5–10 mg His6-tagged protein mL-1 medium) 
according to the protocol of the manufacturer. 10 mL Ni-beads (50% suspension, in 
nitrilotriacetic acid and ethanol, 5 mL beads) were centrifuged (2 000g, 5 min, 4 °C) 
and washed 3 × 20 mL with IMAC Buffer A (see Table III-4B) before they were 
incubated with crude lysate for 45 min on a roller at 4 °C. The bead suspension was 
then transferred in a fritted polypropylene tube (5 mL, Qiagen) which has been 
cleaned with IMAC Buffer A. The beads were washed with 20 CV IMAC Buffer B 
(see Table III-4B) followed by 20 CV IMAC Buffer C (see Table III-4B). The target 
protein was eluted with 3 CV IMAC Buffer D (see Table III-4B). The sample was 
concentrated without further analysis, dialysed in IEX Buffer A (see Table III-4B), 
filtered to remove debris and further purified. 
III.2.5.2.2 Ion exchange chromatography (IEX) 
Anion exchange chromatography was carried out using a HiTrap™ Q HP (5 mL, 
pre-packed Q Sepharose™ High Performance, quaternary ammonium strong anion) 
according to the protocol of the manufacturer on an ÄKTAFPLC system (flow rate, 
3.0 mL min-1; pressure limit, 0.8 MPa). Using a 50 mL superloop, the lysate was 
loaded on the column. It was previously equilibrated with IEX Buffer A (see Table 
III-4B). After 10 CV column wash HsNMT was eluted by increasing the 
concentration of salt with IEX Buffer B (see Table III-4B) to 500 mM. The gradient 
employed was 0–100% in 40 CV and 100% for 2 CV. The fractions were analysed 
by SPA and SDS-PAGE, whereby active fractions were pooled, concentrated, 
dialysed into SPA Buffer (see Table III-4A), filtered to remove debris, aliquoted and 
stored at -20 °C.   
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Table III-4: Buffered solutions 
A list of all the buffered solutions employed in the expression and purification of (A) PfNMT, (B) 
HsNMT1 and HsNMT2, (C) other buffered systems is displayed. 
 Name of 
Buffers 
Components 
(A) Lysis Buffer 20 mM Na3PO4 pH 7.5, 500 mM NaCl, 20 mM imidazole, 5 mM DTT 
IMAC Buffer A 20 mM Na3PO4 pH 7.5, 500 mM NaCl, 20 mM imidazole, 5 mM DTT 
IMAC Buffer B 20 mM Na3PO4 pH 7.5, 500 mM NaCl, 1 M imidazole, 5 mM DTT 
SEC Buffer 100 mM Na3PO4 pH 7.0, 50 mM NaCl, 5 mM DTT 
IEX Buffer A 50 mM Na3PO4 pH 6.5, 25 mM NaCl 
IEX Buffer B 50 mM Na3PO4 pH 6.5, 1 M NaCl 
SPA Buffer 30 mM Tris/HCl pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA 
(B) Lysis Buffer 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.02 mM EDTA, 0.02 mM EGTA, 
1% Triton X-100, 0.06% -mercaptoethanol, 1 mM benzamidine, 0.2 mM 
PMSF 
IMAC Buffer A 50 mM Tris/HCl pH 7.5, 500 mM NaCl, 0.06% -mercaptoethanol, 1 mM 
benzamidine, 0.2 mM PMSF 
 IMAC Buffer B 50 mM Tris/HCl pH 7.5, 500 mM NaCl, 0.02 mM EDTA, 0.02 mM EGTA, 
20 mM imidazole, 0.06% -mercaptoethanol, 1 mM benzamidine, 0.2 mM 
PMSF 
 IMAC Buffer C 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.02 mM EDTA, 0.02 mM EGTA, 
0.06% -mercaptoethanol, 1 mM benzamidine, 0.2 mM PMSF 
IMAC Buffer D 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.02 mM EDTA, 0.02 mM EGTA, 
300 mM imidazole, 0.06% -mercaptoethanol, 1 mM benzamidine, 0.2 mM 
PMSF 
IEX Buffer A 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 0.1% -mercaptoethanol, 1 mM 
benzamidine, 0.2 mM PMSF 
IEX Buffer B 50 mM Tris/HCl pH 7.5, 500 mM NaCl, 0.1 mM EGTA, 0.1% 
-mercaptoethanol, 1 mM benzamidine, 0.2 mM PMSF 
(C) Towbin Buffer 12.5% 25 × Tris-Glycine Transfer Buffer (Novex®, Invitrogen), 10% MeOH 
 TBS-T Buffer 100 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20 
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III.3 Results 
III.3.1 Plasmodium falciparum NMT 
III.3.1.1 Optimised Overexpression of Recombinant Plasmodium falciparum NMT 
Previously-developed expression and purification procedures for Plasmodium 
falciparum NMT required optimisation due to unsatisfactory yields of 0.4 mg L-1 
(Bowyer 2006; Bowyer, Gunaratne et al. 2007). Invariable factors such as constructs, 
vectors, cell lines and growth media were already well researched by former lab 
member Dr P W Bowyer (Bowyer 2006). To improve expression in Escherichia coli 
by reducing the number of steps required for purification and maximising the yield 
of soluble, active protein, an optimum for IPTG, temperature and expression times 
were investigated.  
The employed vector system was pTrcHisA, which contained a T7lac promoter with 
neighbouring cDNA encoding for His6-tagged PfNMT. In the presence of lactose 
analogue IPTG, the lac repressor no longer prevents RNA polymerase from binding; 
a process of transcription of the gene to mRNA followed by translation to the 
encoded protein is induced. Three different concentrations of IPTG (1.0 mM, 
0.1 mM and 0.01 mM) were employed to explore optimum expression conditions 
(Table III-5). 
The second factor investigated was temperature. Whilst 37 ºC might be optimal for 
E. coli cell growth, it may result in the production of recombinant protein as 
aggregates called inclusion bodies. To increase the proportion of soluble protein, 
temperature is often lowered to e.g. 30 °C (Schein and Noteborn 1989). Further 
improvements may be achieved by means of prolonged induction at even lower 
temperatures (15 ºC – 20 ºC) to increase yields of soluble protein and obtain correct 
folding. Protein expression at three different temperatures (19 ºC, 31 ºC, 37 ºC) was 
examined (Table III-5). 
Two time points (5 h and 19 h) were chosen to test the influence of different levels 
of IPTG and incubation temperature to determine the optimum expression conditions 
for PfNMT in E. coli cells (Table III-5). 
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Table III-5: Optimisation procedure for the overexpression of PfNMT 
Combinations of various IPTG concentrations, incubation temperatures and expression times were 
examined to find improved reaction conditions that yield maximised soluble protein. 
 Variation 
Sets 
Original Expression Conditions  
(Bowyer, Gunaratne et al. 2007) 
Concentration of IPTG [µM] 1 0000 100 
 
100  
 
10  
 
  
Incubation Temperature [°C] 37 31 
 
31  
 
19  
 
  
Expression Time [h] 5 5 
 
19  
 
The PfNMT construct (donated by Dr A A Holder, National Institute of Medical 
Research, UK) was transformed into BL21(DE3) expression cell lines using standard 
procedures. After the culture has reached OD600 nm = 0.6, it was induced with three 
levels of IPTG (1.0 mM, 0.1 mM and 0.01 mM) and incubated at three temperatures 
(19 ºC, 31 ºC, 37 ºC). The samples were then either incubated for 5 h or 19 h 
expression time. Standard Lysis Buffer was used to partition the protein into soluble 
and insoluble fractions. It also contained a non-ionic detergent to solubilise cell walls 
and membrane components to release cellular proteins. Additionally, lysozyme and 
DNAase were necessary to maximise the amount of target protein in the soluble 
fractions as well as sonication procedures. It was furthermore found that DTT needs 
to be present at all times to prevent precipitation of the target protein. 
The experiment was carried out in duplicate. The soluble fractions were loaded on 
SDS-gels and stained with Coomassie Blue for comparative studies. Figure III-1A 
illustrates soluble fractions after 5 h incubation time, whereas isolated proteins from 
19 h incubation period are shown in Figure III-1B. The direct comparison to 
enriched PfNMT confirms the expression of PfNMT (Figure III-1C). 
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(A)  
(B)  (C)  
 
Figure III-1: Optimisation of expression conditions for PfNMT 
10 µg samples of protein were loaded per lane, separated by SDS–PAGE and visualised by 
Coomassie Blue stain (top) or Anti-His Western Blot (bottom). The protein expression after 5 h 
incubation time (A) was compared to 19 h expression period (B). Other variables included 
temperature (19 ºC, 31 ºC, 37 ºC) and IPTG concentration ((a) 1.0 mM IPTG, (b) 0.1 mM IPTG, (c) 
0.01 mM IPTG). A direct comparison of the soluble fractions with enriched PfNMT as a control, 
confirms expression of PfNMT (C).  
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The assessment of the level of overexpressed recombinant PfNMT was carried out 
with ImageJ (Figure III-2). The intensity of PfNMT bands in the Coomassie-stained 
SDS-PAGE gel were first normalised to the total amount of protein in the lane, 
followed by the intensity of the stain to enable direct comparison between all 
reaction conditions. Values were normalised to the maximum average. 
The results are presented in Figure III-3; a bar graph with the relative amount of 
PfNMT and error bars representing standard deviation. Nine expression conditions 
were compared for an incubation period of 5 h and 19 h. 
It was found that increased incubation time resulted in a higher production of 
PfNMT over time. No significant effects were found for different levels of IPTG in 
the experiment. A slight increase of PfNMT production was noted when IPTG was 
reduced from 1.0 mM to 0.1 mM for each temperature at 5 h incubation time (Table 
III-6A). However this trend was not followed with further decrease in IPTG to 
0.01 mM. Conversely, it seemed that a low amount of IPTG (0.01 mM) was 
favoured with longer incubation times (Table III-6B). 
The expression of PfNMT was also largely unaffected by the three chosen incubation 
temperatures (Table III-6). However, degradation was noticed at 37 °C. Protein 
production at 31 and 19 °C was satisfactory. 
Optimisation trials of PfNMT expression suggested higher production of target 
enzyme at long expression times (19 h) and ambient temperatures (19–31 °C). 
  
III NMT EXPRESSION, ISOLATION & ANALYSIS 
 
68 | P a g e  
 
(A)  
 
(B)  
 
Figure III-2: Analysis of PfNMT with ImageJ 
Intensity of protein bands was analysed with ImageJ Software (1.40g). The intensity of the PfNMT 
band (black triangle) was normalised to the loading of total protein (black rectangle) as well as the 
colour intensity of the gel to enable direct comparison between all conditions (A, B, Lane 2-10). 
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Figure III-3: Evaluation of expression levels in various conditions 
The intensity of normalised PfNMT bands was evaluated according to concentration of IPTG, 
incubation temperature and time. The bar graph compares nine different conditions with respect to 
incubation time of 5 h and 19 h. The values of each column are listed in the data table. 
 
Legend: 
1 – 1.0 mM IPTG, 37 °C  4 – 1.0 mM IPTG, 31 °C  7 – 1.0 mM IPTG, 19 °C 
2 – 0.1 mM IPTG, 37 °C  5 – 0.1 mM IPTG, 31 °C  8 – 0.1 mM IPTG, 19 °C 
3 – 0.01 mM IPTG, 37 °C  6 – 0.01 mM IPTG, 31 °C  9 – 0.01 mM IPTG, 19 °C 
 
Table III-6: Comparison of average expressed PfNMT 
This table lists the average amounts of expressed PfNMT from E. coli with regards to the incubation 
time 5 h (A) and 19 h (B). Data was taken from Figure III-3. 
 1.0 mM IPTG 0.1 mM IPTG 0.01 mM IPTG 
37 °C 0.76 0.86 0.76 
31 °C 0.66 0.71 0.92 
19 °C 0.77 0.78 0.62 
(A) 5 h 
 1.0 mM IPTG 0.1 mM IPTG 0.01 mM IPTG 
37 °C 1.00 1.07 1.14 
31 °C 1.03 1.05 1.08 
19 °C 1.06 0.98 1.23 
(B) 19 h  
1 2 3 4 5 6 7 8 9
5h 0.76 0.86 0.76 0.66 0.71 0.92 0.77 0.78 0.62
19h 1.00 1.07 1.14 1.03 1.05 1.08 1.06 0.98 1.23
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III.3.1.2 The Optimisation of Purification Methods for PfNMT 
For isolation of the target protein from a mixture of proteins, a single 
chromatographic step is rarely sufficient. Separate, sequential steps of different 
modes of separation are necessary. A purification protocol for PfNMT has 
previously been described; however, it involves a time-consuming procedure 
yielding low amounts of active protein, 0.4 mg L-1 (Bowyer, Gunaratne et al. 2007). 
It is a three-step procedure that includes immobilised metal affinity chromatography 
(IMAC, Figure III-4A), followed by size exclusion chromatography (SEC, Figure 
III-4B) and concludes with cation exchange chromatography (IEC, Figure III-4C). 
(A)
 
(B)
 
(C)
 
Figure III-4: Purification of PfNMT as optimised by Dr P W Bowyer 
The previously established three-step purification procedure for PfNMT is illustrated (Bowyer, 
Gunaratne et al. 2007). The target protein was enriched using a HisTrap column (A), a size exclusion 
column (B) and lastly a cation exchange column (C). Enzyme activity was tested in a scintillation 
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proximity assay (SPA) and is shown next to the chromatogram. Active fractions are highlighted in 
blue. The fraction number correlates to solvent volu
 
Optimisations were carried out to minimise the number of 
in an attempt to obtain larger amounts of active PfNMT
size exclusion chromatography reduced overall yields greatly
avoided if possible. The column has a small volume capac
the impure sample fractions needs to be concentrated significantly prior 
This may have cause
revised procedure the first stage remained 
Step 2 and Step 3 was investigated as well as different affinity columns to exploit 
chemical properties of the target and unwanted proteins 
analysed with the scintillation proximity assa
 
Figure III-5: Optimisation of the purification procedure for PfNMT
A scheme of different chromatographic columns for the second purification step in an effort to 
eliminate a third step and thus maximise yield
bold (Bowyer, Gunaratne et al. 2007)
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The batch purification was followed by ion exchange chromatography, where the pI 
of PfNMT is an important factor in deciding which column type is appropriate 
(Table III-1). The lysate was either purified on a cation exchange column at pH 6.5 
(Figure III-7) or on an anion exchange column at pH 7.5 (Figure III-8). As expected, 
most of the target protein, with a calculated pI of 8.40, bound to the cation exchange 
column (Figure III-7B). PfNMT was eluted with increasing salt gradient. The anion 
exchange chromatography resulted in PfNMT in the flowthrough as well as bound to 
the column (Figure III-8C). Unbound target protein was pure and did not have to be 
subjected to a third purification step, unlike bound PfNMT. The final 
chromatographic procedure carried out was size exclusion (Figure III-8B). 
As listed in Table III-7, initial batch purification with a HisTrap column removed 
roughly 99% of total protein. IMAC purified sample was subjected to either cation or 
anion exchange chromatography, of which cation IEX resulted in the highest amount 
of enriched PfNMT with 1.0 mg L-1 total yield. Purification with the latter system 
yielded less protein, 0.7 mg L-1 total yield, due to a necessary third purification step.  
 
 
Table III-7: Analysis of yields of PfNMT after each purification step 
The total amount of protein for each step is listed in the table. It was calculated after each 
purification step according to the absorption at 280 nm. The value for the crude was estimated. 
* purity estimated from intensity of protein band in Coomassie-stained SDS-PAGE gels (with ImageJ) 
  
Total Protein After 
Expression 
Total Protein 
After IMAC 
Total PfNMT After 
Cation IEX 
Total PfNMT After 
Anion IEX(and SEC) 
612 mg 
(for 2 L culture) 
 
Crude 
5.1 mg 
(for 2 L culture) 
 
~72% pure* 
0.95 mg 
(yield: 1.0 mg L-1) 
 
>95% pure* 
0.95 mg 
(yield: 0.7 mg L-1) 
 
>95% pure* 
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(A) 
 
(B) 
 
(C) 
 
 
Figure III-6: Step-by-step analysis of PfNMT purification - Step 1 
This figure show details of the IMAC purification of crude lysate. Batch purification of the lysate was 
carried out with a HisTrap column. Chromatogram (A) shows the purification of PfNMT and (B) 
additional purification attempts of the flowthrough. Activity of the enzyme was tested with the SPA 
(Chapter V, p. 121). Active enzyme fractions are highlighted in blue. The SDS-PAGE gel (C) was 
used to analyse the protein composition after each step. 5 µg samples of protein were loaded per lane 
and the gel was developed with Coomassie Blue stain (top) or anti-His Western Blot (bottom). 
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(A) 
 
 
(B) 
 
 
Figure III-7: Step-by-step analysis of PfNMT purification - Step 2a (cation exchange) 
This figure shows ion-exchange chromatography of the IMAC-purified material. With pH of 6.5, it 
was loaded on to a cation exchange column (A). The activity of the enzyme was tested with the SPA 
(Chapter V, p. 121). Active enzyme fractions are highlighted in blue. The SDS-PAGE gel (B) was used 
to analyse the protein composition after each step. 5 µg samples of protein were loaded per lane and 
the gel was developed with Coomassie Blue stain (top) or anti-His Western Blot (bottom). 
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(A) 
 
 
(B) 
 
 
(C) 
 
 
Figure III-8: Step-by-step analysis of PfNMT purification - Step 2b (anion exchange) 
This figure shows ion-exchange chromatography of the IMAC-purified material. With pH of 7.5, it 
was loaded on an anion exchange column (A). PfNMT that bound to the column was subsequently 
enriched on a size exclusion column (B). The activity of the enzyme was tested with the SPA 
(Chapter V, p. 121). Active enzyme fractions are highlighted in blue. The SDS-PAGE gel (C) was 
used to analyse the protein composition after each step. 5 µg samples of protein were loaded per lane 
and the gel was developed with Coomassie Blue stain (top) or anti-His Western Blot (bottom). 
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III.3.2 Homo sapiens NMT 
Isoforms of two distinct families of Homo sapiens NMT, HsNMT1 and HsNMT2, 
were expressed and enriched for in vitro assays to determine specificity of the 
inhibitors that are ideally selective for PfNMT over the human analogue.  
Initially, His6-tagged HsNMT1 and HsNMT2 plasmids in a pET-15b vector system, 
(kind donations from Dr S McElroy (Drug Discovery Unit, University of Dundee, 
UK)) were amplified and transformed into DH5™ expression cell lines before 
insertion into E. coli BL21(DE3) cells. 
Protein purification was carried out according to methods established by 
Dr S McElroy which involved initial batch purifications with an immobilised 
Ni2+ column followed by an anion exchange column. Fractions of the final 
purification step were analysed by SPA to determine NMT activity (Chapter V, 
p. 121), from which active fractions were pooled to use in the inhibition assays. 
Figure III-9 demonstrates the IEX step for HsNMT2 (A) and SPA analysis (B). 
Figure III-10 shows Coomassie-stained SDS-PAGE gels of all purification stages for 
the enrichment of HsNMT1 and HsNMT2. 
The yield of HsNMT1, which has an approximate size of 56 kDa, was 1.5 mg L-1 
using a 3 L E. coli culture (Figure III-10A). Under equivalent conditions, HsNMT2 
yielded 0.6 mg L-1 from E. coli (Figure III-10B). The approximate size was also 
56 kDa. The His6 tag was still present for both human NMTs as can be seen in the 
anti-His Western blot (Figure III-10).  
 
 
(A)      (B) 
Figure III-9: Human NMT protein purification 
The chromatogram displays the 2nd purification step (A), the anion exchange chromatography of 
HsNMT2. The blue highlighted area represents active enzyme which was determined in the SPA (B). 
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(A)  (B)  
Figure III-10: SDS-PAGE analysis of purification stages of HsNMT1 and HsNMT2 
The SDS-PAGE gels show the purification procedure of HsNMT1 (A) and HsNMT2 (B) expressed 
from E. coli in two steps. Legend: (1) Lysate prior to any purification, (2) eluent after IMAC, (3) 
enriched enzyme after IEX, (4) Western Blot with Anti-His stain. Lane 1-3 were visualised with 
Coomassie stain. 5 µg samples of protein were loaded per lane. 
 
 
III.3.3 Candida albicans NMT 
Dr P W Bowyer kindly donated purified Candida albicans N-myristoyl transferase 
(Figure III-11). The construct used to overexpress CaNMT in E. coli was pET11c. 
Colonies, grown on amp-agar, were transformed into BL21(DE3) expression cell 
lines using standard procedures. Conditions for overexpression were 5 h incubation 
period at 37 ºC, followed by harvest, cell lysis and purification over an anion 
exchange column (Bowyer 2006). 
 
 
Figure III-11: SDS-PAGE analysis of enriched CaNMT 
The Coomassie-stained SDS-PAGE gel verifies enriched CaNMT, 5 µg sample of protein was loaded. 
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III.3.4 Leishmania major NMT 
Purified N-myristoyl transferase of Leishmania major (Figure III-12) was kindly 
donated by Prof D F Smith (Department of Biology, University of York, UK). 
Colonies of LmNMT plasmid pET15b in BL21(DE3) were grown on kanamycin-
agar, overexpressed in LB medium and subsequently purified (Rein 2008). 
 
  
Figure III-12: SDS-Page analysis of enriched LmNMT 
The Coomassie-stained SDS-PAGE gel confirmed enriched LmNMT, 5 µg protein was loaded. 
 
 
III.4 Conclusion and Discussion 
The main objective of this chapter was to express and purify Plasmodium falciparum 
N-myristoyl transferase for the analysis of potency of synthesised potential 
antimalarials. A published protocol was followed but was found to yield low 
amounts of protein (Bowyer, Gunaratne et al. 2007). Small-scale experiments were 
set up to increase the level of recombinant protein and to reduce the number of 
purification steps involved.  
Expression of soluble protein is dependent on various factors; incubation period, 
temperature and concentration of expression inducer IPTG were varied. Small-scale 
experiments showed that overexpression of PfNMT was greatly amplified when the 
expression time was increased from original 5 h to 19 h incubation period. A 
temperature of 31 °C and 0.1 mM of IPTG were found to work well in combination 
with 19 h incubation period to produce large amounts of PfNMT.  
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Not only could the level of expression of recombinant protein be increased, 
importantly the three-step purification procedure was reduced to a two-step 
enrichment by elimination of gel filtration chromatography which accounted for a 
large loss in protein yield. The initial purification step was metal chelate affinity 
chromatography (1 mL, HisTrap column) because the protein was His6-tagged. This 
largely removed proteases, non-protein material and untagged endogenous proteins 
from bacteria out of the mixture and also reduced the volume for subsequent steps. 
The second purification step was carried out with cation exchange chromatography 
(Resource S) with yields of enriched PfNMT, 1.0 mg L-1. Purification trials with an 
anion instead of cation exchange column yielded similar amounts; however, a third 
step, gel filtration, was necessary.  
Expression protocols from E. coli as well as purification procedures were 
significantly improved to enhance yields for PfNMT from 0.4 mg L-1 to 1.0 mg L-1. 
Not only was the analysis of potency of inhibitors against PfNMT important, but 
also the activity against human NMT. HsNMT1 and HsNMT2 were expressed and 
enriched to test PfNMT inhibitors for potency and selectivity against the human 
enzyme. Yields of 1.5 mg L-1 HsNMT1 and 0.6 mg L-1 HsNMT2 were attained. 
For additional in vitro testing of potential inhibitors against other organisms, stocks 
of N-myristoyl transferase of Candida albicans and Leishmania major were used 
from Dr P W Bowyer and Prof D F Smith respectively (Bowyer 2006; Rein 2008). 
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IV SYNTHESIS OF ANTIMALARIAL AGENTS 
 
IV.1 Introduction 
A small collection of the best inhibitors against CaNMT, the “ Pfizer series” , was 
supplied to our research group and tested for activity against Plasmodium falciparum 
NMT (Bowyer 2006). The most active compounds showed potency in the low 
micromolar region; UK-370,509 was selected as the lead inhibitor with 30 µM 
activity in vitro against PfNMT. The structure of UK-370,509 can be segmented into 
three main parts (Figure IV-1). The benzothiazole scaffold (Section C) was to remain 
constant throughout the studies in this thesis. Variations in structure could be 
achieved from the C6-position of the benzothiazole unit and from reactions with the 
N-terminus of the aminobenzothiazole. Building block B, an amino acid analogue, 
was attached via the formation of an amide bond. Unit A was connected to B via the 
formation of a 2° amine bond. 
 
 
Figure IV-1: Segmentation of the lead compound into three main parts (A, B and C) 
 
C B A
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As seen below, there is some information that the C6-position may be crucial for the 
selectivity of N-myristoyl transferase across organisms. Small-sized substituents 
such as a fluorine-atom or hydrogen in the C6-position showed greater activity 
against PfNMT than larger substituents such as pyridine or dimethylamide (Figure 
IV-2). Activity against human NMT was 10-fold lower for UK-370,509 and 
UK-370,713. However, a pyridine group in that position greatly increased activity 
against human NMT for UK-370,710; the compound inhibited human NMT four 
times stronger than PfNMT (Figure IV-2). The substituent presumably underwent 
interactions with surrounding amino acids in the peptidic binding pocket of human 
NMT, such as hydrogen bonding, favouring tighter binding of the inhibitor. Due to 
time contraints, Section A and B were the main focus of this library. 
 
 
Figure IV-2: Comparison of selectivity of inhibitors with different building blocks D 
The compounds were tested for potency against PfNMT and for selectivity over human NMT in an in 
vitro assay (Bowyer 2006). The lead compound was compared to analogues with differing units D, 
colour-coded in red. 
 
  
31 
32 
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Further investigations examined the orientation of substituents of building block B. 
Structures investigated by Pfizer consisted of two types: disubstituted cyclohexane 
and the open-chain equivalent. There is some evidence that indicated rigidity of the 
ring structure is essential for potency (Pfizer, unpublished data). Variations to the 
cyclohexane were achieved by the positioning of the amine and carboxylic acid 
functionalities; either in 1,3- or 1,4-position and trans or cis orientated (Figure IV-3). 
There are gaps in the “ Pfizer series” , but Figure IV-3 proposes the significance of the 
orientation of substituents with regards to activity against PfNMT. The additional 
CH2-group, to distance the peptide bond from the amine bond, did not seem to 
increase activity for UK-362,091 compared to UK-370,753. In fact, the activity was 
reduced 10-fold. Perhaps the additional CH2-group has to change the orientation of 
the 2° amine moiety in the peptidic binding pocket. 
 
Figure IV-3: Comparison of IC50 data against PfNMT with varying building block B 
IC50 data of selected compounds from the “Pfizer series” with different orientations of substituents, 
colour-coded in red (Bowyer 2006). 
31 
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There were a number of different building blocks A in the “ Pfizer series”  with 
characteristics such as aromaticity, the inclusion of heteroatoms and halogens 
(Figure IV-4). Results demonstrated an increase of activity against PfNMT with 
additional heteroatoms and halogens in the aromatic ring system (UK-372,699 vs. 
UK-370,753) but their orientation was essential for significant activity (UK-370,627 
vs. UK-370,624). 
This chapter describes the synthesis of potential antimalarial compounds with 
variations in building blocks A and B, to discover high potency against Plasmodium 
falciparum NMT and in addition good selectivity over human NMT. 
 
Figure IV-4: Comparison of IC50 data against PfNMT with varying building block A 
IC50 data of selected compounds from the “Pfizer series” with differing units A were analysed and 
compared to UK-370,753 which is nearly as potent as lead compound UK-370,509 (Bowyer 2006). 
Changes from UK-370,753 are colour-coded in red.  
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IV.2 Material and Methods 
IV.2.1 Chemicals and Reagents 
Solvents and reagents were obtained from commercial sources (Sigma-Aldrich, 
NovaBiochem, Neomps, J. T. Bruker, Merck, BDH). Ultrapure laboratory grade 
water was obtained from in-house Elix® and MilliQ® millipore water purification 
systems. 
 
IV.2.2 Methods and Equipment 
Unless otherwise stated, all reactions were carried out in anhydrous solvents and in 
an inert atmosphere of nitrogen with standard Schlenk techniques. Elevated 
temperatures were maintained in thermostat-controlled oil baths. Organic solutions 
were concentrated in vacuo using a rotary evaporator (Heidolph Rotavapor R110) 
with a diaphragm vacuum pump (Büchi Vac® V-500). Lyophilisation was performed 
on a Christ Alpha1-4 freeze drier. 
pH was measured with a Hanna Instrument 8519 digital pH meter, which was 
calibrated with BDH colour key buffer solutions at pH 4 and pH 7. Centrifugation 
was performed with a Jouan BR4 i centrifuge at 5 000 rpm for 5 min. 
Reactions were followed by means of TLC where the reaction mixture was spotted 
on aluminium-coated TLC-plates (Merck, Si60, F254) and visualised under UV-light 
(BDH UV spectrometer), using acidic p-anisaldehyde followed by heating as 
required. 
Flash column chromatography was carried out on BDH silica gel (Si60, 33–70 7m). 
An alternative method of compound purification and analysis was RP-HPLC. 
Compound purification was performed on a preparative HPLC from Gilson (column 
specifications: ACE, 5 µM, C18, 250 × 21.2 mm, ACT) and compound analysis with 
an analytical HPLC from Gilson (column specifications: ACE, 5 µM, C18, 
250 × 4.6 mm, ACT). UV detection was set at 220 nm (Gilson 155 UV/Vis detector, 
Anachem). The solvent system employed a gradient of ACN (+ 0.1% TFA) in H2O 
(+ 0.1% TFA). The purity of compounds was determined by NMR, IR, accurate 
mass spectroscopy, TLC and HPLC. 
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For structural characterisation of synthesised compounds, one-dimensional 1H- and 
13C-NMR spectra, as well as two-dimensional NMR spectra were recorded on 
Bruker AV spectrometer at 300, 400, 500 MHz or 75, 100, 125 MHz respectively. 
NMR spectroscopy at 500 and 125 MHz were carried out by P R Haycock and 
D Sheppard at the departmental NMR Service (Imperial College London). The 
internal references were either CDCl3 (H = 7.26 ppm, C = 77.23 ppm), DMSO-d6 
(H = 2.50 ppm, C = 39.51 ppm), MeOH-d4 (H = 3.31 ppm, C = 49.10 ppm) or 
DMF-d7 (H = 8.03 ppm). The average temperature upon recording was 25 °C 
(300 K). DEPT135, COSY and HMQC-NMR spectroscopy were used as a guide to 
assign signals in 1H and 13C-spectra. Chemical shifts, , are reported in units of ppm 
and coupling constants, J, in Hz. 
Compounds were also analysed with a Fourier transform infra-red (FT-IR) 
spectrophotometer. Crystalline material was deposited on the diamond of the 
Universal ATR accessory of a PerkinElmer Spectrum 100 FT-IR spectrophotometer. 
The IR spectra were then analysed with Spectrum Express, Version 1.01.00 
(PerkinElmer). Abbreviations in assignments are as follows: s – strong, m – medium, 
w – weak, br – broad, sh – sharp. 
Mass analysis was executed on an AUTOSPEC P673 spectrometer by J Barton at the 
departmental Mass Spectrometry Service (Imperial College London). Unless 
otherwise stated, nominal and accurate mass analysis using electronic ionisation (EI) 
was obtained. 
Three melting point apparatus have been employed for the determination of melting 
points of compounds: Griffin and Gallenkamp (Sanyo). OptiMelt (Automated 
Melting Point System) from Stanford Research Systems was also used with a 
temperature accuracy of ± 0.3 °C (up to 100 °C) and ± 0.5 °C (up to 250 °C). 
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IV.2.3 Common Synthetic Protocols 
Below is a list of general procedures that were carried out in this project. Detailed 
synthesis for each compound as well as a complete characterisation is outlined in the 
Appendix (VIII.1, p. 193). 
 
IV.2.3.1 General Method for the Boc-Protection of Primary Amines 
To a stirred solution of amine (1.0 eq.) and NEt3 (6.0 eq.) in MeOH, with a final 
amine concentration of 1 M, was added dropwise di-tert-butyl dicarbonate in 
methanol (2.1 eq.) after which the reaction mixture was heated at 60 °C. After 18 h 
at 60 °C the reaction mixture was filtered and all volatiles removed in vacuo. The 
residual yellow oil was dissolved in 2% NaHCO3 (aq) (50 mL) and washed with 
hexane (3 × 50 mL). The aqueous phase was acidified with cold 1 M HCl (aq) to 
pH 2–3 upon which precipitation occurred. The aqueous phase was then extracted 
with EtOAc (3 × 50 mL), the organic phases combined, dried (MgSO4), filtered and 
the solvent removed in vacuo to yield the boc-protected product (Ho, Michael Crider 
et al. 2001). 
 
IV.2.3.2 General Method for Boc-Deprotection 
The Boc-group was cleaved in TFA–H2O–TIPS (90:5:5, V:V:V, 20 eq. TFA). After 
1 h no further evolution of gas was observed. Cold Et2O was added until 
precipitation occurred (approximately 1:10, V:V, reaction mixture:Et2O). Precipitate 
was collected by means of centrifugation, washed with cold Et2O (3 × 2 mL), and 
dried in vacuo to yield the desired product as a TFA salt (Yoshida, Hayakawa et al. 
2005). 
 
IV.2.3.3 General Method for Peptide Bond Formation 
To a stirred solution of carboxylic acid (1.0 eq.) in DMF, with a final concentration 
of 0.5 M, were added amine (1.1 eq.), PyBOP (1.1 eq.) and DIPEA (2.0 eq.) at 0 °C. 
It was warmed to RT after 10 min on ice. After a couple of hours reaction time, the 
reaction mixture was diluted with DCM (90 mL), washed with 1 M HCl (aq) 
(3 × 100 mL), H2O (3 × 100 mL), brine (1 × 100 mL), dried (Na2SO4), filtered and 
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all volatiles removed in vacuo. The crude was either purified by precipitation or 
purified over silica (Li 2001).  
 
IV.2.3.4 General Method for Reductive Amination 
To a stirred solution of the 1° amine TFA salt (1.0 eq.), anhydrous NEt3 (2.0–2.2 eq.) 
and activated molecular sieves in anhydrous DMF, with a final amine concentration 
of 0.2 M, was added the aldehyde (1.0–2.0 eq.). After 1 h NaBH(OAc)3 (2.0–4.0 eq.) 
was added. After overnight reaction, the reaction mixture was quenched with 
2% NaHCO3 (aq) (10 mL) and washed with DCM (3 × 10 mL). The combined 
organic phases were extracted with H2O (3 × 30 mL), brine (1 × 20 mL), dried 
(MgSO4), filtered, and the solvent removed in vacuo to give the crude. Further 
purification was performed on HPLC to yield the desired product as a TFA salt 
(Abdel-Magid, Carson et al. 1996; Yamazaki, Kaneko et al. 2005). 
 
IV.2.3.5 General Method for the Acetylation of 2° Amines 
First, the free base was generated upon the addition of NEt3 (1.0 eq.) to the 2° amine 
(1.0 eq.) under stirring. Acetylating reagent was added and stirred for 1 h. All 
volatiles were removed in vacuo to give the crude product. Further purification was 
performed on HPLC to yield the desired product. 
 
IV.2.3.6 General Method for Alkylation of 2° Amines 
To a stirred solution of 2° amine TFA salt (1.0 eq) and NEt3 (2.2 eq.) in DCM, with 
a final amine concentration of 0.1 M, was added halide alkylation reagent (1.0 eq.). 
The reaction mixture was diluted with DCM (90 mL), washed with 1 M HCl (aq) 
(3 × 100 mL), H2O (3 × 100 mL), brine (1 × 100 mL), dried (Na2SO4), filtered and 
all volatiles were removed in vacuo. The crude product was either purified over 
silica or with preparative HPLC. 
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IV.3 Results 
IV.3.1 Synthesis of the Lead Compound 
The first task was to re-synthesise UK-370,509 from the “ Pfizer series” , the lead 
compound for the current studies (Compound 31) (Figure II-15). Retrosynthetic 
analysis discriminated between two major bonds, highlighted in Figure IV-5A. The 
amide bond can be created with standard peptide coupling conditions. Synthesis is 
very straightforward between a primary amine and an activated carboxylic acid in a 
basic environment (Figure IV-5B). The 2° amine bond, however, can be synthesised 
in several ways. Alkylation of a primary amine is not a preferred option as the 
reaction occurs quickly and uncontrollably; dialkylation is difficult to prevent. A 
better route is reductive amination, whereby the primary amine reacts with an 
aldehyde to form the intermediate hemiaminal which dehydrates to form an imine. 
The unstable species is readily reduced by metal hydrides to a secondary amine 
species (Figure IV-5C). 
 
(A)  
(B)  
(C)  
Figure IV-5: Analysis of the lead compound 
The retrosynthetic analysis of UK-370,509 (A) revealed two linkages: a peptide bond (1.) and an 
amine bond (2.). The peptidic coupling occurs between the lone pair on the nitrogen that attacks the 
activated carboxylic acid to form a stable amide bond (B). Reductive amination is a two-step process 
whereby an imine is formed and subsequently reduced with a metal hydride reagent to form a 
secondary amine (C). 
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The solution phase synthesis of 35 was successful. Figure IV-6 outlines the four-step 
synthesis. Initially, the N-terminus of building block B, cis-1,4-aminocyclo-
hexanecarboxylic acid, was Boc-protected. The reaction was performed with Boc 
anhydride under standard Boc-protecting methods with good yields of 70%. The 
peptidic coupling step between the N-terminus of 2-aminobenzothiazole and the 
C-terminus of 36 was carried out with PyBOP as the activating reagent and gave 37 
in a 90% yield. Optimisation trials of amide bond formation for building up the 
library will be discussed in IV.3.2.2 (p. 93). Prior to the final reductive amination 
step, the N-terminus was deprotected under strong acidic conditions. The resulting 
salt was reacted with aldehyde to form an imine in situ, which was then reduced to a 
secondary amine, which gave 35 in a 60% yield. Again, optimisation procedures of 
each individual step are discussed in the following subchapters. On the whole, the 
four-step synthetic route of the lead compound was quite successful and resulted in 
an overall yield of 40%. 
 
 
Figure IV-6: Synthetic route to lead compound 35 
Reagents and reaction conditions: (i) Boc2O, NEt3, MeOH, 60 °C, 12 h, 70% yield; (ii) 
2-aminobenzothiazole, PyBOP, DIPEA, DMF–DCM, 0 °C, 12 h, 90% yield; (iii) TFA–TIPS–H2O 
(18:1:1, V:V:V), 79% yield; (iv) 2-naphthaldehyde, NaBH(OAc)3, NEt3, DCE, 12 h, 60% yield. 
 
The reaction was followed by NMR spectroscopy. Figure IV-7 displays NMR data 
of each intermediate of the synthetic route to synthesise 35. Key protons were 
labelled as follows: a – C(CH3)3, b – CHNH, c – CHNH, d – CHCOO. The first 
major shift is the CHCOOH proton (d) in the peptidic coupling step; it shifts quite 
far upfield from 3.4 ppm to 2.8 ppm. The aromatic benzothiazole protons are very 
well resolved as two doublets and two triplets in the area of 7–8 ppm. The chemical 
shift of the methyl protons of the tert-butyl group (a) typically at 1.3 ppm were no 
38 
36 37 
35 
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IV.3.2 The Design of Building Block B 
Utilised building blocks B were amino acid analogues (Figure IV-8). Unnatural 
amino acids such as aminocyclohexylcarboxylic acids were examined with a focus 
on cis-1,4- and cis-1,3-aminocyclohexylcarboxylic acid (Figure IV-8A and B). To 
investigate the importance of building block A with regards to inhibition of PfNMT, 
compound RCB was synthesised as a control. For this case, cyclohexylcarboxylic acid 
and cyclohexylacetic acid (Figure IV-8D and E), derivatives of aminocyclo-
hexylcarboxylic acid that lack amino functionalities for further coupling reactions, 
were employed. Another option for building block B was proline as L-proline is a 
natural amino acid and thus readily available for purchase (Figure IV-8C). 
Five-membered rings have not (to our knowledge) been investigated by Pfizer, but 
data from other research groups suggest that size of block B is not important for 
activity of compounds; rather it seems to act as a spacer for substituents, which in 
turn interacts with amino acids in the target binding domain (Yamazaki, Kaneko et 
al. 2005). Also, both substituents (N- and C-terminus) have a completely different 
orientation compared to the disubstituted cyclohexyl building blocks. The dimension 
of the peptide binding site could be explored by variations in position of the two 
substituents RA and RC. 
 
 
(A)    (B)    (C)    (D)    (E)  
Figure IV-8: Proposed building blocks B 
A selection of cyclohexyl- and cyclopentyl analogues was studied as building block B, namely cis-1,4-
aminocyclohexylcarboxylic acid, cis-1,3-aminocyclohexylcarboxylic acid, L-proline, cyclohexyl-
carboxylic acid and cyclohexylacetic acid (from left to right). 
 
The proposed scheme to make lead compound analogues is pictured in Figure IV-9. 
The N-terminus of building block B was protected (Step 1) prior to the coupling step 
B


 

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of the carboxylic acid functionality and the amine of component C (Step 2). Once the 
protecting group of the N-terminus of unit B was removed (Step 3), building block A 
was attached in a reductive amination step (Step 4a) for 1° amines or via alkylation 
for 2° amines (Step 4b). Each individual step is discussed in the following 
subchapters. 
 
 
Figure IV-9: Proposed synthetic reaction scheme 
Unprotected amine functionalities of building block were protected (Step 1) prior to coupling to 
building block C under standard peptide coupling conditions (Step 2). After deprotection of the 
N-terminal protecting group (Step 3), the amine was coupled to building block A (Step 4). Reductive 
amination was employed with 1° amines; however, alkylation was performed on 2° amines. 
 
IV.3.2.1 Step 1: N-Terminal Protecting Groups 
Any free amine groups that were not desired to react with the C-terminus of the 
carboxylic acid moiety of unit B were protected prior to peptide bond formation 
between RC and RB. The tert-butoxycarbonyl (Boc) group was chosen because of its 
stability towards catalytic hydrogenolysis and most basic and nucleophilic reagents 
(Greene and Wuts 1999). The reaction mechanism is displayed in Figure IV-10. 
 
 
Figure IV-10: Mechanism of Boc-protection 
Boc-protected amines are generated under aqueous conditions with base and Boc
 
anhydride. 
 
Boc-protection was performed under standard conditions (IV.2.3.1, p. 86). The 
generation of Boc-protected amines was achieved with a base and Boc anhydride 
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under aqueous conditions in moderate yields of 60% for 36 (Castonguay, Lherbet et 
al. 2002). Boc-protected cis-1,3-aminocyclohexanecarboxylic acid and L-proline 
were commercially available. 
 
 
Figure IV-11: Boc-protection (formation of 36) 
Reagents and reaction conditions: (i) Boc anhydride, NEt3, MeOH, 60 °C, 12 h, 60% yield 
(Castonguay, Lherbet et al. 2002) 
 
IV.3.2.2 Step 2: Amide Bond Formation 
Peptide bond formation between the N-terminus of aminobenzothiazoles and the 
C-terminus of cyclohexyl derivatives was aided by activating reagents to create an 
activated ester. A much more electropositive carbon atom favours the nucleophilic 
attack of the nitrogen atom. There are various ways for the conversion of carboxylic 
acids into activated esters, of which some were examined (Reviews: (Albericio and 
Carpino 1997; Han 2004; Katritzky, Suzuki et al. 2004; Montalbetti and Falque 
2005; Valeur and Bradley 2009)). The carboxylic acid was converted either into acyl 
halides, mixed anhydrides or esters. All activated reagents were made in a separate 
step, followed by the immediate treatment with the amine species to form a peptide. 
 
IV.3.2.2.1 Acyl Halides 
Central reaction partners to form amide bonds are functional groups that exhibit 
strong electron-withdrawing effects, such as halogens. The conversion of carboxylic 
esters to acyl halides may be achieved with reagents such as thionyl chloride or 
oxalyl chloride in a nucleophilic addition elimination reaction (Montalbetti and 
Falque 2005). The carbonyl group of the acyl halide is more susceptible towards 
nucleophiles due to the electron-withdrawing effect of the electronegative halogen. 
The formation of the peptide bond proceeds via the nucleophilic attack of the amine 
at the carbonyl (displayed in Figure IV-12). The reaction with acyl chloride and 
aminobenzothiazole, Figure IV-13, yielded 39 in moderate yields of 78% (Yoshida, 
36 
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Hayakawa et al. 2005). Peptide bond formation with acyl chlorides or other acyl 
halides was not carried out with more building blocks B; these were not readily 
available commercially. Although acyl halides are one of the easiest to produce 
activated esters with, there are drawbacks due to easy hydrolysis and racemisation 
via ketene formation (Montalbetti and Falque 2005). For this reason, other activating 
reagents were investigated. 
 
 
Figure IV-12: Reactions with acyl halides 
A peptide bond can be formed easily when a nucleophilic amine reacts with an activated ester such as 
an acyl halide (X = halogen) (Montalbetti and Falque 2005). 
 
 
Figure IV-13: Synthesis of 39 
Reagents and reaction conditions: (i) 4-pyrrolidine-pyridine, DMF, RT, 12 h, 78% yield (Yoshida, 
Hayakawa et al. 2005). 
 
IV.3.2.2.2 Esters 
An alternative halogenic activating reagent was pentafluorophenol (Kisfaludy, Löw 
et al. 1973; Carey, Bordas et al. 1997; Kaplan and McGrath 1997; Rajappan and 
Hosmane 1998; Montalbetti and Falque 2005). It absorbs strongly in the UV region 
and the reaction can thus be readily tracked by TLC. The suggested reaction 
mechanism with pentafluorophenyl trifluoroacetate (Pfp TFA) is outlined in Figure 
IV-14. A mild base deprotonates the carboxylic acid to form a carboxylate ion, 
which then reacts with the carbonyl atom of Pfp TFA in a nucleophilic addition-
elimination step. The mixed anhydride intermediate has two electrophilic carbonyls. 
If the pentafluorophenyl anion attacks C1, an activated ester is formed to readily 
react with amine species, resulting in a peptide bond. If the pentafluorophenyl anion 
attacks C2, which is much more electrophilic due to the electron-withdrawing 
39 
IV SYNTHESIS OF ANTIMALARIAL AGENTS 
 
95 | P a g e  
 
character of the CF3-substituent, Pfp TFA and the carboxylate species are 
re-generated and the reaction will start again until starting material has been 
consumed.  
The reaction was performed under basic conditions with Pfp TFA and NEt3 and 
monitored by TLC (McReynolds, Bhat et al. 2002). The starting material was 
consumed within 1 h after which the amine was added. However, the outcome of this 
reaction was unsuccessful with yields of less than 10% of 37. Different reaction 
conditions to improve the reactivity of the ester, by the addition of HOBt to form an 
even more activated ester, were also unsuccessful (Albericio 2000). Presumably the 
activating reagent pentafluorophenyl trifluoroacetate had already decayed. 
 
 
Figure IV-14: Activation with pentafluorophenyl trifluoroacetate 
The proposed mechanism of activation with Pfp trifluoroacetate comprises of the electrophilic attack 
of the carboxylic anion to the activating reagent. After several steps the amine reacts with the 
pentafluorophenyl-activated carbonyl species to form the amide product. 
 
The following coupling reactions were carried out with HOBt and HBTU, of which 
the latter belongs to the family of guanidinium peptide coupling reagents. For a long 
time HBTU was assumed to be a uronium salt (Figure IV-15A); however, crystal 
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studies have shown that its true structure is the guanidinium salt (Figure IV-15B). It 
is less active compared to the uronium species due to a greater amount of energy 
required to break the C-O bond compared to the C-N bond (Carpino, Imazumi et al. 
2002). Hence, they require a longer pre-activation time. Furthermore, guanidinium 
salts are much more attractive reagents than carbodiimides because the active esters 
are more stable and may suppress racemisation (Marder and Albericio 2003).  
The mechanism of the HBTU/HOBt reaction is proposed in Figure IV-16. The 
carboxylate reacts with the guanidinium salt to form an intermediate ester that reacts 
rapidly with the benzotriazole derivative HOBt. The added amine can then readily 
react with the activated ester via peptide bond formation (Li and Xu 2000; 
Montalbetti and Falque 2005; Valeur and Bradley 2009). 
The reaction of 36, the Boc-protected cis-1,4-aminocyclohexylcarboxylic acid, with 
2-aminobenzothiazole was carried out under standard peptide coupling procedure in 
basic conditions with HBTU, HOBt and NEt3. It gave 37 in 22% yield, higher than 
with the previous Pfp TFA activation method. However, activation of 
cyclohexylacetic acid with HBTU/HOBt followed by the reaction with 
2-aminobenzothiazole resulted in a very low amount of 40, only 2% (Figure IV-17). 
 
(A)    (B)  
Figure IV-15: Proposed structures of HBTU 
The uronium salt (A) was thought to be the structure of HBTU until crystallographic studies revealed 
it is a guanidinium salt (B) (Carpino, Imazumi et al. 2002). 
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Figure IV-16: HBTU/HOBt activation of carboxylic acids 
The reaction mechanism of HBTU/HOBt activation is illustrated. First, an ester is formed with HBTU 
under basic conditions. The ester is then attacked by HOBt to form a more reactive species. The 
amine attacks the carbonyl and readily forms a peptide bond (Li and Xu 2000; Montalbetti and 
Falque 2005; Valeur and Bradley 2009). 
 
 
 
Figure IV-17: Synthesis of 40 
Reagents and reaction conditions: (i) HBTU, HOBt, DIPEA, DMF–DCM, RT, 12 h, 2% yield. 
 
Alternative coupling reagents were investigated and included phosphonium salts 
such as PyBOP and PyAOP, which are usually 1-hydroxybenzotriazole-based, just 
like the uronium and guanidinium salts. They are often used in combination with 
HOBt or HOAt (Figure IV-18) and are very common in solid phase peptide synthesis 
(SPPS) (Katritzky, Suzuki et al. 2004). Furthermore, PyBOP causes little 
racemisation. 
The reaction mechanism with PyBOP is illustrated in Figure IV-19 and is very 
similar to the previous mechanism for HBTU/HOBt activation (Li and Xu 2000; 
Montalbetti and Falque 2005; Valeur and Bradley 2009). The carboxylate reacts with 
40 
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PyBOP in basic conditions to form an intermediate activated ester. HOBt then 
attacks the ester to form an even more reactive ester. The amine species can then 
react readily with the activated ester to form a peptide bond. 
PyBOP is commonly used in N-acylations; it is able to activate the carboxylic acid 
without combining it with HOBt (Li 2001). Reactions were carried out under basic 
conditions with PyBOP and DIPEA at 0 °C. High yields of 90% (Table IV-1), 66% 
(Figure IV-20A) and 86% (Figure IV-20B) for similar building block Bs were 
obtained and simple work-up methods such as precipitation in cold diethyl ether to 
eliminate by-products of PyBOP easily, made carboxylic activation with PyBOP a 
desirable method. 
 
(A)  (B)  (C)  (D)  
Figure IV-18: 1-Hydroxybenzotriazole-based activating reagents 
Various activating reagents are illustrated: PyBOP (A), PyAOP (B) and their respective coupling 
partners HOBt (C) and HOAt (D). 
 
 
Figure IV-19: Activation of carboxylic acids with PyBOP 
The reaction mechanism of PyBOP/HOBt activation is illustrated. First, an ester is formed with 
PyBOP under basic conditions. The ester is then attacked by HOBt to form a more reactive species. 
The amine attacks the carbonyl and readily forms a peptide bond (Valeur and Bradley 2009). 
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Table IV-1: Optimisation of peptide bond formation 
The activation of compound 36 was optimised using various activating reagents as. The outcome 
(% yield of 37) is compared to demonstrate the most favourable reaction condition for further peptide 
coupling steps. The reaction that produced the highest yield is highlighted in grey. 
  
 
Activating Reagents Reaction Conditions Yield 
Halides: 
Pentafluorophenol 
1.2 eq. Pfp TFA, 2.0 eq. NEt3, 1.0 eq. carboxylic acid, 0.9 eq. 
amine, RT 
7% 
Guanidinium salt: 
HBTU 
1.5 eq. HBTU, 1.0 eq. HOBt, 2.0 eq. DIPEA, 1.0 eq. carboxylic 
acid, 0.9 eq. amine, RT 
22% 
Phosphonium salt: 
PyBOP 
1.1 eq. PyBOP, 2.0 eq. DIPEA, 1.0 eq. carboxylic acid, 1.1 eq. 
amine, 0 °C 
90% 
 
 
(A)  
(B)  
Figure IV-20: PyBOP-aided peptide bond formation (synthesis of 41 and 42) 
(A) Reagents and reaction conditions: (i) PyBOP, DIPEA, DMF–DCM, 0 °C, 12 h, 66% yield; (B) 
reagents and reaction conditions: (i) PyBOP, DIPEA, DMF–DCM, 0 °C, 4 h, 86% yield. 
 
The reaction with Boc-L-proline, compound 42, gave rise to some interesting NMR 
data. Analysis of 42 showed a mixture of two slowly exchanging species, probably 
rotamers. NMR spectra were recorded at two different temperatures, 298 K and 
323 K. Spectra are usually taken at 298 K, whereby the hydrogen atom at the 
41 
42 
36 37 
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stereocentre (CHN-Boc) appears as an apparent doublet. However upon increase of 
temperature, the apparent doublet merges to a singlet. The system has more energy 
and hence the substituents rotate much faster around the ;-bond. Hence at 323 K, a 
broad singlet at 4.5 ppm (CHN-Boc) and a broad doublet at 3.50 ppm (CH2N-Boc) 
were noted which became an apparent doublet (CHN-Boc) and an apparent 
quadruplet (CH2N-Boc) when cooled down to 298 K (Figure IV-21). 
 
 
  
  
Figure IV-21: Comparison of NMR data of compound 42 at different temperatures 
Spectra were taken at two different temperatures, 298 K and 323 K. The isomers of compound 42 
were distinguishable at lower temperatures. The singlet at 4.5 ppm split into an apparent doublet 
once the temperature was reduced from 323 K to 298 K. The NMR spectra were taken in CDCl3 with 
the reference peak at 7.24 ppm. Note solvent peaks of ethyl acetate at 4.12 ppm (q). 
 
  
 
42 
T = 323 K 
T = 298 K 
CcyclopentylH2 
CcyclopentylH2 
CHN-Boc 
CHN-Boc 
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Simple amide bonds coexist as cis-trans isomers in solution (Dugave 2006). The 
preferred orientation is the trans-conformation due to less steric hindrance of the 
amide hydrogen, H, with C (Wedemeyer, Welker et al. 2002). The cis-trans 
equilibrium seems to be coupled to the overall molecular conformation. The 
transition state involves not only changes in torsion angles about the X-Pro peptide 
bond but is also affected by numerous single bonds within the molecule (Figure 
IV-22) (Grathwohl and Wüthrich 1981). 
 
 
Figure IV-22: cis-trans Isomerisation of proline 
The peptide fragment -X-Pro- isomerises from cis- to trans-conformation. R denotes the side chain of 
X, kct and ktc the cis-trans and trans-cis interconversion rates respectively (Grathwohl and 
Wüthrich 1981). 
 
IV.3.2.3 Step 3: The Removal of N-Terminal Protecting Groups 
The tert-butoxycarbonyl group is acid labile and can be cleaved with strong acids via 
an E1-mechanism (Figure IV-23, (Kocienski 1994)). Scavengers may be employed to 
prevent alkylation of the substrate by the stable 3° carbocation. Soft nucleophiles 
such as thiophenols or thioethers are suitable. The Boc-protection group was 
removed with TFA employing a standard decoupling procedure (IV.2.3.2, p. 86). 
Compounds were precipitated with cold diethyl ether to generally yield >80% as the 
TFA salt (Figure IV-24). 
 
 
Figure IV-23: Mechanism of Boc-deprotection 
Tert-butyl carbamates are cleaved under anhydrous acidic conditions to form the free amine 
(Kocienski 1994). 
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(A)  
(B)  
(C)  
Figure IV-24: Boc-deprotection (Formation of 38, 43 and 44) 
(A) 79% yield, (B) 99% yield, (C) 84% yield. Reagents and reaction conditions: (i) TFA–H2O–TIPS 
(90:5:5, V:V:V), RT, 1 h. 
 
IV.3.2.4 Step 4a: Reductive Amination 
After the deprotection step, combining the 1° amine with building block A was the 
last step for the library of modified lead compound analogues. A complete list for 
diverse units A is in Section IV.3.3.1 (p. 105). Synthesis was achieved during the 
reaction between a 1° amine and an aldehyde in the presence of a reducing agent. 
The mechanism is outlined in Figure IV-25. The N-terminus reacts with the carbonyl 
to form an unstable intermediate. The hemiaminal dehydrates to form an imine (also 
called Schiff’ s base), which is then readily reduced by alkyl hydride reducing agents, 
where an H-nucleophile attacks the C-atom of the imine to form an amine (Abdel-
Magid, Carson et al. 1996). Optimisation of this procedure is discussed in 
Section IV.3.3.2 (p. 108). 
 
44 42 
37 38 
41 43 
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Figure IV-25: Mechanism of reductive amination 
The reductive amination consists of two steps. The reversible formation of the imine results in the 
reaction of an amine with a carbonyl to form an intermediate hemiaminal. After the elimination of 
water, the imine reacts in an irreversible step with the added reducing agent such as NaBH(OAc)3 to 
form the product, an amine (Abdel-Magid, Carson et al. 1996). 
 
IV.3.2.5 Step 4b: N-Alkylation 
After deprotection, yielding 2° amines, the RA unit was attached as the last step. A 
common method for transforming secondary amines into tertiary amines is via 
alkylation with alkyl halides. In Figure IV-26, the mechanism of alkylation is 
outlined. This straightforward synthesis involves the nucleophilic attack of the 
2° amine towards the C-atom of the alkyl halide. The formed in situ tetrahedral 
intermediate is deprotonated by addition of base to yield an alkylated amine. 
 
 
Figure IV-26: Mechanism of alkylation 
Secondary amines can be alkylated with alkyl halides. The tetrahedral intermediate is treated with 
base to yield alkylated amines.  
 
Figure IV-27 gives an overview of synthesised compounds 45, 46 and 47, ready to 
be tested for activity against PfNMT in vitro. Compound 45 is a direct analogue of 
lead compound 94 with aminobenzothiazole as unit RC and methylnaphthalene as 
building block RA. Both components are joined by (S)-proline. The alkylation 
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reaction with bromomethylnaphthalene gave a relatively low yield of 28% yield. For 
synthesis of 46, the reaction was observed over time at two different temperatures, 
RT and 0 °C. TLC analysis of the reaction mixture showed multiple spots suggesting 
degradation or polymerisation over time for both reaction trials. But by-product 
formation was much greater at elevated temperatures. Starting material and alkyl 
halide was also still present after 24 h reaction time. Overall, changes in temperature 
to favour product formation and different reaction times still led to low yields of 
15%. Hence reductive amination for 47 was attempted with 44 and 1-benzofuran-5-
carbaldehyde. The reaction was more successful with 77% yield of compound 47. 
 
 
Figure IV-27: Synthesis of lead compound analogues (45, 46, 47) with proline as building 
block B 
Reagents and reaction conditions: (i) bromomethylnaphthalene, NEt3, DCM, RT, 18 h, 28% yield; (ii) 
benzylbromide, NEt3, DCM, RT, 18 h, 14% yield; (iii) 1-benzofuran-5-carbaldehyde, acetic acid, 
DMF–DCM, molecular sieves, RT, 1h; (iv) NaBH(OAc)3, RT, 18 h, 77% yield. 
 
IV.3.3 Building a Library with Variations in Building Block A 
The main focus was centred on building block A. As mentioned previously (Figure 
II-19), the addition of unit A may cause a conformational change in the surrounding 
amino acids of the peptidic binding pocket, thus extending the cavity. As a result 
tighter interactions with even more AA in the target binding site are possible, 
creating a better inhibitor. Studies indicated large-sized aromatic groups as well as 
the addition of heteroatoms may play an important role upon binding (IV.1, p. 80). 
Hence a collection was synthesised to systematically investigate several aspects of 
binding that included size, aromatic character, electron withdrawing and donating 
44 
46 45 47 
IV SYNTHESIS OF ANTIMALARIAL AGENTS 
 
105 | P a g e  
 
properties, as well as H-bond donor and acceptor groups (Figure IV-28). A complete 
discussion regarding the choice of unit A is outlined in Section V.3.3.3.1 (p. 143). 
 
 
Figure IV-28: Complete list of building blocks A 
A list of aldehydes for variations of the lead compound is shown. Variations of building block A were 
subject to availability. 
 
IV.3.3.1 Building Up a Small-Sized Library 
Parallel synthesis was carried out to start a small-sized library. First an excess of 
aldehyde, 2.0 eq. was employed to investigate the rate of reaction for various 
building blocks A (Table IV-2A, Table IV-3A). The other reagents were 2.0 eq. 
NEt3, 2–4 eq. NaBH(OAc)3 and molecular sieves in DMF in a two-step procedure 
with 1 h imine formation and overnight reaction time for reduction, followed by 
aqueous work-up. 
Unfortunately, overalkylation products were noticed. The ratio of monosubstituted 
product vs. disubstituted by-product was dependent on ring size as well as electronic 
properties of the aromatic system. The yield of compound 48 with an aliphatic unit A 
A
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was much smaller compared to the yield of compound 49 with an aromatic system as 
unit A (1% vs. 16%). A large amount of disubstituted by-product was noticed. 
Generally, the formation of monoalkylated species was unfavoured under these 
reaction conditions due to the competitive side reaction of dialkylation.  
To minimise overalkylation, the amount of aldehyde was lowered from 2.0 eq. 
(Table IV-2A, Table IV-3A) to 1.5 eq. (Table IV-2B, Table IV-3B) and 1.0 eq. 
(Table IV-2C). As a result disubstitution diminished, driving the product reaction to 
completion, resulting in a higher yield. The yield of compound 48 increased greatly 
from 1% with 2.0 eq. aldehyde to 29% with 1.5 eq. aldehyde. Simultaneously the 
amount of formed disubstituted by-product, 50, dropped from 63% to <1%. This was 
also noted with compound 51, with an increase in yield from 3% to 17% and a 
significant decrease for the disubstituted by-product 52 from 78% to <1%.  
Overall, there was a drop in by-product formation once the aldehyde substrate was 
reduced; however the yield of the product was not greatly increased. Usually 
moderate yields of 20% were monitored with exception of higher yields around 50% 
for some compounds. Thus the reaction was studied in detail to improve yields and 
reduce by-product formation. 
 
Table IV-2: Generation of a small-sized library with cis-1,4-cyclohexyl building block B 
The library was generated in a two-step-synthesis under the following reaction conditions: (i) 1.0 eq. 
amine, 1.0–2.0 eq. aldehyde, 2.0–2.2 eq. NEt3, 2.0–4.0 eq. NaBH(OAc)3, 0.2 M in DMF and 
molecular sieves (IV.2.3.4, p. 87). A more detailed procedure for each individual compound can be 
found in the Appendix (VIII.1, p. 193). 
 
 
(A) 2.0 eq. aldehyde 
Compound 
Number 
RA Yield [%] 
MS      DS 
 Compound 
Number 
RA Yield [%]. 
MS        DS 
49/53 
 
16 5  61/62 
 
21 17 
MS DS 
IV SYNTHESIS OF ANTIMALARIAL AGENTS 
 
107 | P a g e  
 
Compound 
Number 
RA Yield [%] 
MS      DS 
 Compound 
Number 
RA Yield [%]. 
MS        DS 
54/55 
 
31 41  63 
 
11 n.i. 
56/57 
 
25 7  64 
 
48 n.i. 
58 
 
5 n.i.  51/52 
 
3 78 
59/60 
 
7 23  65/66 
 
10 13 
48/50 
 
1 63  67 
 
2 n.i. 
Note: MS  – monosubstituted; DS  – disubstituted; n.i. – not isolated 
 
(B) 1.5 eq. aldehyde 
Compound 
Number 
RA Yield[%] 
MS    DS 
 Compound 
Number 
RA Yield[%] 
MS     
DS 
68 
 
3 n.i.  67 
 
2 n.i. 
69 
 
17 n.i.  71 
 
26 n.i. 
70 
 
3 n.i.  72 
 
19 n.i. 
48 
 
29 n.i.  51 
 
17 n.i. 
Note: MS – monosubstituted; DS  – disubstituted; n.i. – not isolated 
 
(C) 1.0 eq. aldehyde 
Compound 
Number 
RA Yield[%] 
MS     DS 
 Compound 
Number 
RA Yield[%] 
MS     DS 
35 
 
67 n.i.  73 
 
51 n.i. 
Note: MS  – monosubstituted; DS – disubstituted; n.i. – not isolated 


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Table IV-3: Generation of a small-sized library with cis-1,3-cyclohexyl building block B 
The library was generated in a two-step synthesis under the following reaction conditions: (i) 1.0 eq. 
amine, 1.5–2.0 eq. aldehyde, 2.0–2.2 eq. NEt3, 2.0–4.0 eq. NaBH(OAc)3, 0.2 M in DMF and 
molecular sieves (IV.2.3.4, p. 87). A more detailed procedure for each individual compound can be 
found in the Appendix (VIII.1, p. 193). 
 
 
 
(A) 2.0 eq. aldehyde      (B) 1.5 eq. aldehyde 
Compound 
Number 
RA Yield [%]  
MS      DS 
 Compound 
Number 
RA Yield [%]  
MS        DS 
74/75 
 
10 14  80 
 
15 n.i. 
76/77 
 
45 32  81 
 
13 n.i. 
78/79 
 
3 36  82 
 
28 n.i. 
Note: MS – monosubstituted; DS – disubstituted; n.i. – not isolated 
 
IV.3.3.2 Optimisation of the Reductive Amination Step 
There are several comprehensive reviews on reductive amination (Gomez, Peters et 
al. 2002; Abdel-Magid and Mehrman 2006) with Abdel-Magid et al. employing 
sodium triacetoxyborohydride, for various aliphatic and aromatic ketones and 
aldehydes, as the general reducing agent which is much milder compared to the 
commonly used NaBH4. Furthermore, it gave consistently higher yields and fewer 
side products. This method however had limitations with aromatic, unsaturated 
ketones and sterically hindered ketones (Abdel-Magid, Carson et al. 1996). 
Acetic acid may be added as a catalyst during reductive amination of ketones, but it 
is not essential for aldehydes. Under the weakly acidic to neutral reaction conditions, 
the imine is protonated to form an iminium ion, which is subsequently reduced to the 
amine product (Abdel-Magid, Carson et al. 1996). However, the pH needs to be 
carefully monitored for selective reduction of the imine over the aldehyde. At pH 


MS DS 
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values in the range 3–4, aldehydes and ketones are reduced effectively to the 
respective alcohol. The rate of reaction will decrease by a more neutral environment. 
At pH of 6–7, other species such as more basic imines will be reduced selectively. 
Also, if reaction conditions are too acidic, the 1° amine substrate is protonated and 
thus cannot act as a good nucleophile for the attack on the carbonyl species. 
Methanol may be used as a proton source (Borch, Bernstein et al. 1971). 
The reductive alkylation of primary amines to yield secondary amines may result in 
overalkylation. This side reaction has been observed and reported extensively in 
literature, especially regarding sterically unhindered aldehydes. The problem of 
dialkylation can be overcome by a stepwise procedure of first forming the imine, 
followed by the reduction to the amine with reducing agent. In addition, by using 
less than 1 eq. of the carbonyl species relative to the amine species, overalkylation 
may be reduced (Abdel-Magid, Carson et al. 1996; Szardenings, S. et al. 1996; 
Yamazaki, Kaneko et al. 2005). 
Indirect reductive amination can be summed up in an initial step of formation of 
intermediate imine followed by reduction to the amine species in a final step. The 
reaction times differ largely and are dependent on the substrate. Hence the reaction 
was performed in deuterated solvent (CDCl3), to observe imine formation at various 
time points using NMR spectroscopy. The alternative of the isolation of imines 
would be too difficult as imines are quite unstable. General conditions to synthesise 
35 were used as according to the literature (Abdel-Magid, Carson et al. 1996). 
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Reagents and reaction conditions: (i) 1.5 eq. aldehyde, 2.2 eq. NEt3, 0.03 M in CDCl3; (ii) 3.2 eq. 
NaBH(OAc)3, aqueous work-up. 
 
 
 
Figure IV-29: Complete NMR analysis for reductive amination to yield 35 
Formation of 35 was investigated with NMR spectroscopy. A series of NMR spectra were taken in 
CDCl3 (H = 7.26 ppm) that show reduced aldehyde (2-naphthylmethanol), aldehyde (2-naphthalene), 
amine, the reaction mixture after 24 h reaction time prior to the addition of reducing agent and after 
the addition of reducing agent followed by aqueous work-up (from bottom to top). Red boxes and red 
arrows point out characteristic proton shifts for reductive amination: first the imine peak at 8.5 ppm 
and second the aliphatic NCH2 protons after reduction at 3.8 ppm. The peaks of the base NEt3 are 
characteristic at 2.56 (q) and 1.03 (t) ppm. The bottom two spectra have been included as a control 
and the key spectral regions are blank as expected. 
35 
38 
Step 2: 2° Amine formation 
Step 1: Imine formation 
Control: Amine 
Control: Aldehyde 
Control: Reduced aldehyde (alcohol) 
CnaphthylHO CaromH CnaphthylCH2OH 
NHCH2 NCH 
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NMR data are pictured in Figure IV-29, which shows a summary of each reaction 
step including controls of only aldehyde and amine for comparative purposes. Red 
boxes point out key characteristic spectral features for each step; first the imine 
proton that has a unique peak at 8.5 ppm upon addition of aldehyde and base to the 
amine (Step 1) and second the pair of aliphatic protons of the 2° amine at 4.8 ppm 
which appear after the addition of reducing agent and aqueous work-up (Step 2). The 
imine proton disappears during the second step of reductive amination. 
The reaction at various time points, to investigate the formation of the imine 
intermediate product is shown in Figure IV-30. The top NMR segment shows the 
aromatic region of 7–10 ppm to look at the imine proton more closely. The intensity 
of the imine proton at 8.5 ppm increases over time, whereas the intensity of the 
aldehyde proton decreases. However there is no continuous amplification of the peak 
of the imine proton noted at the observed time points of 12–40 h (Table IV-4). The 
intensity of the peak at 12 h is similar in intensity to the peak at 24 h.  
This can also be noted elsewhere for other hydrogen atoms. The bottom NMR 
section illustrates the aliphatic hydrogen shifts: 3.0 ppm to 3.5 ppm for CHNH(2), 
2.5 ppm to 2.7 ppm for CHCONH and 2.0 ppm to 2.3 ppm for CH2CHN. This was 
expected as the environment changes for these particular protons upon addition of 
the aldehyde species. It was furthermore noted that the downfield shifts were also 
complete after 12 h reaction time. 
 
Table IV-4: Progression of imine formation 
The table lists the ratio of the imine proton vs. the aldehyde proton with regards to Figure IV-30. The 
integral was calculated with respect to the aromatic hydrogen from the amine substrate. 
Reaction Time 10 min 12 h 21 h 24 h 40 h 
NCH 0.2 0.6 0.7 0.7 0.7 
CHO 5.9 4.4 3.8 3.5 2.9 
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Figure IV-30: Detailed time analysis of imine formation 
The first step of reductive amination, imine formation, for compound 35 was studied at various time 
points with NMR spectroscopy. The displayed series is a more detailed study of Figure IV-29. Two 
sections of the spectra are displayed (from bottom to top: control aldehyde, control amine, 10 min, 
12 h, 21 h, 24 h, 40 h reaction time). The characteristic protons are highlighted in red boxes. The top 
Time point: 40 h 
Time point: 24 h 
Time point: 21 h 
Time point: 12 h 
Time point: 10 min 
Control: Amine 
Control: Aldehyde 
Time point: 40 h 
Time point: 24 h 
Time point: 21 h 
Time point: 12 h 
Time point: 10 min 
Control: Amine 
Control: Aldehyde 
CnaphthylHO NCH 
CcyclohexylHN 
CcyclohexylHCON 
CcyclohexylH2 
CcyclohexylH2 
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spectra point out the imine proton with a unique peak at 8.3 ppm. The bottom spectra show the shift of 
the aliphatic protons where the original peak is pointed out with a black arrow and the shifted peak of 
the same proton with a red arrow. 
 
According to results from the previous NMR spectroscopic analysis, imine formation 
was complete after at least 12 h but the speed of imine formation was still unknown 
as the imine hydrogen was already present at 10 min and complete imine formation 
was already noted at the next time point of 12 h. The time period in between 10 min 
and 12 h was subject to the next NMR series in line to investigate this matter further 
(Figure IV-31). Foremost, a different deuterated solvent was employed as several 
problems arose in trial number one with CDCl3. The amine species were sparingly 
soluble and the deuterated solvent also seemed to be contaminated (7.2 ppm, dd; 
Figure IV-29).  
Hence the next set of NMR spectroscopic experiments was carried out in DMF-d7. It 
greatly improved solubility and all reagents were completely dissolved. The reaction 
was carried out in two steps; reaction conditions for the imine formation were as 
follows: 1.2 eq. aldehyde, 2.2 eq. NEt3 at 1 mM in DMF-d7. An NMR was taken 
every three hours for the first day to determine the time point for complete imine 
formation under the particular reaction conditions. The second step was to 
investigate the reduction with NaBH(OAc)3. This was carried out with stepwise 
addition of reducing agent to determine how many equivalents were needed for full 
reduction of the amine product and remaining starting material of the aldehyde. 
The formation of the intermediate imine is documented in Figure IV-31 over various 
time points. Table IV-5 displays the ratio between imine formation and aldehyde 
consumption; the integral of NCH increases whereas CHO decreases. The aldehyde 
proton did not diminish completely as a slight excess of 1.2 eq. was used in the 
reaction. The values in the table indicate complete conversion to the imine after an 
overnight reaction. The tertiary aliphatic protons also shift downfield as documented 
earlier. This step was completed overnight as well. In combination with the 
information of the previous NMR experiment, complete imine formation occurred 
within 12 h. 
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Reagents and reaction conditions: (i) 1.2 eq. aldehyde, 2.2 eq. NEt3, 0.001 M in DMF-d7; (ii) 
2 × 3 eq. NaBH(OAc)3, aqueous work-up.  
 
 
         
Figure IV-31: NMR analysis of imine formation over time for compound 49 
The first step of reductive amination, imine formation, for compound 49 was studied at various time 
points with NMR (5 min, 3 h, 5 h, 9 h, 23 h, 26 h, 28 h, 52 h from 2nd bottom to top) The bottom 
spectrum of the amine was added for analysis as a control. Synthesis as carried out in DMF-d7 
(H = 8.03 ppm). Protons of NEt3 can be found at 1.2 and 2.6 ppm. The characteristic protons are 
highlighted in red boxes and pointed out with red arrows. The characteristic peak for the imine 
proton was at 8.3 ppm. The aliphatic protons of the starting material are pointed out with a black 
arrow and the shifted peaks of the same proton of the imine intermediate with a red arrow. 
CnaphthylHO CaromH 
NCH 
Time point: 52 h 
Time point: 28 h 
Time point: 26 h 
Time point: 23 h 
Time point: 9 h 
Time point: 5 h 
Time point: 3 h 
Time point: 5 min 
Control: Amine 
49 
38 
CcyclohexylH2 
CcyclohexylH 
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Table IV-5: Progression of imine formation 
The table lists the ratio of the imine proton vs. the aldehyde proton with regards to Figure IV-31. The 
integral was calculated with respect to the aromatic hydrogen from the amine substrate. 
Reaction Time 5 min 3 h 5 h 9 h 23 h 26 h 28 h 52 h 
NCH 0.17 0.17 0.55 0.59 0.82 0.83 0.80 0.94 
CHO 1.0 0.83 0.67 0.56 0.40 0.17 0.36 0.34 
 
For the second step of the reaction, the reduction of the imine, 3 eq. of reducing 
agent in DMF-d7 was added to the reaction mixture. NMR spectroscopic analysis 
showed that the imine proton was completely gone but to reduce all of aldehyde 
substrate a second batch of 3 eq. NaBH(OAc)3 had to be added (data not shown). 
To study other parts of reductive amination more closely, a model reaction was 
devised and carried out in deuterated solvent at 0.1 M concentration of the aldehyde 
to follow the reaction by NMR. The first aspect was the influence of the amount of 
aldehyde substrate on the reaction time of the initial imine formation which was not 
looked at in the previous two NMR experiments. Table IV-6 suggests that addition 
of base to the amine salt was essential for imine formation as it breaks it up. Also, 
the reaction time was greatly reduced from 24 h to just 3 h with a slight excess of 
aldehyde. Imine formation was nearly complete within 24 h using 1.0 eq. aldehyde 
but when the amount of aldehyde substrate was increased to 1.5 eq., full imine 
formation was observed after 3 h. The order of addition was also investigated by 
NMR spectroscopy but there was no noticeable difference in reaction time between 
later additions of reducing agent or a one-pot synthesis (data not shown). 
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Table IV-6: Model reaction to study reductive amination 
Various reaction conditions were explored such as the amount of aldehyde, base, reaction time and 
order of addition to develop the speed of formation of the intermediate imine and subsequent 
reduction to the amine species. 
 
 
Amine Aldehyde Base Reaction Time Imine Proton* 
1.0 eq. - 1.2 eq.  0% 
1.0 eq. 1.0 eq. - 24 h 0% 
1.0 eq. 1.0 eq. 1.2 eq. 3 h / 24 h 83% / 92% 
1.0 eq. 1.5 eq. 1.2 eq. 3 h  97% 
* yields based on integral area of peak in NMR  
 
IV.3.4 Investigation of the A-B Linkage 
Crystallographic studies, as seen in Figure II-14, indicated that the C-terminus of 
NMT, which partially forms the peptide binding site, may interact with secondary 
amine moieties (Hasegawa, Morikami et al. 2003). This was examined more closely 
for this compound series. The 2° amine functionality was modified for three selected 
units A (naphthyl, benzyl and benzofuran) and in vitro assays were performed to 
examine the contribution of this amine (Figure IV-32). 
 
 
Figure IV-32: Modification of the A-B Linkage 
Variations of secondary amine moieties can be attained either through overalkylation during the 
reductive amination step (a), acetylation (b), or alkylation (c). 
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Modifications of the secondary amine bond that were looked into include dialkylated 
species, the by-product of the reductive amination step (Figure IV-32a), acetylation 
of the 2° amine (Figure IV-32b) and methylation (Figure IV-32c). As pointed out 
earlier, reductive amination of a primary amine can easily result in overalkylation. 
The dialkylated by-product was isolated for testing as well as the secondary amine 
product, which was then modified further. 
Acetylation of secondary amines was achieved with acetic anhydride under solvent 
free conditions (IV.2.3.5, p. 87). A moderate yield of 61% was obtained after 
purification procedure for 83. Acetylation of compounds 84 and 85 also resulted in 
yields of 74% and 14% respectively (Figure IV-33). 
Methylation was carried out with 35 (IV.2.3.6, p. 87); however, a dimethylated 
species was isolated. According to mass spectroscopy, the 2° amine that was 
methylated did not result in a quaternary amine. The second CH3-group could be 
attached to the nitrogen of the amide bond (Figure IV-34). 
(A)  
(B)  
(C)  
Figure IV-33: Synthesis of compounds 83, 84 and 85 
Reagents and reaction conditions: (i) 1.0 eq. 2° amine, 1.0 eq. NEt3, 0.2 M in Ac2O, 2 h, RT. 
 
 
Figure IV-34: Synthesis of compound 86 
Reagents and reaction conditions: (i) 1.0 eq. 2° amine, 2.0 eq. ICH3, 3.0 eq. K2CO3, 0.1 M in DMF, 
no h, 18 h. 
83 
84 
85 
47 
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IV.4 Conclusion and Discussion 
A chemical library was established with analogues based on UK-370,509. The lead 
compound from the “ Pfizer series”  was successfully re-synthesised in a four-step 
route with an overall yield of 40%. It began with Boc-protection of the amine moiety 
of cis-1,4-aminocyclohexylcarboxylic acid, building block B, with good yields of 
70%. The C-terminus was coupled to 2-aminobenzothiazole in a peptidic coupling 
step with excellent yields of 90%. After Boc-deprotection in strong acidic 
conditions, the N-terminus was reacted with an aldehyde, building block A, to form a 
secondary amine bond under reductive amination conditions with moderate yield of 
60%. Compound 35 was verified with spectroscopic methods including NMR, IR 
and mass analysis. 
Each step of the synthesis was systematically optimised to facilitate synthesis of 
numerous lead compound variants for the library. The formation of the amide bond 
connecting the C-terminus of building blocks B with the N-terminus of 
2-aminobenzothiazole was examined with three different units B; cis-1,4- and 
cis-1,3-aminocyclohexylcarboxylic acid, as well as proline. Out of various peptide 
coupling conditions such as acyl halides, HBTU/HOBt and PyBOP, the last gave by 
far the best results of 70–90% yield. 
The focal point of this library was building block A to improve potency and 
selectivity against Plasmodium falciparum NMT with respect to human NMT. A 
large range of aldehyde derivatives was used to explore several characteristics of the 
target binding site. Examples included variations in size, aromaticity, electron 
withdrawing and donating properties, as well as H-donor and -acceptor groups. 
Parallel synthesis was carried out on a small scale, 0.1 mmol. Aldehydes were 
attached in a reductive amination step to 1° amine functionalities of RCB. For 
2° amines, the N-terminus was alkylated with halide substrates. However, it was 
found that the yield greatly increased when 2° amines were also subjected to the 
reductive amination protocol. The reaction mechanism of reductive amination of 
secondary amines is similar to that of primary amines (Figure IV-25); however, it 
involves an iminium ion as the reaction intermediate. 
Several issues arose, one being limited solubility. Initially the reactions were carried 
out in DCM for more facile work-up. However, it was found that reactions worked 
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better in DMF–DCM. Solubility of the starting material, reagents and product were 
greatly enhanced. To eliminate water from the reaction, anhydrous solvents and 
reagents, as well as pre-activated molecular sieves were employed to increase yields. 
Reductive amination was carried out in two steps with 2.0 eq. aldehyde to form the 
imine followed by subsequent reduction with reducing agent after 1 h and aqueous 
work-up. Average yields were relatively low, typically 15%, although yields of 50% 
were also observed. A competitive side reaction was observed with higher yields of 
disubstituted by-product. It was found that an excess of aldehyde favoured 
overalkylation. The ratio of monosubstituted product vs. disubstituted by-product 
was dependent on the properties of the aldehyde such as size and aromaticity. 
Disubstituted by-products were reduced by 1/10th by using less aldehyde in the 
reaction mixture, typically 1.0 eq. The average yield was increased to 60%. 
To improve yields even further, the two-step reaction was analysed thoroughly with 
NMR spectroscopy. It was found that after 1 h reaction time, imine formation was 
not completed. Only about 20% conversion was observed after a period of 3 h. That 
would support the observed average yields above. NMR studies indicated that imine 
formation was complete after overnight reaction with reduction occurring 
spontaneously. Hence further reactions for next generation libraries should employ 
1.0 eq aldehyde to react with the amine for 24 h before addition of reducing agent. 
Further research could go into the selectivity of C6-substituents against N-myristoyl 
transferase for different species. It could be attached via ring formation of the 
benzothiazole. It was examined in a Master thesis project (Tomlinson 2007). After 
initial solubility issues of the product after ring formation, it was decided to switch 
from combinatorial solution chemistry to solid phase assisted synthesis to build a 
small scale library as it is a faster method to prepare a bigger number of compounds 
simultaneously. The C6-position was substituted with a carboxylic acid (Matsuoka 
1997) that could in turn be attached to resins, for example rink amide resin. 
Unfortunately, the attempt to exploit solid phase assisted synthesis has not yet been 
achieved. Types of resins, most favourable reagents, coupling hours and cleavage 
cocktails need to be investigated further. In summary, the lead compound from the 
“ Pfizer series”  had been re-synthesised successfully in high yields. The four-step 
synthetic route was optimised for the generation of a small-sized library of analogues 
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which could then be tested in vitro for potency against PfNMT and selectivity over 
human NMT (Chapter V). 
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V IN VITRO EVALUATION OF INHIBITORS 
 
V.1 Introduction 
The potential of synthesised antimalarial candidates was explored initially in vitro 
prior to testing in in vivo systems (Chapter VI). The combination may aid to evaluate 
inhibitory modes against PfNMT and outline structure-activity relationships (SAR) 
to guide further improvement for antimalarial drug design. 
There are two main formats of assays for NMT activity that have been reported in 
the literature: continuous and discontinuous. The latter method has generally 
employed radioactively labelled substrates. The label is incorporated into the product 
making detection simple due to the extremely sensitive tag, usually tritium. Kinetic 
analysis of the reaction requires multiple sample extractions and product isolation of 
radioactive material, which can be done in various ways; ELISA (Takamune 2002), 
HPLC (Towler and Glaser 1986; Glover, Goddard et al. 1988; McIlhinney and 
McGlone 1989), IEX (Paige, Chafine et al. 1989), selective adsorption on acidic 
alumina (Wagner and Retey 1990) and phosphocellulose paper binding (King and 
Sharma 1991; Panethymitaki, Bowyer et al. 2006). These assays have the advantages 
of high sensitivity and hence the need for only small amounts of reaction material; 
this outweighs the disadvantages of needing to take samples of product over the 
reaction time course and the inherent hazards associated with radioactive assays. 
Continuous assays allow for automated measurements to study the progress of the 
whole reaction, which results in an increased number of data points. Fluorescent tags 
are an alternative to radioactive manipulation (Pennise, Georgopapadakou et al. 
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2002). This assay format is generally more cost effective and easier to handle, yet the 
relative insensitivity requires large amounts of substrate and a bulky fluorophore 
may prevent substrate interactions. Similar problems of high dose requirements of 
reagents also occur with reported enzyme linked assays where, for example, CoA 
formation was coupled to the NAD+/NADH system and pyruvate dehydrogenase 
whereby NADH formation was continuously detected spectrophotometrically 
(Boisson and Meinnel 2003). Continuous assays would, in principle, be valuable for 
kinetic studies; however, the sensitivity limitations and consequently higher 
concentration of substrates and enzyme make this format impractical for our studies. 
The method employed in this project was based on a published medium-throughput 
discontinuous assay (French, Zhuang et al. 2004). In this publication, [3H]-labelled 
myristoyl CoA was reacted with biotinylated peptide in the presence of HsNMT1 to 
form tritiated myristoylated biotinylated peptide which was then bound to 
streptavidin-coated 96-well plates. Reactants were washed off and wells filled with 
scintillant fluid to allow the amount of isolated product to be measured. This method 
was adapted by using streptavidin-coated scintillation beads instead (Bowyer, 
Gunaratne et al. 2007). Washing steps were eliminated and handling of radioactive 
material was reduced. 
 
V.1.1 The Scintillation Proximity Assay 
The inhibitory properties of the compounds were analysed in the SPA, as outlined in 
Figure V-1, against Plasmodium falciparum N-myristoyl transferase (PfNMT) for 
potency and two Homo sapiens NMTs (HsNMT1 and HsNMT2) for selectivity. 
[3H]-Labelled myristoyl CoA and biotinylated peptide were incubated in the 
presence of NMT to form radiolabelled myristoylated biotinylated peptide. The 
inhibitor will interfere with N-myristoylation of the peptide substrate which was 
based on the N-terminus of PfARF1; GLYVSRLFNRLFQKK(biotin) (Stafford, 
Stockley et al. 1996; Gunaratne, Sajid et al. 2000; Bowyer, Gunaratne et al. 2007). A 
mixture of unreacted peptide and N-myristoylated peptide were subsequently 
captured by streptavidin-coated scintillation beads due to the high affinity between 
biotin and streptavidin. The tetrameric protein has four biotin-binding sites, of which 
each forms multiple H-bonds and van der Waals interactions with biotin (Figure 
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V-2). Upon binding, the surface polypeptide loops arrange themselves to bury biotin 
in the protein interior resulting in strong bonds (Weber, Ohlendorf et al. 1989). 
The close proximity of the tritium label in the captured species to the polymer beads 
containing scintillant fluid enables energy transfer of the --decay of tritium 
(Equation V-1). The energy released, with an approximate travel path of 1.5 µm, is 
transferred to the scintillant molecules, which in turn causes excitation of the 
fluorophore. Upon relaxation, energy is emitted in the form of light, which is 
detected by the scintillation counter and converted into electrical signals. Only 
tritium labels within close range to the scintillant exhibit an effect; this makes 
physical separation between unbound and bound material redundant, minimising 
time and handling of radioactive material. 
Read-out values were used to interpret and quantify N-myristoylation. High counts 
indicate a great level of N-myristoylation and reduced signals suggest substantial 
levels of inhibition. A plot of enzyme activity as a function of inhibitor concentration 
gives an inhibition curve from which an IC50 was derived. The IC50 represents the 
concentration of a drug that is required for 50% inhibition in vitro. The data was 
used to rank the inhibitors from which structure-activity relationships were deduced. 
The plot was performed with GraFit, using non-linear regression analysis involving a 
3 parameter fit to the data (Equation V-2B). Regression analysis is a technique to 
calculate the best fit curve in minimising the deviation of data from the curve 
(Leatherbarrow 2007). 
 
V.1.2 Kinetic Analysis 
Inhibitors were not designed for the myristoyl CoA binding site, hence concentration 
of myristoyl CoA substrate in the assay should be at a saturating level, well above 
Km. Due to the Bi Bi reaction mechanism, a saturated myristate binding pocket will 
lead to an accessible peptide binding site for either peptide substrate or inhibitor; 
evaluating the level of inhibition of N-myristoylation of the compounds.  
The Km is the substrate concentration at which the rate of reaction is half its 
maximum value. Kinetic parameters (Km and Vmax) were derived according to the 
Michaelis Menten model (Equation V-3, Figure V-3) with GraFit. 
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Figure V-1: SPA to test inhibitors against NMT 
SPA was used to quantify inhibitory properties against NMT. Tritium-labelled myristate and 
biotinylated peptide substrate were incubated in the presence of NMT as well as the inhibitors. Both 
unmyristoylated and myristoylated, biotinylated peptide were captured with streptavidin-coated 
scintillation beads. Only the radioactive myristoylated biotinylated peptide produced signals, which 
were interpreted by the scintillation counter and transformed into electrical pulses. Ratios of signal to 
inhibitor concentration were used to evaluate relative IC50-values. 
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(A)  (B)  
Figure V-2: Assumed biological unit of a saturated streptavidin-biotin complex 
(A) This crystal structure shows the biological unit of tetrameric streptavidin with four coordinated 
biotin molecules (pdb file 1stp, (Weber, Ohlendorf et al. 1989)); (B) Biotin. 
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Equation V-1: Beta minus decay 
Radioactive decay of tritium is referred to as beta minus decay (-) whereby neutrons are converted to 
protons forming stable nuclei of helium. Furthermore beta particles similar to electrons as well as 
antineutrinos are emitted. 
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Equation V-2: Equations for best fit curve 
The data is either fitted to a 4 parameter (A) or a 3 parameter equation (B) if background corrected. 
A graph is plotted from this data (rate of reaction vs. substrate concentration) from which an IC50 
value can be determined. 
(Legend: y is the response, x is the concentration of substrate, range is the maximum y range, s is the 
slope factor). 
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Equation V-3: Michaelis Menten kinetics 
The basic Michaelis Menten enzyme kinetic equation (A) to calculate Vmax and Km of the substrates is 
derived from the enzymatic reaction (B) by substituting constants for Km,, the Michaelis constant (C). 
For straightforward graphical interpretation values are plotted in a double reciprocal (Lineweaver-
Burk) plot (D). 
(Legend:  is the rate of reaction where all enzymes are unbound, Vmax is the maximum rate where the 
enzyme is completely saturated with substrate, [S] is the substrate concentration, Km is the Michaelis 
constant) 
 
 
(A)        (B)  
Figure V-3: Graphical evaluation of enzyme inhibition 
The graph illustrates an enzyme saturation curve with plotted data of rate of reaction vs. substrate 
concentration (A). The double reciprocal conversion leads to the Lineweaver-Burk plot (B) from 
which kinetic constants can easily be determined.  
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V.2 Material & Methods 
V.2.1 Chemicals and Reagents 
Solvents and reagents of the highest available purity were obtained from commercial 
sources (BDH, GE Healthcare [formerly known as Amersham Biosciences], 
Sigma-Aldrich). Ultrapure laboratory grade water was obtained from in-house Elix® 
and MilliQ® millipore water purification systems. All solutions were prepared in 
ultrapure laboratory grade water. 
3H-[9,10]-Myristoyl CoA and PVT scintillant beads were supplied by 
GE Healthcare. Unlabelled myristoyl CoA was purchased from Sigma. The peptide 
substrate was synthesised by Dr P W Bowyer (Bowyer 2006). Confirmed active 
candidates assayed for comparative purposes were supplied by Pfizer PLC. The 
myristoyl CoA analogue S-(2-oxo)pentadecyl CoA, named non-hydrolysable 
myristoyl CoA, was used as a positive control and was synthesised by Dr E W Tate. 
The triazole-based compounds 87, 88, 89, 90, 91, 92, 93 were made by J Sudlow as 
part of a Master thesis project (Figure V-4, (Sudlow 2008)). The synthesis of all 
other inhibitors is described in Chapter IV. 
 
 
 
  
Figure V-4: Triazole-based inhibitors 
 
 
V.2.2 Methods and Equipment 
Buffered solutions are catalogued in Table V-1. The pH was measured at room 
temperature with a pH meter (Hanna instruments 8519). Calibration was performed 
with ‘colour key’  buffer solution from BDH (red – pH 4.0 ± 0.02 at 20 °C,  
yellow – pH 7.0 ± 0.02 at 20 °C). Adjustments of the pH were made with a suitable 
acid or base, e.g. HCl, NaOH, NH3.  
87 88 89 90 
91 92 93 
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Plates for the SPA were standard opaque-coloured 96-well plates (Perkin Elmer) 
with separate thin film seals from Nunc, Apogent. A procedure of heating (Digital 
Heatblock, VWR) in combination with vortexing (Vortex-Genie2, Scientific 
Industries) was employed to improve solubility of inhibitors. Plates were incubated 
in an oven, set at 37 °C (IP60, LTE). Signal counting was performed with a Plate 
Chameleon multilabel reader (Hidex Oy, Finland) and analysis carried out with 
MikroWin software (MikroWin 2000, Version 4.33, Mikrotek Laborsysteme 
GmbH). Kinetic data such as Km-determination and IC50-values were evaluated with 
GraFit (Leatherbarrow 2007). 
 
V.2.2.1 General SPA Procedure 
The reactions were carried out in standard opaque 96-well plates. 25 µL Buffer or 
inhibitor, 25 µL NMT solution and 25 µL 125 nM [3H]-myristoyl CoA at a specific 
activity of 8 Ci mmol-1 were incubated for 5 min at 37 °C. To the reaction mixture 
was added 25 µL 250 nM peptide solution and it was further incubated for precisely 
30 min at 37 °C. The reaction was quenched by the addition of 100 µL Bead-Stop 
Solution (Table V-1E). The plate was then sealed with a new film because of 
condensation during the incubation step, which led to reductions in signal. 
Measurements were performed the following day on a Plate Chameleon multilabel 
reader (Hidex Oy, Finland) to ensure complete settlements of the beads. 
 
V.2.2.1.1 Assay Substrates 
The components of the SPA buffer (30 mM Tris/HCl at pH 7.4, 0.5 mM EDTA and 
EGTA) were adopted from literature (King and Sharma 1991). DTT as well as Triton 
X-100 was added additionally (Table V-1A). Instead of 2.5 mM DTT and 1% Triton 
X-100 (Bowyer, Gunaratne et al. 2007), 1.25 mM DTT and 0.1% Triton X-100 were 
sufficient. Aliquots of 20 × Tris/HCl, EDTA, EGTA and 1 M DTT (800 ×) were 
stored separately at -20 °C. A 10% Triton X-100 solution (100 ×) was stored at RT. 
The Stop Solution (Table V-1C) was prepared fresh as storing the mixture at RT 
resulted in precipitation, most likely due to MgCl2. The Bead Solution (Table V-1D) 
was stored at 4 °C. 
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Stocks of [3H]-myristoyl CoA at 3.51 µM at a specific activity of 8 Ci mmol-1 were 
prepared with dilutions of 3.51 µM cold myristoyl CoA and 3.51 µM [3H]-labelled 
myristoyl CoA at a specific activity of 32 Ci mmol-1. Finally, the mixture was 
diluted further with 4% DMSO Standard SPA Buffer for a final concentration of 
125nM at a specific activity of 8 Ci mmol-1. The specific activity for inhibition 
studies was always 8 Ci mmol-1 unless otherwise stated. Unlabelled myristoyl CoA 
was stored in 200 µM stocks in ethanol–0.01 M NaOAc pH 5.6 buffer (1:1, V:V) at 
4 °C. [3H]-Myristoyl CoA was stored at -20 °C. 
DMSO peptide stocks (GLYVSRLFNRLFQKK(biotin)-NH2) were prepared in 
4% DMSO Standard SPA Buffer at a top concentration of 200 µM and were stored 
at 4 °C. 
In these SPA studies, 73 ng (1.40 µmol) PfNMT, 3 ng (0.06 µmol) CaMNT, 6 ng 
(0.11 µmol) HsNMT1, 83 ng (1.46 µmol) HsNMT2 and 300 ng (6.12 µmol) 
LmNMT were employed. Aliquots of NMT were kept in storage buffer (Table V-1F) 
at -20 °C. To prevent copious freeze-thaw cycles, thawed enzymes were used once. 
NMT was thawed on ice and prepared in cold 4% DMSO Standard SPA Buffer just 
before use.  
 
Table V-1: List of buffered solutions for the in vitro assay 
 Name of Buffer Components 
(A) Standard SPA Buffer 30 mM Tris × HCl (adjusted to pH 7.4 with HCl), 0.5 mM EGTA, 
0.5 mM EDTA, 1.25 mM DTT, 0.1% Triton X-100 
(B) 4% SPA Buffer 4% DMSO in Standard SPA Buffer (A) 
(C) Stop Solution 0.2 M H3PO4 (buffered to pH 4.0 with NaOH), 750 mM MgCl2, 
0.05% (w/v) BSA, 0.01% (w/v) NaN3 
(D) Bead Solution 50 mg mL-1 PVT scintillant beads in PBS/0.05% NaN3 
(E) Bead-Stop Solution 2% Bead Solution (D) in Stop Solution (C) 
(F) Storage Buffer 20% glycerol in Standard SPA Buffer (no DTT, no Triton X-100) 
 
V.2.2.1.2 Controls 
Several interplate controls were included in each SPA experiment to ensure optimal 
enzyme activity, such as an enzyme dilution series and enzymatic assays over time.  
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The dilution series was carried out with a dilution factor of 1.5 at five different 
concentrations. The performance of the enzyme was examined over time at 1, 5, 10, 
15, 20, 25, 30, 35, 40, 50, 60, 90 min.  
Other controls include no enzyme, which served as the background control. This 
value was subtracted from every signal throughout the course of the assay. 
V.2.2.1.3 Inhibitors 
A collection of inhibitors, 100 mM, 25 mM and 10 mM, were prepared in dry 
DMSO and stored at -20 °C. Stocks were diluted 25-fold with 50 °C warmed-up 
Standard SPA Buffer (Table V-1A) for in vitro tests. Furthermore, inhibitors were 
incubated at 50 °C in a heating block for 1 h to enhance solubility. 
V.2.2.1.4 IC50-Determinations  
All inhibition assays were carried out in triplicate. The percentage activity was 
calculated from uninhibited reaction vs. inhibited reaction. Thus a negative control 
with no inhibitor was included on every plate, as well as a strong inhibitor of known 
activity for a positive control. Non-hydrolysable myristoyl CoA was chosen to 
ensure that the efficacy of batches of enzymes were comparable.  
As an initial evaluation of an unknown compound, “ single point”  assays of potential 
inhibitors were performed in triplicate at a single concentration (100 µM) against 
various NMT enzymes in order to save time and material. All inhibitors that showed 
inhibition in the single point assay at 100 µM against recombinant NMT enzymes 
were assessed more thoroughly. IC50-values were determined over a range of 
12 concentration points. The top three concentration points were 1 000, 250 and 
100 µM. In well numbers 4–12, dilutions were carried out from 100 µM with a 
dilution factor of 1.5 typically. 
V.2.2.1.5 Km-Determinations 
The assay was carried out according to V.2.2.1 (p. 128). Different concentrations of 
tritiated myristoyl CoA (500–2 nM) were prepared in 2-fold dilution steps to 
investigate the myristate binding pocket. The final concentration of biotinylated 
peptide was kept constant at 250 nM. The inhibitors were added at a concentration 
around the respective IC50-value. The approximate amount of PfNMT in each well 
was 73 ng (1.40 µmol) and 3 ng (0.06 µmol) for CaNMT. 
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V.3 Results 
V.3.1 Kinetic Analysis of Substrates 
V.3.1.1 Mode of Inhibition 
To evaluate the mode of inhibition (MOI) of the drug molecules, the effect on IC50 
was examined using different concentrations of one substrate at a constant value of 
the second substrate. This shows which binding pocket (peptide or myristate) is 
blocked by the inhibitor and also gives insight into the degree of competitiveness. 
The IC50-value of one inhibitor was compared for varying concentrations of peptide 
and myristoyl CoA. Conclusions about competitive binding for either substrate can 
be drawn from the IC50-shift. 
The myristate binding pocket was investigated by changing concentration of 
myristoyl CoA and subsequent analysis of the inhibitory effect of two structurally 
different compounds. Non-hydrolysable myristoyl CoA (Figure V-5A) was thought 
to be competitive against myristoyl CoA (Figure V-5B) due to its high structural 
similarity. Compound 54 (Figure V-5C) on the other hand was hypothesised to target 
the peptidic binding domain. By variations in the concentration of myristoyl CoA, 
the IC50 of competitive inhibitors will vary accordingly. Yet IC50-values of 
uncompetitive inhibitors will remain fairly constant. 
The MOI studies were performed with inhibitor concentration producing 50% 
inhibition in vitro to clearly see effects of changing substrate concentration. The IC50 
of 54 was calculated as 19.9 ± 2.7 µM; hence 20 µM of inhibitor 54 was the working 
concentration in the assay. Non-hydrolysable myristoyl CoA was a much more 
potent inhibitor with an IC50 of 3.4 ± 0.8 nM; 10 nM of non-hydrolysable myristoyl 
CoA was used in the SPA. The final concentration of myristoyl CoA substrate at a 
specific activity of 8 Ci mmol-1 varied from 250 nM to 2 nM over 12 concentration 
points with a dilution factor of 2. 
Non-hydrolysable myristoyl CoA closely resembles myristoyl CoA, the main 
substrate, from which the myristic acid group is transferred to N-terminal Gly of 
substrate peptides during N-myristoylation. Non-hydrolysable myristoyl CoA bears 
an additional CH2-group in between the thioester, splitting the functional group to 
ketone and thioether moieties (Figure V-5A and B). The lone pair of electrons of the 
amine from the N-terminus of the peptide will not attack the ketone and thus 
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N-myristoylation of the peptide will not occur. Figure V-6A displays the kinetic 
evaluation; non-hydrolysable myristoyl CoA is a competitive inhibitor against 
myristoyl CoA and thus targets the myristoyl CoA binding pocket. The inhibitor 
slowed down the rate of reaction at low concentrations of myristoyl CoA. However 
an increase of substrate may saturate the apoenzyme so that the inhibitor has no 
access to free binding pockets. The values of the rate of reaction reached similar 
values to the control reaction upon addition of large amounts of myristoyl CoA. At 
500 nM substrate concentration, the fitted blue curve nearly corresponded with the 
grey line. It could be said that competitive inhibition was overcome at 50-fold 
concentration of the substrate. Vmax-values were equivalent. 
On the other hand, compound 54, which represents the investigated compound 
series, is an inhibitor that targets the peptidic binding pocket. Figure V-6B suggests 
54 is a non-competitive inhibitor for myristoyl CoA. Increase of substrate 
concentration did not affect the rate of inhibition. A flattening of the curve indicates 
Vmax may never be reached, even at higher inhibitor concentrations. Compound 54 
does not target the myristate binding pocket but most likely the peptide binding 
domain. 
(A)  (B)  (C)  
Figure V-5: MOI study 
Shifts in IC50 for different inhibitors were examined to determine mode of inhibition for potential 
antimalarials. MOI of a known inhibitor, non-hydrolysable myristoyl CoA (A), that is competitive 
against myristoyl CoA (B, tritiated substrate) in the myristoyl CoA binding pocket was compared to 
MOI of an unknown inhibitor 54 (C) which should solitarily target the peptidic binding pocket. 
 
 
54 
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(A)  
 
(B)  
Figure V-6: Influence of myristoyl CoA on enzyme kinetics of inhibitors 
The rate of reaction was measured without any inhibitor (dark grey-coloured) and compared to the 
rate of reaction with inhibitor (light grey-coloured) while changing concentration of one substrate, 
myristoyl CoA, and keeping the second substrate concentration, that of the peptide, constant. Two 
inhibitors were evaluated: Non-hydrolysable myristoyl CoA (A) and 54 (B). The small-sized plot is a 
double reciprocal (Lineweaver-Burk) plot. 
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V.3.1.2 Km-Determination 
Figure V-7 shows the graphical evaluation of kinetic parameters for myristoyl CoA 
in PfNMT (A) and CaNMT (B). The Km for myristoyl CoA for the malarial enzyme 
was calculated to be 14.3 ± 0.4 nM and for fungal NMT 9.9 ± 1.1 nM. The rate of 
reaction seemed to be faster for CaNMT but overall Km-values for myristoyl CoA in 
PfNMT and CaNMT are similar. This was expected, as the myristoyl CoA binding 
site is highly conserved throughout species. A final working concentration of 
250 nM [3H]-myristoyl CoA, which is well above Km, was employed in the SPA. 
The experimentally determined Km-value of 14 nM for myristoyl CoA in PfNMT 
was comparable to literature data (12 nM, (Bowyer 2006)). 
 
(A)  
(B)  
Figure V-7: Determination of Km for myristoyl CoA 
The rate of reaction was measured by varying the concentration of myristoyl CoA; peptide 
concentration was kept constant. Km was determined for PfNMT (A) and CaNMT (B) from the fitted 
data by GraFit from the Michaelis Menten equation. The double reciprocal (Lineweaver-Burk) plot is 
pictured on the right. 
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V.3.2 Optimisation Procedures for SPA 
V.3.2.1 The SPA Buffer 
The highest count of signal was achieved when the SPA buffer was made up fresh 
every day prior to in vitro experiments (Figure V-8A). It was furthermore found that 
the signal increased by using 1.25 mM instead of 2.5 mM DTT (Figure V-8B). As an 
alternative to DTT, TCEP, a milder reducing agent for disulfides, was also tried; 
however, it did not improve enzyme activity (Figure V-8B). 2.5 mM TCEP was even 
worse than the control without a reducing agent. Overall, the best results were 
obtained using 1.25 mM DTT. 
 
(A)  
 
(B)  
Figure V-8: In the search for optimum concentration of buffer components 
Buffer conditions (CaNMT, A) were examined as well as different reducing agents (PfNMT, B). 
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V.3.2.2 Substrate Optimisation 
The assay aimed for a high signal count that was at least ten times the level of 
background noise so that inhibition could be easily detected. Signal intensity can 
also be varied with enzyme concentration in such way that larger amounts of enzyme 
generally lead to an increase in signal (Figure V-9). However, upon increase of the 
enzyme concentration substrate depletion may occur represented by the tailing off of 
the straight line; the amount of 135 ng PfNMT was too high for the SPA. For lower 
concentrations (45 and 90 ng) however, the graph could be approximated to a 
straight line throughout the reaction time of 30 min, whereby the amount of enzyme 
is rate limiting. Thus the gradient can be estimated as the initial rate of reaction. 
 
 
Figure V-9: Signal dependence on enzyme concentration 
The rate of reaction was examined with three different amounts of PfNMT; 45 ng (light grey-
coloured), 90 ng (medium grey-coloured) and 135 ng (dark grey-coloured). The reaction was stopped 
at various time points. 
 
Aliquots of enzyme were constantly tested for activity in a dilution series (Figure 
V-10A) and over time (Figure V-10B). It was observed that Plasmodium falciparum 
NMT was more stable on ice than Candida albicans or human NMT. Again, plotted 
values need to resemble a straight line in the dilution series and be linear up to 
30 min for the time series to confirm stable enzyme activity. 
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(A)   (B)  
Figure V-10: Time and dilution series 
These graphs represent control reactions performed prior to any inhibition studies. Aliquots of 
PfNMT were analysed by dilution (A) and time (B). 
 
The Km-value for the peptide substrate GLYVSRLFNRLFQKK(biotin)-NH2 is 
1.2 ± 0.4 µM (Bowyer 2006). To determine the optimum amount of peptide for the 
assay, the peptide concentration was varied from 500–62.5 nM using 2-fold dilution 
at four different myristoyl CoA concentration points (62.5 nM, 125 nM, 250 nM, 
500 nM). Figure V-11A displays the results, whereby the signal strength of peptide 
concentration at 62.5 nM and 125 nM were similar at all four myristoyl CoA 
concentrations. However on increasing the peptide substrate to 250 nM, at least 
125 nM myristoyl CoA had to be present for optimum N-myristoylation. Best results 
were achieved with 500 nM peptide and 250–500 nM myristoyl CoA. 
However an increase in peptide also meant the addition of more beads to the reaction 
mixture to sufficiently bind all biotinylated peptides. Results in Figure V-11B show 
a linear trend, the higher the peptide concentration, the more beads were required to 
capture everything for evaluation. At a peptide concentration of 500 nM, at least 
0.475 mg beads were needed.  
As this is a cost-related issue, it was decided to work with 250 nM peptide substrate 
(well below the Km of 1.2 µM in PfNMT), 0.1 mg streptavidin-coated scintillation 
beads and 125 nM myristoyl CoA at 8 Ci mmol-1 (well above the Km of 14.3 nM in 
PfNMT). 
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(A)  
 
(B)  
Figure V-11: Substrate optimisation for the SPA 
The optimum amount of myristoyl CoA was determined (A) as well as the required amount of 
scintillation beads for specific peptide concentrations at 250 nM myristoyl CoA (B). 
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V.3.2.3 The Inhibitors 
DMSO is a vital component of the assay, being needed to aid solubility of inhibitors 
in the buffer and prevent precipitation. It had to be borne in mind that future in vivo 
experiments could not be carried out at high DMSO concentrations as it interferes 
with the viability of cells. The original 1% DMSO final concentration (Fig. 4.18, 
(Bowyer 2006)) was increased to 4% to maximise compound solubility. 
To further improve solubility of inhibitors, the buffer was warmed up to 50 °C in a 
heating block before the addition of inhibitors to the Standard SPA Buffer. 
Sonication was tried but improved dissolution little for moderately soluble 
compounds (Oldenburg, Pooler et al. 2005). Vigorous vortexing in between heating 
stages of up to 2 h at 50 °C was employed, a method that appeared to facilitate 
dissolution. 
One possible reasons for precipitation of compounds is too much water present in 
DMSO stocks (Oldenburg, Pooler et al. 2005). Compounds were therefore prepared 
in anhydrous DMSO (<99.9%, Sigma-Aldrich) which greatly improved solubility. 
However DMSO absorbs water readily in freeze–thaw cycles and new batches of 
inhibitors would have needed to be prepared constantly. Inhibitors were tested in the 
SPA straight after preparation of the DMSO stocks and freeze–thaw cycles were kept 
to a minimum. 
Nevertheless, precipitation still occurred for many compounds when used at a final 
concentration of 1 mM. Stepwise addition of Standard SPA Buffer to inhibitor stocks 
dissolved in 100% DMSO was unsuccessful; compounds were found to precipitate 
typically at 80% DMSO concentration. 
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V.3.3 Potency and Selectivity Studies of Inhibitors 
V.3.3.1 Interplate Control Reactions 
A positive control experiment using non-hydrolysable myristoyl CoA (Figure V-5A) 
was included whenever the in vitro SPA was performed; this was to observe steady 
enzyme activity and ensure optimal and consistent conditions for the assays. Figure 
V-12 displays inhibition curves of non-hydrolysable myristoyl CoA against NMT of 
various organisms, from which IC50-values were deduced. The values are 
summarised in Table V-2. Non-hydrolysable myristoyl CoA is a potent inhibitor 
against NMT with activity in the low nanomolar region from 2–17 nM. The 
inhibition values from all species were within the same range, which is consistent 
with the highly conserved myristoyl CoA binding site in the enzyme. 
 
 
Figure V-12: IC50 determination of non-hydrolysable myristoyl CoA against a range of NMTs 
The activity of non-hydrolysable myristoyl CoA (A) was examined against NMT of various organisms; 
PfNMT, CaNMT, HsNMT1, HsNMT2 and LmNMT. Error bars have been omitted for clarity. 
 
Table V-2: Inhibition data of non-hydrolysable myristoyl CoA against NMT 
Non-hydrolysable myristoyl CoA was tested against N-myristoyl transferase as an indicator of stable 
enzyme activity. The values were determined with GraFit. 
N-Myristoyl Transferase PfNMT HsNMT1 HsNMT2 CaNMT LmNMT 
IC50-Value [nM] 3.7 ± 0.7 6.7 ± 1.5 17.3 ± 1.5 1.9 ± 0.4 6.2 ± 2.3 
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V.3.3.2 The Lead Compound 
Lead structure 35 for inhibition studies of this project was based on Pfizer compound 
UK-370,509 (Figure V-13A, B). Out of several compounds originally produced by 
Pfizer as fungal NMT inhibitors and tested for activity against PfNMT, UK-370,509 
was one of the most active with an IC50-value of 30 ± 3 µM (Bowyer 2006). 
 
(A)   (B)  
(C)   (D)  
Figure V-13: The lead compound 
The lead compound (35, B) was based on Pfizer compound UK-370,509 (31, A), which was provided 
as an unknown salt composition (Pfizer, unpublished results). Since inhibitor 31 is of unknown salt 
composition, various salts were tested to investigate differences in activity; namely the TFA salt (94, 
C) and the HCl salt (95, D). 
 
The inhibitor was re-synthesised (IV.3.1, p. 88) and tested in the SPA against 
PfNMT for comparison with data gathered previously from UK-370,509. Expected 
inhibition should occur in the low micromolar range. Initial inhibition studies 
resulted in an IC50 of 75.0 ± 8.2 µM, a value in the same range to SPA data of 
UK-370,509 with 30 µM (Figure V-14A). 
However, the inhibition data could not be replicated (Figure V-14B). An apparent 
IC50 of 490 µM was determined from a separate set of assays performed in triplicate. 
Reasons for non-reproducible results may lie in solubility issues with the compound 
at higher concentrations (>100 µM). By diluting a highly concentrated stock of 
1 mM in DMSO 25-fold with Standard SPA Buffer, precipitation was noticed for 
both UK-370,509 and 35. Furthermore, different salt combinations (Figure V-13C, 
D) were examined to investigate solubility issues further; a TFA salt (94), an HCl 
salt (95) and a free amine (35) were tested and activity was compared (Figure V-15). 
35 31 
94 
95 
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Some improvement was noted for the HCl salt, but all showed limited and variable 
solubility at the higher concentrations needed to obtain reasonable inhibition. 
 
(A) (B)  
Figure V-14: Inhibition studies of lead compound 35 
Inhibition of PfNMT was validated for the lead compound 35. However comparable data was only 
produced in one attempt (IC50 = 75.0 ± 8.2 µM, A). In more extensive experiments it was found that 
inhibition results were not repeatable, probably due to solubility issues at higher concentrations 
(IC50 = 490 ± 105 µM, B). 
 
(A)   (B) 
Figure V-15: Inhibition studies of different salt combinations of the lead compound 
To study the effects of different salts on solubility and activity the free amine (35), the TFA salt (94) 
and the HCl salt (95) of the lead compound were studied. Data points represent a mean of triplicate 
determinations. The standard deviation for each individual point was <15% of the value; error bars 
have been omitted for clarity. Figure A shows the inhibition data and Figure B states the inhibitory 
data for each of the three compounds tested. 
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V.3.3.3 Activity against Plasmodium falciparum NMT 
V.3.3.3.1 In Vitro Analysis of 1st Generation Library – Variations of Unit A 
The 1st generation library of potential antimalarial drugs was based on 35 with the 
original cis-1,4-cyclohexane attached to the benzothiazole scaffold via an amide 
bond and variations of building block A; for synthesis see Chapter IV. The collection 
investigated several aspects to systematically explore the peptidic binding domain 
such as size, aromaticity, electron withdrawing and donating properties, as well as 
H-donor and acceptor groups. Variations of building block A were furthermore 
subject to availability. The IC50 data is documented in Table V-3 and inhibition 
curves displayed in Figure V-17. 
To probe the dimensions of the peptidic binding pocket, the size of the aromatic ring 
(49, 94, 68 in Table V-3) as well the spacing of the aromatic ring from the amine 
(49, 70 in Table V-3) were investigated first. For variations in size the following 
groups were chosen: methylbenzene (49), methylnaphthalene (94) and 
methylanthracene (68). A tendency towards larger aromatic ring systems to increase 
potency in PfNMT was noted (Figure V-17A). Compound 68 was more active 
against PfNMT than 94 and 49. GraFit was used to estimate IC50-values of some 
compounds as they were largely insoluble at a top concentration of 1 mM in the 
buffer system. It was estimated that 68 had an IC50 of 177 µM, whereas the smaller-
sized aromatic substituents, such as naphthyl and benzyl, both showed weaker 
inhibition characteristics with 0.5 mM and 1 mM respectively. The small increase of 
activity could be driven by an increase of logP. Solubility issues prohibited thorough 
examination. 
Ethylbenzene substituent (70) as opposed to methylbenzene (49) was selected to 
investigate possible CH–% interactions further into the cavity. No change in activity 
was observed with an IC50 of 1.66 mM for compound 70 compared to 1 mM for 49 
(Figure V-17B). The spacer unit was perhaps too small to have significant impact on 
more optimal binding. 
Next, aliphatic vs. aromatic character was compared with building blocks 
methylcyclohexane (48) and methylbenzene (49) respectively (Table V-3). There 
was no enhancement in activity against PfNMT observed with an IC50 of 1 mM for 
both compounds 48 and 49 (Figure V-17C). 
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The introduction of heteroatoms gives aromatic ring systems opportunities for polar 
interactions such as hydrogen bonding, 5-methylbenzofuran (54) was assessed 
(Table V-3). Compound 54 was far more potent against PfNMT than the lead 
compound 94 (Figure V-17D) with an IC50 of 19.9 ± 2.7 µM (Figure V-16). 
The degree of aromaticity of 49 was explored through groups that may either 
increase or decrease the electron density of the ring system (49, 61, 63, 67, 59, 58, 64 
in Table V-3). The effects of p-fluoromethylbenzene (61) and pentafluoro-
methylbenzene (63) were investigated. Fluoride for example is highly 
electronegative and decreases the overall electron density of the aromatic ring as it 
pulls them towards itself, also called negative inductive effect. The positive 
mesomeric effect, by which the aromatic ring is activated, is overruled by the 
electronegativity of the element because fluoride has such a high electronegative 
value. Other groups that exhibit a –I/+M effect and additional H-donor properties in 
case of the first substituent were 2,3-dihydroxymethylbenzene (67), p-methoxy-
benzene (59) and p-methylsulfonylbenzene (58). Compound 64, m-nitromethyl-
benzene, deactivates the aromatic ring system due to the –I/–M character. 
Compounds 61 and 63 were not active at the highest concentration of 1 mM (Figure 
V-17E, i). All other inhibitors (67, 59, 58 and 64) displayed some activity at 1 mM 
(Figure V-17E, ii). However, they were not sufficiently potent against PfNMT to 
determine an IC50-value, apart from 59 with a determined IC50 of 702 ± 49 µM. No 
distinct conclusion could be drawn about electron–withdrawing or electron–donating 
substituents that favour interactions with surrounding amino acids in the target 
binding site. 
Overall, only compound 54 was active against PfNMT and inhibited 
N-myristoylation in the low micromolar region with an IC50 of 19.9 ± 2.7 µM 
(Figure V-16). Ideally, the working concentration of a good inhibitor should be in 
the nanomolar range for optimum target binding. For purpose of this discussion, in 
this thesis definition of inhibitors is as follows; strong inhibitors display inhibition at 
a concentration <100 µM, moderate inhibitors show activity 100–500 µM and weak 
inhibitors have an IC50 in the range of 500–1 000 µM. 
Analyses of results so far suggested that building block A should possess an 
aromatic core in combination with a heteroatom such as a benzofuran group. 
Favourable interactions of the aromatic ring system could potentially be with other 
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aromatic groups of nearby amino acids in the peptidic binding pocket for CH–% 
interactions. An ionic interaction of the heteroatom with surrounding amino acids is 
also likely. The next library focused on analogues of 54. 
 
Table V-3: Evaluation of activity against PfNMT of the 1st generation library – Variations of 
building block A 
This table summarises results of the SPA for compounds of the 1st generation library against PfNMT. 
Several properties were evaluated such as ring size and aromaticity. The inhibitors in this table are 
ordered in groups to compare these characteristics. The SPA was carried out in triplicate, whereby 
the average, normalised to the uninhibited reaction, was quoted with standard deviation error. Many 
samples were insoluble at >100 µM, thus the IC50 was estimated with GraFit to observe trends; 
extrapolated curves are marked with *. 
The active compound against PfNMT is highlighted in grey. 
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Compound Number RA IC50 Determination [µM] Trend 
94 
 
481 ± 62* 
 
54 
 
19.9 ± 2.7  
 
   
49 
 
1 005 ± 124 
 
61 
 
>1 000  
63 
 
>1 000 
 
67 
 
993 ± 135  
59 
 
687 ± 32  
58 
 
350 ± 359*  
64 
 
>1 000  
 
 
 
Figure V-16: IC50 determination of compound 54 
This figure shows the inhibition curve of 54 against PfNMT generated with GraFit. The IC50 was 
determined as 19.9 ± 2.7 µM. 
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(A) Size of aromatic ring system   (B) Size of spacer 
  
 
(C) Aromatic character    (D) Introduction of heteroatoms 
 
  
 
 
(E) i) Variation of degree of aromaticity  (E) ii)  
  
Figure V-17: Inhibition curves of compounds tested against PfNMT 
Various compounds were tested for potency against PfNMT and the inhibition curves are shown. The 
size of the aromatic ring (A), the spacing out of the aromatic unit (B), aromatic character (C), 
influence of heteroatoms (D) and differing electron density of the aromatic ring system (E) were 
investigated. Data points represent the mean of triplicate samples. The standard deviation on each 
individual point was <15% of the value; error bars have been omitted for clarity. 
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V.3.3.3.2 In Vitro Analysis of 2nd Generation Library – New Variations of Building 
Block A 
The next step included investigations of close analogues to compound 54 as this was 
the only compound from the 1st generation library to show enhanced activity against 
PfNMT. The results are shown in Table V-4 and inhibition curves are displayed in 
Figure V-18. 
Heteroatoms play a role in binding as results suggest (V.3.3.3.1, p. 143). Replacing 
the oxygen atom (54) with a heteroatom from the same group, sulfur (72), may affect 
binding. Due to the larger size of the soft sulfur atom, it may be a more favourable 
electron acceptor than oxygen. The activity against PfNMT of the inhibitor with 
5-methylbenzothiophene as building block A was equal to 5-methylbenzofuran. The 
calculated IC50 of 54 was 19.9 ± 2.7 µM (Figure V-19A) compared to 24.5 ± 4.9 µM 
for 72 (Figure V-19B). Subtle differences in the slope of the inhibition curves were 
noted. The Hill slope found for 72 was much shallower than for 54 (Figure V-18A). 
This may be due to different kinetics of the inhibitors or solubility issues. 
Compound 73, the nitrogen analogue, showed moderate signs of inhibition with an 
IC50 of 116 ± 11 µM but no overall improvement of activity compared to 54 (Figure 
V-18A, Figure V-19C). It can be assumed that the additional proton donor moiety in 
that position was of no use for effective interactions with surrounding AA of the 
target binding site. 
Next, size and character of the aromatic system including differing heteroatoms were 
examined a bit closer with 54 and 72 as well as 51 and 65. A loss of activity was 
noted for both 5-methylbenzofuran and 5-methylbenzothiophene lead compound 
analogues with IC50 >1 mM when the system was reduced to methylfuran or 
methylthiophene as unit A. An increase in size (69) did not improve inhibition of 
PfNMT either (Figure V-18B); neither did the loss in aromaticity (71) compared to 
inhibitor 54 (Figure V-18B), IC50 >1 mM was observed for both. 
The insertion of yet another heteroatom (56), however, led to moderate activity with 
an IC50-value of 379 ± 42 µM though 56 is not as active as 54 (Figure V-18B, Figure 
V-19D). 
By excluding the heteroatom from the ring system to a methoxy-group, –OCH3 acted 
as an electron donating group (–I/+M effect). Inhibition was not improved. 
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Compound 59 weakly inhibited PfNMT with an IC50 of 687 ± 32 µM (Figure 
V-18B). 
In general, the tested analogues of compound 54, the 2nd generation library, did not 
reveal more potent N-myristoyl transferase inhibitor candidates. Nevertheless, four 
compounds were discovered that display activity against PfNMT in the low 
micromolar region with 5-methylbenzofuran, 5-methylbenzothiophene, 
5-methylindole and methylbenzodioxole as building block A; the inhibition curves 
of each are displayed in Figure V-19. Of those inhibitors, two compounds are very 
active, 54 and 72, with an IC50 of 19.9 ± 2.7 µM and 24.5 ± 4.9 µM respectively. 
The results suggest that building block A should contain a heteroatom such as 
oxygen or sulfur for ideal ionic interactions. Additionally the position of the 
heteroatom is also important as increase or decrease in size of the aromatic core 
resulted in loss of activity.  
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Table V-4: Evaluation of activity against PfNMT of the 2nd generation library – Variations of 
building block A 
This table summarises results of the SPA for inhibitors of the 2nd generation library against PfNMT. 
The compounds were based on 54, whereby analogues were tested differing in heteroatoms, 
aromaticity and ring size for example. The inhibitors in this table are ordered in groups to compare 
these characteristics. The SPA was carried out in triplicate, whereby the average, normalised to the 
uninhibited reaction, was quoted with standard deviation error.  
Active compounds against PfNMT are highlighted in grey. 
 
 
Compound Number RA IC50 Determination [µM] Trends 
54 
 
19.9 ± 2.7 
 
72 
 
24.5 ± 4.9  
73 
 
116 ± 11  
 
   
54 
 
19.9 ± 2.7 
 
69 
 
>1 000  
71 
 
1 206 ± 395  
56 
 
379 ± 42  
59 
 
687 ± 32  
 
  
 
54 
 
19.9 ± 2.7 
 
51 
 
1 090 ± 114  
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Compound Number RA IC50 Determination [µM] Trends 
72 
 
24.5 ± 4.9 
 
65 
 
1 488 ± 206  
 
 
(A) Different heteroatoms    (B) Various changes 
  
 
 
(C) i) Changes in size with different heteroatom ii) Changes in size with different heteroatom 
  
 
Figure V-18: Inhibition curves of compounds tested against PfNMT 
Analogues of 54 were tested for potency against PfNMT and the inhibition curves are shown. 
Different heteroatoms (A) and size of aromatic ring system (C) among other various factors (B) were 
explored. Data points represent the mean of triplicate samples. The standard deviation on each 
individual point was <15% of the value; error bars have been omitted for clarity. 
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(A) IC50 of 54 against PfNMT = 19.9 ± 2.7 µM (B) IC50 of 72 against PfNMT = 24.5 ± 4.9 µM 
  
 
(C) IC50 of 73 against PfNMT = 116 ± 11 µM (D) IC50 of 56 against PfNMT = 379 ± 42 µM 
  
 
Figure V-19: IC50 determination of 54, 72, 73 and 56 
This figure shows the inhibition curve of 54, 72, 73 and 56 against PfNMT generated with GraFit.  
 
 
V.3.3.3.3 Examination of Remaining Building Blocks – Linkage of Units A and B 
Building blocks A and B were connected to each other via an amine bond. The 
secondary amine was created during the reaction of a primary amine moiety with an 
aldehyde after subsequent reduction, namely reductive amination (Figure IV-25). 
The secondary amine moiety was examined closely as it was thought to interact with 
the C-terminal carboxylate of N-myristoyl transferase (Hasegawa, Morikami et al. 
2003). 
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Figure V-20: Modifications of the secondary amine moiety 
The secondary amine can be either acetylated or alkylated (from left to right). The modified 
compounds were tested for activity against PfNMT to investigate the importance of the secondary 
amine moiety. 
 
Consequently, the 2° amine moiety was modified and investigated for three 
compounds, 94, 49 and 54 (Figure V-20). The most straightforward alteration was 
acetylation with acetic anhydride which yielded 83, 84 and 85 respectively (IV.3.4, 
p. 116). The acetyl group was chosen as it is a fairly small and may not sterically 
hinder interactions between the nitrogen atom and surrounding AA. However, a 
complete loss in activity was recorded for 85 (Figure V-21).  
The other modification of the secondary amine moiety tested was a tertiary amine 
with two RA groups attached, the by-product of the reductive amination, 97, 53 and 
55 were tested but no activity against PfNMT was observed (Figure V-21). The 
large-sized aromatic unit may possibly interfere with the correct orientation in the 
target site for optimal binding.  
Another reason for loss in activity in both cases of acetylation and alkylation is the 
removal of the 2° amine functionality. The findings suggest that the 2° amine is 
needed. It may function as a proton donor and interacts most likely with the 
C-terminal carboxylate (Figure II-17). 
  
B A
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Table V-5: Evaluation of activity against PfNMT – The RA-RB-Linkage 
This table summarises results of the SPA for assorted inhibitors against PfNMT to evaluate the 
influence of the 2° amine moiety. The compounds were based on 94, 49 and 54. The inhibitors in this 
table are ordered in groups to compare these characteristics. The SPA was carried out in triplicate, 
whereby the average, normalised to the uninhibited reaction, was quoted with standard deviation 
error. Many samples were insoluble at >100 µM, thus the IC50 was estimated with GraFit to observe 
trends; extrapolated curves are marked with *. 
The active compound against PfNMT is highlighted grey. 
 
 
Compound 
Number 
R’ RA IC50 Determination 
[µM] 
Trends 
94 
 
 
481 ± 62*  
83 
 
 
>1 000  
97 
  
>1 000  
 
    
49 
 
 
1 005 ± 124  
84 
 
 
>1 000  
53 
  
>1 000  
 
    
54 
 
 
19.9 ± 2.7  
85 
 
 
>1 000  
55 
  
>1 000  
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(A) Naphthyl derivatives    (B) Benzyl derivatives 
  
 
(C) Benzofuran derivatives 
 
 
Figure V-21: Inhibition curves of compounds tested against PfNMT 
Analogues of 94, 49 and 54 with a modified 2° amine moiety were tested for potency against PfNMT, 
the inhibition curves are shown. The acetylated version (83, 84, 85) was investigated as well as the 
dialkylated species (97, 53, 55). Data points represent the mean of triplicate samples. The standard 
deviation on each individual point was <15% of the value; error bars have been omitted for clarity. 
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V.3.3.3.4 Examination of Remaining Building Blocks – Variations of Unit B 
The starting point for building block B was the cis-1,4-aminocyclohexyl unit (Figure 
V-22A), as it had proven to be the most effective group out of the “ Pfizer series” , 
which included alkyl chains, aliphatic ring or heterocyclic systems (Pfizer, 
unpublished research). In addition to further explore the cavity of the peptidic 
binding domain another building block was chosen that had a different orientation of 
substituents; the cis-1,3-aminocyclohexyl unit (Figure V-22B). The trans-isomer of 
either was not readily available. To investigate the need for building block A in 
general, Figure V-22C, D and E were also examined. To further explore the binding 
site a different size of the aliphatic ring system, as well as the introduction of 
heteroatoms and linker molecules, were utilised (Figure V-22F, G and H). 
 
(A)  (B)  (C)  (D)  
(E)   (F)   (G)  (H)  
Figure V-22: A wide selection of building block B 
Various building blocks have been used and tested such as the cis-1,4-aminocyclohexyl (A), cis-1,3-
aminocyclohexyl (B), 1,4-aminocyclohexyl (C), cyclohexyl (D), methylcyclohexyl (E), proline (F) and 
triazole (G and H) units. 
 
They were tested in vitro against PfNMT in combination with three different 
building blocks A (methylbenzene, methylnaphthalene, 5-methylbenzofuran). 
Several conclusions may be gathered from the experiments. First of all, the results 
showed compounds that lack unit A (39, 40, 38, 37, 44) inhibited PfNMT weakly. 
Compound 37 displayed the highest activity out of the five compounds with an 
IC50-value of 743 µM. 
The level of inhibition could not be improved much with triazoles or proline as 
unit B. This may be due to the lack of the secondary amine functionality. To 
investigate this, compound 89 was synthesised and tested. Activity was restored with 
1196 µM although not as active as 94 with 481 µM. Presumably, 96 would be even 
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more active against PfNMT because 5-methylbenzofuran is a better choice as 
building block A compared to methyl-benzene and methylnaphthalene. Nevertheless, 
compounds with 5-methyl-benzofuran did not guarantee activity. The substituents of 
building block B need to have optimal orientation in the binding pocket. This was 
not the case for either proline (Figure V-22F) or triazole (Figure V-22G).  
From the range of building blocks B, cis-1,4- and cis-1,3-aminocyclohexyl units 
were the most appropriate for the particular section of the molecule as all of them 
were active; 1005 µM for 49 and 473 µM for 76 with methylbenzene, 481 µM for 94 
and 359 µM for 74 with methylnaphthalene as well as 19.9 ± 2.7 µM for 54 and 
35.9 ± 1.9 µM for 78 with 5-methylbenzofuran as unit A. 
These correlations were investigated thoroughly with more building blocks A. The 
results of activity against PfNMT are listed in Table V-6 and the inhibition curves 
are shown in Figure V-23. Results indicate that there is no considerable difference in 
inhibition between the cis-1,4- and cis-1,3-aminocyclohexyl unit. Inhibition data was 
very similar, especially for the most potent inhibitor from the library so far. 
Compound 54 and 72 from the the cis-1,4-aminocyclohexyl series inhibited PfNMT 
at 19.9 ± 2.7 µM and 25.5 ± 4.9 µM respectively. The cis-1,3-amino-cyclohexyl 
analogue 78 and 81 displayed equal activity against PfNMT with IC50-values of 
35.9 ± 1.9 µM and 44.8 ± 3.1 µM.  
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Table V-6: Evaluation of activity against PfNMT 
This table summarises results of the SPA for inhibitors against PfNMT comparing the activity of cis-
1,3-cyclohexyl vs. cis-1,4-cyclohexyl building block B. The inhibitors in this table are ordered in 
groups to compare these characteristics. The SPA was carried out in triplicate, whereby the average, 
normalised to the uninhibited reaction, was quoted with standard deviation error. Many samples were 
insoluble at >100 µM, thus the IC50 was estimated with GraFit to observe trends; extrapolated curves 
are marked with *. All compounds were tested as the TFA salt. 
Active compounds against PfNMT are highlighted grey. 
 
 
Compound Number RB RA IC50 Determination [µM] 
38 
 
 
1946 ± 346 
43 
 
 
743 ± 54 
 
   
37 
 
 
2317 ± 348 
41 
 
 
>1 000 
 
   
49 
 
 
1005 ± 124 
76 
 
 
473 ± 46 
 
   
94 
 
 
481 ± 62* 
74 
 
 
359 ± 57 
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Compound Number RB RA IC50 Determination [µM] 
54 
 
 
19.9 ± 2.7 
78 
 
 
35.9 ± 1.9 
 
   
72 
 
 
24.5 ± 4.9 
81 
 
 
44.8 ± 3.1 
 
   
73 
 
 
116 ± 11 
80 
 
 
275 ± 48 
 
   
56 
 
 
379 ± 42 
82 
 
 
620 ± 159 
 
 
(A) No unit A     (B) tert-Butyl derivatives 
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(C) Benzyl derivatives    (D) Naphthyl derivatives 
  
 
(E) Benzofuran derivatives   (F) Benzothiophene derivatives 
  
 
(G) Indole derivatives    (H) Benzodioxole derivatives 
  
Figure V-23: Comparison of IC50 data between cis-1,3- and cis-1,4-cyclohexyl building block B 
This figure compares inhibition curves between the cis-1,4- and cis-1,3-cyclohexyl building block B 
against PfNMT generated with GraFit. The following compounds were tested: 38 and 43 (A), 37 and 
41 (B), 49 and 76 (C), 94 and 74 (D), 54 and 78 (E), 72 and 81 (F), 73 and 80 (G), as well as 56 and 
82 (H). 
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V.3.3.3.5 Examination of Remaining Building Blocks – Variations of Unit C 
Not much is known about the benzothiazole scaffold, but research has shown vital 
interactions of the aromatic ring system as well as ionic interactions with the 
heteroatoms (Hasegawa, Morikami et al. 2003). The benzoxazole scaffold, a close 
analogue, was synthesised and tested for activity against PfNMT; however, there 
was no inhibition recorded (Table V-7). This may be due to the missing secondary 
amine moiety in building block B that is likely to be necessary for interactions with 
the C-terminus, from which part of the peptidic binding domain is formed. Hence no 
conclusion could be drawn about the improvement of building block C. 
 
Table V-7: Evaluation of activity against PfNMT 
This table summarises results of the SPA for assorted inhibitors against PfNMT to evaluate building 
block C. The compounds were based on 94, 49 and 54. The inhibitors in this table are ordered in 
groups to compare these characteristics. The SPA was carried out in triplicate as a single point assay 
at 100 µM.     
Compound 
Number 
RCB RA IC50 Estimation [µM] 
87 
 
 
>1 000 
91 
 
 
>1 000 
88 
 
 
>1 000 
92 
 
 
>1 000 
90 
 
 
>1 000 
93 
 
 
>1 000 


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V.3.3.4 Activity against Homo sapiens NMT 
Four compounds were found to be very active against PfNMT: 54, 78, 72 and 81. 
They inhibit in vitro N-myristoylation in the low micromolar region. Drug molecules 
should not only be potent against the enzyme of the target parasite but also display 
selectivity towards the human analogue. Potential antimalarials are ideally very 
specific towards the target. To evaluate selectivity of the synthesised compounds 54, 
78, 72 and 81 were tested against HsNMT1 and HsNMT2. The results are listed in 
Table V-8 and inhibition curves are displayed in Figure V-24. 
All four compounds are shown to be very active against both isomers of human 
NMT. The IC50-value of 54 was calculated as 37.8 ± 11.8 µM for HsNMT1 and 
35.6 ± 4.7 µM for HsNMT2 (Figure V-24A). Also equally active against both forms 
of human NMT was the sulfur analogue 72 with an IC50 of 25.2 ± 6.8 µM for 
HsNMT1 and 16.3 ± 2.3 µM for HsNMT2 (Figure V-24B). The IC50 of 78 was 
determined as 48.8 ± 16.4 µM for HsNMT1 and 35.3 ± 4.3 µM for HsNMT2 (Figure 
V-24C). However, the sulfur analogue of 78, 81, did not display such high activity 
against HsNMT2 with an IC50 of 170 ± 33 µM and against HsNMT1 50.2 ± 11.1 µM 
(Figure V-24D). 
 
Table V-8: Evaluation of activity against human NMT 
This table summarises the results of the SPA where the most potent inhibitors found against PfNMT 
were tested against human NMT, both HsNMT1 and HsNMT2. The inhibitors in this table are ordered 
in groups for easier comparison. The SPA was carried out in triplicate, whereby the average, 
normalised to the uninhibited reaction, was quoted with standard deviation error. All compounds 
were tested as the TFA salt. 
 
Compound Number RB RA IC50 Determination [µM] 
HsNMT1                HsNMT2 
54 
 
 
37.8 ± 11.7 35.6 ± 4.7 
78 
 
 
48.8 ± 16.4 35.3 ± 4.3 


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Compound Number RB RA IC50 Determination [µM] 
HsNMT1                HsNMT2 
72 
 
 
25.2 ± 6.8 16.3 ± 2.3 
81 
 
 
50.2 ± 11.1 170 ± 33 
 
 
(A) IC50 data of compound 54   (B) IC50 data of compound 78 
  
 
(C) IC50 data of compound 72   (D) IC50 data of compound 81 
  
Figure V-24: Inhibition curves of selected inhibitors against human NMTs 
Inhibition curves of four compounds against PfNMT are displayed: 54 (A), 78 (B), 72 (C) and 81 (D). 
(Legend: brown = HsNMT1 (1), yellow = HsNMT2 (2)) 
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Overall, all four compounds were very effective against human NMT with activity in 
the low micromolar region. They did not display high selectivity towards PfNMT in 
comparison with the human homologue (Table V-9, Figure V-25).  
 
Table V-9: Comparison of potency and selectivity against malarial and human NMT 
The rate of inhibition of the four most potent inhibitors against PfNMT was compared against human 
NMT for selectivity, cis-N-(benzo[d]thiazol-2-yl)-4-(benzofuran-5-ylmethylamino)cyclohexane-
carboxamide (54), cis-N-(benzo[d]thiazol-2-yl)-4-(benzothiophene-5-ylmethylamino)cyclohexane-
carboxamide (78), cis-N-(benzo[d]thiazol-2-yl)-3-(benzofuran-5-ylmethylamino)cyclohexane-
carboxamide (72) and cis-N-(benzo[d]thiazol-2-yl)-3-(benzo-thiophene-5-ylmethylamino)cyclo-
hexanecarboxamide (81).  
 
Compound 
Number 
RB RA IC50-Value 
(PfNMT) 
[µM] 
IC50-Value 
(HsNMT1) 
[µM] 
IC50-Value 
(HsNMT2) 
[µM] 
54 
 
 
19.9 ± 2.7 37.8 ± 11.7 35.6 ± 4.7 
72 
 
 
24.5 ± 4.9 25.2 ± 6.8 16.3 ± 2.3 
78 
 
 
35.9 ± 1.9 48.8 ± 16.4 35.3 ± 4.3 
81 
 
 
44.8 ± 3.1 50.2 ± 11.1 170 ± 33 
 
  


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(A) Activity of 54                                            (B) Activity of 78 
      
 
(C) Activity of 72                                           (D) Activity of 81 
     
Figure V-25: Comparison of potency and selectivity against malarial and human NMT 
Inhibition curves of four compounds are displayed against PfNMT, HsNMT1 and HsNMT2: 54 (A), 
78 (B), 72 (C) and 81 (D). Data points represent the mean of triplicate samples. The standard 
deviation error on each individual point was <15% of the value; error bars have been omitted for 
clarity. 
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V.3.3.5 Activity against NMT of other organisms 
Inhibitors were also tested against Candida albicans NMT (CaNMT), Leishmania 
major NMT (LmNMT) and Trypanosoma brucei NMT (TbNMT). Inhibitory studies 
against the latter organism were conducted by Dr S Elroy (Drug Discovery Centre, 
University of Dundee, UK). The data is listed in Table V-10. 
Only 54 and 78, the most active inhibitors against PfNMT, were tested against 
Leishmania major NMT, an N-myristoyl transferase of another species. Both 
compounds inhibited the enzyme moderately with an IC50 of 270 µM and 180 µM 
respectively. 
Compounds 54 and 78 displayed strong inhibition against fungal NMT; an 
IC50-value of below 4 µM was recorded as the most potent. In fact, numerous 
compounds were active against CaNMT with a selection listed in Table V-10. 
However no inhibitors showed any signs of inhibition against TbNMT (Table V-10) 
at a top concentration of 50 µM. It is likely that the peptidic binding pocket from 
TbNMT differs largely from the malarial enzyme peptidic binding domain as 
phylogenetic analysis had indicated (Figure II-10). 
 
Table V-10: Evaluation of activity against CaNMT, LmNMT and TbNMT 
This table summarises results of the SPA for assorted inhibitors against CaNMT, LmNMT and 
TbNMT. The inhibitors in this table are ordered in groups to compare these characteristics. The SPA 
was carried out in triplicate unless otherwise stated, whereby the average, normalised to the 
uninhibited reaction, was quoted with standard deviation error. All compounds were tested as the 
TFA salt. 
 
Compound 
Number 
RB RA IC50 Determination [µM] 
CaNMT*             LmNMT**   TbNMT*** 
49 
 
 
134 ± 23 n.t. >50 
94 
 
 
62.0 ± 15.2 n.t. >50 
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Compound 
Number 
RB RA IC50 Determination [µM] 
CaNMT*             LmNMT**   TbNMT*** 
48 
 
 
211 ± 54 n.t. n.t. 
54 
 
 
10.8 ± 2.2 268 ± 106 >50 
67 
 
 
443 ± 119 n.t. n.t. 
56 
 
 
203 ± 34 n.t. >50 
59 
 
 
211 ± 8 n.t. n.t. 
51 
 
 
495 ± 53 n.t. n.t. 
     
43 
 
 
190 ± 28 n.t. >50 
74 
 
 
14.0 ± 2.4 n.t. >50 
76 
 
 
140 ± 19 n.t. >50 
78 
 
 
3.8 ± 0.6 180 ± 96 >50 
*SPA against CaNMT, multiple point analysis for IC50 determination, in triplicate; **SPA against 
LmNMT, single point analysis for IC50 determination; ***SPA carried out by Dr S Elroy at University 
of Dundee; n.t. = not tested 
 
 
  


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V.4 Conclusion and Discussion 
Optimal concentrations of all substrates have been investigated; 125 nM 
[3H]-myristoyl CoA at a specific activity of 8 Ci mmol-1, 250 nM PfARF1 substrate 
(GLYVSRLFNRLFQKK(biotin)-NH2) and 0.1 mg streptavidin-coated scintillation 
beads were employed in the SPA to monitor N-myristoylation. Additionally DMSO 
was added at a final concentration of 1% to increase solubility of inhibitors. To 
further maximise solubility of compounds tested, they were incubated in the buffer at 
50 °C and subjected to regular heat–vortex cycles over 1 h. Enzymes were thawed on 
ice shortly before the assay was conducted. The most favourable concentration for 
NMTs of various enzymes was established with enzyme dilution and time series. It 
was found that 73 ng (1.40 µmol) PfNMT, 3 ng CaMNT (0.06 µmol), 6 ng 
(0.11 µmol) HsNMT1, 83 ng (1.46 µmol) HsNMT2 and 300 ng (6.12 µmol) 
LmNMT gave satisfactory results in the SPA. 
The recombinant PfARF1 substrate was used as a peptide substrate in previous 
studies for CaNMT and human NMT (Bowyer, Gunaratne et al. 2007). Hence it was 
used as a peptide substrate against all enzymes in this project. However, for more 
accurate inhibition results different peptide substrates should be synthesised for 
human NMT and LmNMT. Synthetic peptide substrates for the latter may be based 
on HASPA, HASPB or ARL (Panethymitaki, Bowyer et al. 2006). Adequate peptide 
substrates for human NMT may be based on the N-terminus of p60Scr (McIlhinney, 
Patel et al. 1994; Giang and Cravatt 1998). Results of interactions with the peptidic 
binding pocket of NMT of various organisms may be more precise if more specific 
substrates were used. 
Non-hydrolysable myristoyl CoA is an inhibitor that targets the myristoyl CoA 
binding pocket to inhibit N-myristoylation. As this site is highly conserved 
throughout species, non-hydrolysable myristoyl CoA is not a drug candidate for 
malaria (Figure II-10). Selectivity, especially between PfNMT and the human 
analogue is an essential criterion in drug development. The compound was assayed 
as a positive control to confirm high activity of different batches of enzyme as each 
assay was carried out with a new aliquot of enzyme to avoid degradation due to 
frequent freeze–thaw cycles. The activity of the enzyme over time was investigated 
to assure comparable enzyme activity levels. The inhibition values were all within 
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the same range and highlight the vast level of conservation of the myristoyl CoA site 
in NMT (Figure V-12). 
About 50 inhibitors were synthesised and tested for activity against PfNMT. The 
1st generation library incorporated a variety of building blocks A with diverse 
characteristics to investigate the binding pockets more thoroughly. 
Research indicated that the size of the aromatic group is important, suggesting that 
larger-sized aromatic groups increase interactions with AA in the target binding site: 
anthracyl > naphthyl > benzyl, benzofuran > furan, benzothiophene > thiophene. 
No conclusions can be drawn about the level of aromaticity as building block A 
compared to an aliphatic unit. Aromaticity was explored by utilising building 
block A with differing substituents, such as fluoro-substituted groups to decrease 
aromaticity and methoxy-groups to enhance electron density of the ring. 
Activity study showed that the insertion of heteroatoms greatly increased activity, 
although the number of heteroatoms was not as important as the position of the 
heteroatom for vital polar interactions: benzofuran > benzodioxole > naphthyl. The 
most active inhibitors against PfNMT had IC50-values in the low micromolar range: 
54 (19.9 ± 2.7 µM), 78 (35.9 ± 1.9 µM), 72 (24.5 ± 4.9 µM) and 81 (44.8 ± 3.1 µM). 
The inhibition curves for 72 and 81 were quite shallow. More data points should be 
collected as 13 µM, the last data point, of 72 still inhibited PfNMT by ~30%. The 
shape of the curve would change, leading to a more precise IC50-value. The Hill 
slope factor for the graph was 0.5, too inaccurate for comparison. 
In addition, it was also found that the secondary amine functionality was vital for 
strong inhibition of PfNMT as modifications of 54 lead to a complete loss in activity. 
It is thought to interact with the C-terminus of the enzyme which partially forms the 
peptide binding site. 
The four most potent inhibitors (54, 78, 72 and 81) from the small-sized library were 
tested for selectivity against both human NMT enzymes, HsNMT1 and HsNMT2. 
All compounds tested displayed activity within the same range as with regards to 
PfNMT, hence 54, 78, 72 and 81 did not exhibit selectivity towards the malarial 
N-myristoyl transferase. 
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VI   IN VIVO EVALUATION OF INHIBITORS 
 
VI.1 Introduction 
The antimalarial drug target development aims at the erythrocytic cycle. The target 
enzyme, N-myristoyl transferase, will be inhibited by optimised potent inhibitors 
possibly leading to parasitic death. Previous work with small molecule NMT 
inhibitors incubated in Plasmodium falciparum infected erythrocytes resulted in a 
significant reduction of parasitemia (Bowyer 2006; Bowyer, Gunaratne et al. 2007).  
The complex life cycle of the parasite was briefly discussed in Chapter II.1.3 (p. 22). 
After rupture of hepatocytes, merozoites reach the bloodstream and invade 
erythrocytes, a complex multi-step process referred to as erythrocytic cycle, where 
the asexual reproduction occurs. For Plasmodium falciparum this is typically 48 h 
(Figure VI-1). After invasion, a parasitophorous vacuole is formed during the ring 
stage or so-called early-stage trophozoites (Figure VI-2A). The rapid maturation of 
trophozoites also leads to changes in erythrocytes. As haemoglobin is consumed the 
crystalline by-product haemozoin accumulates, also called malaria pigment (Pagola, 
Stephens et al. 2000; Wiesner, Ortmann et al. 2003; Baton and Ranford-Cartwright 
2005). After multiplication, the throphozoites form schizonts (Figure VI-2B) and 
mature to merozoites over time. The cell prepares for re-invasion of new 
erythrocytes by replicating and dividing into typically 16–32 merozoites (Bozdech, 
Llinas et al. 2003). After cell rupture, the merozoites quickly and selectively invade 
uninfected erythrocytes (Cowman and Crabb 2006). Induced by stress factors, a 
small proportion undergoes sexual development; they differentiate into female and 
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male gametocytes (Figure VI-2C) and are taken up by feeding mosquitoes (Talman, 
Domarle et al. 2004). 
This section describes in vivo assays, namely FACS, with Plasmodium falciparum 
infected erythrocytes to analyse the effect of synthesised potential antimalarials on 
parasitemia. 
 
 
Figure VI-1: Life stages of Plasmodium falciparum during the erythrocytic cycle I 
The diagram shows the major morphological stages; ring-, trophozoite- and schizont-stage over time 
as well as Giesma stains of each stage (Bozdech, Llinas et al. 2003).  
 
 
 
Figure VI-2: Life stages of Plasmodium falciparum during the erythrocytic cycle II 
A close-up of ring forms (A), mature schizonts (B) and a gametocyte (C) (Suh, Kain et al. 2004). 
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VI.2 Material & Methods 
In vivo studies were entirely carried out by Dr D Moss at The National Institute of 
Medical Research (NIMR), London, UK. 
 
VI.2.1 Chemicals and Reagents 
Dry DMSO for inhibitor stocks was purchased from Sigma Aldrich. 20 mM stocks 
of inhibitors in 100% DMSO were provided to Dr D Moss at NIMR. 
Hydroethidine (HE) fluorescent stain was obtained from Polyscience. Stocks of 
10 mg mL-1 in DMSO were stored at -70 °C. 2% Haematocrit are 2% red blood cells 
in media, i.e. 2 mL erythrocytes in 100 mL media. 70% Percoll was purchased from 
Amersham Biosciences (formerly known as GE Healthcare). Albumax was 
purchased from GIBCO and Giesma from BDH. 
 
VI.2.2 Methods and Equipment 
VI.2.2.1 Theory 
Fluorescent-activated cell sorting (FACS), the in vivo assay of choice for the analysis 
of parasitemia, was based on a published procedure (Bergmann-Leitner, Duncan et 
al. 2006). FACS is a flow cytometric method to analyse cell populations based on 
light scattering properties and fluorescent characteristics of each cell. The machine 
can rapidly separate cells based on size and on colour of the fluorophore. 
FACS is used to study growth inhibition of intraerythrocytic protozoan parasites that 
have been HE-stained. HE is taken up by living cells and metabolically converted to 
ethidium by NADPH oxidase. Ethidium intercalates into DNA, hence the red 
fluorescence distinguishes infected erythrocytes with viable parasites from 
uninfected or infected erythrocytes containing dead parasites (Wyatt, Goff et al. 
1991; van der Heyde, Elloso et al. 1995; Bergmann-Leitner, Duncan et al. 2006). 
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VI.2.2.2 Equipment 
The FACS assay was performed with BD Bioscience FACSCalibur system and 
FACS-flow (BD Bioscience, 342003). FACS reaction tubes were used BD Falcon 
5 mL Polystyrene from BD Bioscience. 
 
VI.2.2.3 Method 
Plasmodium falciparum parasites were routinely cultured in 2% haematocrit at 37 °C 
in RPMI 1640 containing albumax and glutamine. To synchronise parasites, 
heterogeneous populations containing late stages were first centrifuged onto a 
70% Percoll cushion to separate late trophozoite/schizont from rings. Late 
trophozoite/schizonts were then harvested from the Percoll cushion, pelleted and 
washed twice in media to remove residual Percoll. These parasites were re-cultured 
for 3–5 h with fresh red blood cells allowing invasion to occur, assessed using 
Giemsa-stained smears. Following invasion the culture was pelleted and incubated in 
a final concentration of 90% sorbitol, at 37 °C for 10 min to remove remaining 
schizonts. Post sorbitol treatment, the culture was pelleted and washed twice in fresh 
media prior to re-suspension in media to 2% haematocrit for culturing.  
Synchronised cultures were grown for approximately 40 h or until entering the next 
late trophozoite stage. To accurately determine the cultures parasitemia HE labelling 
and FACS counts were made. 50 7L culture was added to 500 µL freshly diluted HE 
(1:200 dilution of 10 mg mL-1 DMSO stock in PBS) and incubated for 20 min at 
37 °C. Samples were then diluted with 1 mL PBS to enable appropriate counts 
(5 000 counts s-1). Staining was stopped by storing samples on ice. For negative 
controls non-infected red blood cells were HE-stained. 
Parasitemia was calculated using the FACSCalibur flow cytometer. In brief, counts 
were initial screened using forward and side scatter parameters and gated for 
erythrocytes. Of the gated population HE-staining was determined using FL2 
detectors at 585 and 542 nm. When expressed as a histogram of HE intensity vs. 
number of erythrocytes, a distinct peak representing late trophozoite/schizont 
infected erythrocytes is evident and can be used to calculate parasitemia of cultures. 
This FACS calculated parasitemia was used to appropriately dilute 1% parasitemia 
in 2% haematocrit per one cycle assay. 
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The compound inhibition assays were carried out in a 96-well plate format, in a final 
volume of 100 7L for each culture (90 µL of stock culture plus 10 7L of 
10 × inhibitor stock). All assays were carried out in triplicate. For each compound a 
serial dilution was made from 20 mM stocks in 100% DMSO. The maximum final 
working concentration was 10 µM, a 200-fold dilution, to ensure the in culture 
DMSO concentration did not exceed 0.5% DMSO. Serial dilutions of inhibitors were 
made with the 10 × stocks of DMSO media (5%) to make certain the DMSO 
concentration remained constant. To each well 10 µL of this 10 × stock was added 
and mixed thoroughly. Following set-up plates were incubated in gassed humidity 
chambers at 37 °C for one invasion cycle typically 44–48 h, to the next trophozoite 
stage, prior to FACS analysis as previously described. 
 
VI.3 Results 
VI.3.1 Preliminary Tests 
VI.3.1.1 The Negative Control 
Compound 38 (Figure VI-3A) displayed no significant inhibitory effect against 
PfNMT at a top concentration of 1 mM in the in vitro SPA (IC50 = 1 946 ± 436 µM), 
hence it was used as an additional negative control for the in vivo FACS assay. As 
expected, no signs of inhibition were observed (Figure VI-3C). Figure VI-3B shows 
histograms of HE intensity vs. number of erythrocytes at varying inhibitor 
concentrations (0 µM, 10 µM, 100 µM from left to right) with a distinct peak 
characterising infected erythrocytes. The parasitemia in cultures was deducted from 
the histogram to create a bar chart shown in from which the inhibitory effects of the 
tested compound were easily deduced. 
(A)  
 
(B) 
0 µM 10 µM 100 µM
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(C)  
Figure VI-3: The negative control 
Cis-4-amino-N-(benzo[d]thiazol-2-yl)cyclohexanecarboxamide · TFA, 38, (A) showed no signs of 
inhibition during the in vivo studies. The histograms in (B) represent FL2-H vs. number of 
erythrocytes at varying inhibitor concentrations, 0 µM, 10 µM, 100 µM from left to right. From it a 
bar chart (C) was prepared to make analysis of parasitemia more straightforward. 
 
VI.3.1.2 The Salt Effect 
VI.3.1.2.1 The Effects of TFA in the FACS Assay 
The first issue to be addressed was the effect of TFA on cell growth and parasitemia, 
as all compounds for inhibition assays were TFA salts. As illustrated in Figure 
VI-4B, TFA had no considerable effect on parasitemia, did not inhibit cell growth 
and no sign of toxicity at a top concentration of 1 mM was recorded. Hence TFA 
salts could be used in the FACS in vivo assay to determine the effects of potential 
inhibitor on parasite growth in infected erythrocytes.  
(A)      (B)  
Figure VI-4: The effects of TFA in the FACS assay 
TFA (A) displays no inhibitory/toxic effects on P. falciparum infected erythrocytes as seen in the 
histogram (B). FACS assay data was obtained from two separate experiments carried out in 
triplicate. 
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VI.3.1.2.2 The Effects of Different Salt Compositions in the FACS assay 
Due to unknown salt composition of the “ Pfizer series” , tests were carried out with 
the lead compound in various salt compositions to investigate possible harmful 
effects of the anion with regards to the in vivo assay. The free amine (35), the HCl 
(95) and the TFA (94) salts were studied (Figure VI-5 from left to right). In vitro 
results showed no considerable difference in activity between the three inhibitors 
with an IC50 for 94 of 491 ± 64 (V.3.3.2, p. 141). Likewise 35, 94 and 95 showed 
similar inhibition results in vivo (Figure VI-6). At a concentration of 20 µM nearly 
full inhibition was noted. The IC50 for 94 was calculated as 2.73 ± 0.39 µM (Figure 
VI-7). 
 
 
Figure VI-5: Diverse salt combinations of cis-N-(benzo[d]thiazol-2-yl)-4-(naphthalen-2-yl-
methylamino)cyclohexanecarboxamide (35, 95, 94) 
The lead compound was tested in different salt compositions: the free amine (35, left), HCl salt (95, 
middle) and TFA salt (94, right). 
 
 
(A)  (B)  
Figure VI-6: FACS data of compounds (35, 95, 94) 
The lead compound was tested in various salt compositions, such as the free amine (35, dark blue-
coloured, left), HCl salt (95, medium blue-coloured, middle) and TFA salt (94, light blue-coloured, 
right). As can be seen in the bar graph (A) as well as the line graph (B) the inhibitory action of all 
salts are comparable. 
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Figure VI-7: More detailed FACS data of compound 94 
On the left hand side is a histogram of the inhibition data of compound 94 in Plasmodium falciparum 
infected erythrocytes. The data was plotted in GraFit (Leatherbarrow 2007) to create an inhibition 
curve, illustrated on the right, from which the IC50-value could be determined. 
 
VI.3.1.3 Positive Controls 
Preceding the newly established FACS assay, another in vivo assay was carried out 
where the parasite was visualised by Giesma-staining and the life stages analysed 
with light microscopy (Bowyer 2006). This time-consuming procedure was to be 
replaced by the FACS assay. For comparative studies for in vivo results from 
compounds previously tested (Bowyer 2006; Bowyer, Gunaratne et al. 2007),  
31–33 from the “ Pfizer series”  were assayed with the latest conditions of the FACS 
assay. The percentage of parasitemia was plotted against the concentration of 
inhibitor the infected erythrocytes were incubated in (Figure VI-8). Overall, results 
were consistent with previous observations. 
Compounds 34–33 show resemblance between in vitro and in vivo data as listed in 
Figure VI-8. The calculated IC50-values for 34 are in the same order of magnitude. 
Full inhibition was noticed at 50 µM and 100 µM, with slight reduction in 
parasitemia at a concentration point of 10 µM. Full parasitemia was noted at 1 µM 
(Figure VI-8B). The estimated IC50-value of 29 µM correlates with the IC50 in vitro 
value of 17 µM. The results for compound 32 and 33 are about 10-fold off. Both 
showed complete inhibition at 50 µM and 100 µM. They still inhibited parasite 
growth at 10 µM; however 32 did not completely stop parasite growth. Full 
parasitemia was observed at 1 µM (Figure VI-8C and D). The IC50 data of 32 and 33 
are 68 µM (in vitro)/7 µM (in vivo) and 37 µM (in vitro)/3 µM (in vivo) respectively. 
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Even though the results are not in the same order of magnitude, they are by no means 
significantly dissimilar.  
However, one compound does not follow the correlation of in vitro vs. in vivo data. 
Inhibitor 31, with in vitro IC50 of 30 ± 3 µM, did not show any signs of inhibition at 
50 µM and only a slight reduction on parasitemia occured at 100 µM (Figure 
VI-8A). Yet in previous in vivo assays significant reduction in parasitemia was 
noticed at concentration points 10 µM and 100 µM (Bowyer, Gunaratne et al. 2007). 
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(D) 33   
 
Figure VI-8: FACS data of compounds 31-33 
On the left hand side is a histogram of the inhibition data of compound 31 (A), 34 (B), 32 (C) and 33 
(D) in Plasmodium falciparum infected erythrocytes. The IC50-values are compared from in vitro SPA 
data (Bowyer, Gunaratne et al. 2007) and in vivo FACS data.  
 
The dissimilar behaviour of compound 31 is also noted in the raw data of the 
histograms. Figure VI-9 compares the effects of parasitemia with 31 and 33. For 
inhibitor 31, there was a general peak shift noted to the left, indicating the presence 
of more ring-stage parasites as opposed to late trophozoite/schizont stages (Figure 
VI-9A). Figure VI-9B clearly illustrates inhibitory effects against the parasite. The 
shift may represent a delay or halt in the growth cycle. Smears from 31 were taken 
and analysed under a microscope. Analysis revealed a reduction in parasitic growth, 
whereby the number of ring-stage parasites increases yet the number of trophozoite-
stage parasites decreases (Table VI-1). Compound 31 may have a different kinetic 
mechanism on P. falciparum compared to the other tested inhibitors. 
In general, the FACS assay was used to gather inhibition data at various 
concentrations points. Plots of the level of reduction in parasitemia relative to the 
inhibitor concentration enabled the estimation of IC50-values in vivo. Similarities 
between in vitro and in vivo results were found. 
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Figure VI-9: FACS histograms of 31 and 33 
The FACS histograms were used to compare levels of parasitemia between two compounds, 31 (A) 
and 33 (B), at different concentrations. As can be seen in (A) the distinct peak of parasite infected 
erythrocytes shifted to the left. With increasing inhibitor concentration the level of parasitemia was 
also reduced. Nevertheless the compound exhibits different kinetic properties compared to (B) where 
parasitemia drops immediately without a shift 
 
Table VI-1: Giesma-stained analysis of inhibitory action of 31 
The table analyses P. falciparum infected erythrocytes, whereby the life stage was recorded. 
Concentration of Inhibitor 
[µM] 
No. of Ring-Stage 
Parasites 
No. of Trophozoite-
Stage Parasites 
No. of Schizont-
Stage Parasites 
0 0.9 14 1.3 
10 2.5 10 n.d. 
50 12 4 n.d. 
n.d. not detected 
 
VI.3.2 In vivo studies of potential antimalarials 
Due to anticipated results from all negative controls such as TFA, non active 
inhibitors and a range of salt compositions as well as comparable data to published 
results of potent inhibitors (Bowyer, Tate et al. 2008), it was concluded that the 
FACS assay gave repeatable and valid information about inhibition of P. falciparum 
0 µM 10 µM 100 µM
0 µM 10 µM 100 µM
(A) 
(B) 
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infected erythrocytes. The following sections describe in vivo inhibition experiments 
carried out with synthesised potential antimalarials. 
 
VI.3.2.1 Analysis of the Best Antimalarial Candidates 
Four compounds (54, 78, 72, 81) have been discovered to inhibit PfNMT in the low 
micromolar region in in vitro studies using the SPA. They were then analysed in vivo 
employing the FACS method. Results showed consistency with previously gathered 
data. No cell toxicity was observed at the highest concentrations used. Figure 
VI-10A displays the activity of compound 54 against P. falciparum in the FACS 
assay. A noticeable drop in parasitemia was observed for concentration points at 
100 µM, 50 µM and 25 µM with near complete inhibition of parasitic growth. At 
10 µM the level of parasitemia was reduced one third. This correlated to the in vitro 
results where the IC50 for 54 was 19.9 ± 2.7 µM. The estimated IC50 in vivo was 
calculated to be 11.9 ± 0.7 µM (Figure VI-10A). They are in the same range and 
confirm that 54 inhibits P. falciparum growth.  
The analogue of 54, compound 78, with a cis-1,3-cyclohexyl group instead of cis-
1,4-cyclohexyl unit showed in the in vitro tests more activity against PfNMT; 
however 78 was far more active, about 10-fold, in the in vivo experiments. 
Parasitemia was reduced considerably at 25 µM, 10 µM and 2 µM. An IC50-value of 
1.74 ± 0.79 µM was estimated (Figure VI-10B). 
The oxygen atom in the benzofuran-based inhibitors was substituted with a sulfur 
atom to make benzothiophene analogues 72 and 81. The inhibitors demonstrated 
activity against PfNMT in the in vitro tests which are in the same range as the 
inhibition results of the oxygen analogues. The FACS assay with Plasmodium 
falicparum infected erythrocytes incubated with 72 and 81 also had an effect on 
parasitemia; complete reduction in parasitemia was recorded at 25 µM and 10 µM 
and low levels for 2 µM. The IC50-values were calculated as 1.43 ± 1.99 µM (Figure 
VI-10C) and 1.99 ± 0.11 µM (Figure VI-10D) respectively. Compound 81 displayed 
the most potent effects on Plasmodium falicparum infected erythrocytes out of the 
series of compounds tested. 
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(A) 54   
(B) 78   
(C) 72   
(D) 81   
Figure VI-10: FACS data of compounds 54, 78, 72 and 81 
On the left hand side is a histogram of the inhibition data of compound 54 (A), 78 (B), 72 (C) and 81 
(D) in Plasmodium falciparum infected erythrocytes. The IC50-values are compared from in vitro SPA 
data and in vivo FACS data. 
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VI.3.2.2 In Vivo Studies of Other Antimalarials 
Other compounds (56, 71, 49) were also tested in the in vivo FACS assay (see Figure 
VI-11). They were not as potent in the in vitro tests as the previous four candidates 
(54, 78, 72, 81). Nevertheless in vivo experiments were conducted with the intention 
of gaining information about inhibition patterns. Weakly inhibiting compounds with 
in vitro IC50-values in the upper micromolar scale should behave similar in in vivo 
experiments. However, IC50 results determined from in vitro SPA and in vivo FACS 
assays do not correlate with each other. Compound 56 inhibited parasite growth 
30-fold more in vivo than in vitro; a larger difference was observed for 71 and 49. 
(A) 56   
(B) 71   
(C) 49   
Figure VI-11: FACS data of compounds 56, 71, 49 
On the left hand side is a histogram of the inhibition data of compound 56 (A), 71 (B) and 49 (C) in 
Plasmodium falciparum infected erythrocytes. The IC50-values are compared from in vitro SPA data 
and in vivo FACS data.  
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IC50 (in vitro) = 1 206 ± 395 µM 
IC50 (in vivo) = 23.0 ± 1.0µM 
IC50 (in vitro) = 1 005 ± 124 µM 
IC50 (in vivo) = 12.9 ± 0.1µM 
IC50 (in vitro) = 379 ± 42 µM 
IC50 (in vivo) = 12.0 ± 2.2µM 
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VI.4 Conclusion and Discussion 
The FACS methodology, an alternative to assay the effect of potential inhibitors in 
P. falciparum infected erythrocytes, was set up by our collaborators Dr A A Holder 
and Dr D Moss at NIMR. In previous years a different method was employed, the 
parasite was visualised by Giesma-staining and analysed with light microscopy. 
Parasite-infected erythrocytes were counted as well as the life stage of the parasite 
was noted (Bowyer 2006). This procedure is very time consuming. FACS is more 
efficient as the machine sorts each cell based on their size and fluorescent properties. 
For comparative studies previously compounds tested by Dr P W Bowyer (Bowyer 
2006; Bowyer, Gunaratne et al. 2007) were analysed with the FACS assay. And 
indeed, results are consistent and thus the developed FACS assay was used to 
determine the effects of potential antimalarials on parasitemia. Assays were carried 
out by Dr D Moss at NIMR. 
A number of negative controls were also investigated to further establish conditions 
of the FACS assay. In vivo effects of one inhibitor as a free amine, HCl salt and TFA 
salt were evaluated because different salt compositions may have influenced 
inhibition. There was no significant change noted; all three compounds had similar 
inhibition patterns. Hence TFA salts of inhibitors were used in the in vivo studies of 
P. falciparum infected erythrocytes. An investigation also ruled out that TFA 
negatively influenced the assay. 
In vitro SPA resulted in four compounds (54, 78, 72, 81) with IC50-values in the low 
micromolar region. Excitingly, potency in the in vivo FACS assay showed 
consistency with data from the in vitro tests; inhibition in the low micromolar region 
was observed. Additionally no cell toxicity was observed by a final concentration of 
maximum 100 µM inhibitor in 0.5% DMSO. However, the assumption the sole 
reason of parasitic death was due to inhibition of NMT cannot be made; an off-target 
effect could also be likely and needs to be investigated further in future projects. 
The most active inhibitor in vitro, IC50 (54) = 19.9 ± 2.7 µM, retained antimalarial 
potency in vivo against P. falciparum infected erythrocytes. The estimated IC50 was 
calculated as 11.9 ± 0.7 µM; with complete inhibition of parasite growth at 25 µM, 
~30% inhibition at 10 µM and little inhibition at 1 µM. However, the inhibitor which 
was most effective in the FACS assay was compound 81 (IC50 = 1.99 ± 0.11 µM). 
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VII STRUCTURE-ACTIVITY RELATIONSHIPS –  
   A FINAL SUMMARY 
 
VII.1 SAR Analysis 
As discussed previously (Figure IV-1) the lead compound from the “ Pfizer series” , 
UK-370,509, was segmented into three parts RA–RC and systematically optimised. 
Table VII-1 shows a summary of in vitro inhibition results against PfNMT. The 
information was divided up into three sections; the size of the aromatic group RA 
was investigated first, followed by studies of aromaticity and the influence of 
heteroatoms on inhibition. 
Initially, crystal structures have shown that through the addition of a building 
block RA a conformational change of the AA in the peptidic binding pocket was 
induced to extend the cavity (Figure II-19, Pfizer, unpublished results). Thus the first 
group in Table VII-1 examined this information by comparing inhibition behaviour 
with RA substituted as methylbenzene (49), methylnaphthalene (94) and 
methylanthracene (68) compared to no unit RA (38). Inhibition studies suggested a 
trend, whereby a larger size of the aromatic group favoured binding in the target site 
resulting in lower IC50-values; the inhibition was doubled with each additional 
C6H6-group. However, the scale of improvement of inhibition was minor. The small 
increase in activity may have been caused by an increase of logP. A noted side-effect 
however, was the increase in insolubility of the compounds with a larger 
hydrophobic group. Ethylbenzene (70) was also tested to probe further into the 
binding pocket but it was not considerably more active than 49. Either an additional 
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CH2-group was not sufficiently long enough for favourable interactions of the benzyl 
ring with possible AA for %-% stacking interactions or the size of the aromatic system 
is vital.  
The level of aromaticity was investigated next with various building blocks RA such 
as aliphatic groups or alterations of aromatic character by substitution of the benzyl 
ring with electron-withdrawing and electron-donating groups. A tendency could not 
be recorded as all compounds inhibited PfNMT poorly; IC50-values were >1 mM. 
However, the insertion of heteroatoms yielded more active inhibitors; oxygen (54), 
sulfur (72) and nitrogen (73) derivatives of 94 exhibited inhibition in the low 
micromolar region. Nevertheless, 73 was a 5-fold weaker inhibitor. The Group VI 
atoms must be necessary for vital polar interactions such as hydrogen bonding with 
surrounding AA of the target binding site. Hence the position of the heteroatom is 
crucial as studies showed weakened inhibition with methylfuran (51) and 
methylthiophene (65) as unit RA with 100-fold less activity than their larger 
analogues 54 and 72. 
Yet the inclusion of an oxygen atom was no guarantee for inhibition. Compounds 
with a second oxygen atom were also tested and although they displayed inhibition 
below 1 mM, they were not as active as 54. 
The size of the aromatic system seemed also important as 5-methylbenzyl-
dihydrofuran (71), a less aromatic system than 5-methylbenzylfuran (54), was not 
very active against PfNMT during the in vitro studies as well as the sulfur substitute. 
But increasing the aromatic system with 5-methyldibenzofuran (69) resulted in a 
complete loss in activity also. Hence 5-methylbenzofuran as group RA is a valid 
choice. The positions of the oxygen atom as well as the %-clouds lead to enhanced 
binding compared to the lead compound, although there is still room for 
improvement. Studies could go into the investigation of 3-methylbenzofuran 
whereby the oxygen atom is in a different position in the ring which may lead to 
different interactions. 
Compounds with a cis-1,4-cyclohexyl group as building block RB that showed some 
activity against PfNMT (IC50 <1 mM) were subsequently synthesised with a cis-1,3-
orientation of the substituents to further explore the binding cavity. In vitro 
inhibition results are listed in the third column of Table VII-1. 
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Results showed that the orientation of substituents on the cyclohexyl ring (cis-1, 4 
vs. cis-,1,3) had no major impact on inhibition of PfNMT. This probably indicates 
that the orientation of the substituents is similar, irrespective of the cyclohexyl linker 
used.  
Another very important aspect is the secondary amine which joins units RA and RB. 
Building blocks RB proline (Column IV, Table VII-1) and triazole derivatives 
(Column V, Table VII-1) lack this moiety which resulted in a complete loss in 
activity. Further studies examined the linkage more closely; compound 94, 49 and 54 
were acetylated and were found to be inactive against PfNMT. 
Altogether several factors are very important for binding in the peptidic pocket of 
Plasmodium falciparum NMT. The %-electron clouds of the benzothiazole unit, RC, 
as well as the heteroatoms probably interact with surrounding AA of the binding site. 
Building block RB possibly serves as a linker to space out the interactive sections of 
the molecule, whereby a rigid unit was preferred over a flexible chain (Pfizer, 
unpublished research). The ideal orientation of the substituents has not been fully 
examined and needs to be explored further, but the cis-1,4-cyclohexyl group was the 
most successful. The linkage from RB to RA, in this case a 2° amine, is needed most 
likely for interactions with the C-terminus of the enzyme that partially forms the 
peptidic binding site (Hasegawa, Morikami et al. 2003). Unit RA appears to be the 
key factor for inhibition against PfNMT. 5-Methylbenzofuran and the sulfur 
analogue attached to cis-4-amino-N-benzo[d]thiazol-2-yl)cyclohexylcarboxamide 
resulted in inhibitors with IC50-values in the low micromolar region. 
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Table VII-1: Summary of inhibition studies in vitro 
This table sums up the compounds that were tested in the SPA against PfNMT. RA was split up into 
three groups of certain criteria; first the size of the aromatic group, second the level of aromaticity 
and third the inclusion of heteroatoms. The table is colour coded as follows: IC50 <100 µM (red-
coloured); IC50 <500 µM and >100 µM (orange-coloured); IC50 <1 mM and >500 µM (gold-
coloured); IC50 >1 mM (pale yellow-coloured); white/blank – not tested. 
 
RB 
RA 
 
 
 
 
 
38 43     743 ± 54 44  
 
49     1005 ± 124 76     473 ± 46 46 87 
 
35     481 ± 62 74     359 ± 57 45 88 
 
68     177 ± 3    
 
70    
 
61    
 
63    
 
64    
 
48    
 
51    
 
54      19.9 ± 2.7 78     35.9 ± 1.9 47 90 
 
71    
 
56     379 ± 42 82     620 ± 159   
 
59     687 ± 32    
 
67     993 ± 135    
 
69    
 
65    
 
72     24.5 ± 4.9 81     44.8 ± 3.1   
 
73     116 ± 11 80     275 ±4.8   
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The four top inhibitors against PfNMT (54, 72, 78 and 81) were investigated more 
closely. The main difference between 54/78 and 72/81 is the orientation of the 
substituents, which are either arranged in a 1,4 or 1,3-position of the cyclohexyl ring. 
The cis-1,4-compound is a single stereoisomer due to a planar symmetry. The 
substituents are orientated one axial and one equatorial. Both possible chair 
conformations are illustrated in Table VII-2A. The “ cis-1,3”  series has two 
enantiomeric carbon atoms. The cyclohexyl unit RB was purchased as a racemic 
mixture. Substituents are either both orientated in an axial or equatorial position 
(Table VII-2B, C). The di-equatorial arrangement (#1) is more likely than the 
di-axial one (#2) due to steric hinderance. Orientation of the substituents are similar 
for compounds of the “ cis-1,4”  and “ cis-1,3”  series with di-equatorial arrangement. 
And indeed, similar inhibition patterns in vitro were noted. 
 
Table VII-2: Comparison of cis-1,4- and cis -1,3-cyclohexyl building block 
The conformation of two building blocks B, cis-1,4-cyclohexane (A) and cis-1,3-cyclohexane (B and 
C), are compared and visualised in the chair conformation. The 1,4 compound is a single 
stereoisomer, but the 1,3 version is a mixture of two enantiomers (B and C). For each compound 
there are two possible chair conformations of the cyclohexyl ring: in the 1,4 series it is possible that 
either or both conformations are present; for the 1,3 compounds it is likely that the di-equatorial 
conformations (#1) will predominate over the crowded di-axial ones (#2). 
 Chemical Structure Chair Conformation #1 Chair Conformation #2 
(A) 
 
  
 
   
(B) 
 
 
 
(C) 
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Inhibitors with an IC50 <1 mM were tested in the in vivo FACS assay with 
Plasmodium falciparum infected erythrocytes. But precise correlations between in 
vitro SPA and in vivo data were difficult to propose. This is due to the fact that in 
vitro evaluations are carried out on specific targets alone. In vivo experiments are 
conducted in a cell environment where numerous factors are in competition with the 
target. Similarities were noted between compounds that inhibited PfNMT in vitro in 
the low micromolar region; they also exhibited high reductions in parasitemia at the 
calculated in vitro IC50. Non-inhibitors, that were ineffective against PfNMT in vitro, 
displayed no activity in vivo as well. But data was not consistent with regards to 
weak inhibitors in vitro as they were more active in vivo, as expected. 
Reduction in levels of parasitemia may be the cause of different interactions. First it 
could be caused by inhibition of Plasmodium falciparum N-myristoyl transferase in 
which case the inhibitor competes with the peptide substrate in the NMT binding 
site, thus inhibiting N-myristoylation. Inhibition results may differ though due to 
several possibilities such as solubility, transport and metabolism of the compound. 
For cases where the activity in vivo is higher than in vitro, effects of solubility may 
be responsible. The environment in the parasitic cell may increase solubility of the 
inhibitor compared to the buffer system in the in vitro assay. A higher concentration 
of compound would then lead to increased inhibition in N-myristoylation. 
Alternatively, not the compound but by-products of metabolised inhibitor may 
influence the function of NMT strongly. The inhibitor could also accumulate in the 
cell and reach toxic levels. However, no negative impact was noted on the integrity 
of the erythrocytes. 
If the compound does not reduce parasitemia solely via the mechanism of 
N-myristoyl transferase, the target site needs to be identified. Studies would need to 
be carried out in future projects to investigate the mode of inhibition in a cell. It is 
important to investigate the specificity of the drug molecule for NMT, a different 
target in the parasite or the display of a non-specific inhibitory effect. 
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VII.2 Conclusions 
This project had the goal of examining the peptidic binding pocket of N-myristoyl 
transferase of the malarial organism Plasmodium falciparum in more depth; a 
small-sized library was synthesised to explore the target site systematically, to 
develop potent inhibitors that in future could be formulated into antimalarial drugs. 
Co-crystal structures of PfNMT and inhibitors have not yet been published that 
could lead to valid information about preferential binding partners. Nevertheless 
successful co-crystal structures of NMT of other organisms such as Candida 
albicans have been solved. Phylogenetic analysis revealed similarities between the 
peptidic binding pocket of CaNMT and PfNMT; hence, a piggy-back approach was 
carried out whereby established potent inhibitors for CaNMT were applied to the 
malarial system. In this thesis the strategic development of the lead compound to 
more potent equivalents against PfNMT yet retaining selectivity over human NMT 
was described. 
Inhibitors were based on a benzothiazole scaffold; the “ Pfizer series”  compounds, 
which have been shown to interact with AA from the peptidic binding pocket of 
NMT, have been methodically altered to create a small-sized library with 
approximately 50 inhibitors. Potency against PfNMT and selectivity over human 
NMT were determined in an established scintillation proximity assay that monitors 
the transfer of [3H]-labelled myristoyl CoA to the N-terminus of a polypeptide 
substrate. The plot of inhibitor concentration with respect to remaining enzyme 
activity gave inhibition curves from which IC50-values were derived. Enzymes 
required for the assay were overexpressed in Escherichia coli and purified yielding 
1.0 mg L-1 P. falciparum NMT, 0.6 mg L-1 Homo sapiens NMT1 and 1.5 mg L-1 
Homo sapiens NMT2. In vitro SPA revealed four compounds that inhibited PfNMT 
in the low micromolar region, 54 (IC50 = 19.9 ± 2.7 µM), 78 (IC50 = 35.9 ± 1.9 µM), 
72 (IC50 = 24.5 ± 4.9 µM) and 81 (IC50 = 44.8 ± 3.1 µM). They were taken forward 
to be tested in vivo against Plasmodium falciparum infected erythrocytes. They 
showed a significant reduction in parasitemia at concentration levels of 25 µM, 
10 µM and 5 µM inhibitor. Unfortunately the inhibitors were not exceptionally 
selective over human NMT with IC50-values in vitro in similar micromolar regions. 
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VII.3 Outlook 
Lead compound optimisation showed limited success; the improved compounds 
inhibit PfNMT in the low micromolar region with an IC50 of 19.9 µM reported for 
the best inhibitor. It is essential for potential drug candidates to inhibit the target site 
at least in the nanomolar region to be considered for further drug validation 
processes.  
The aspiration will not only be an increase in activity against PfNMT but also create 
a larger selectivity against human NMT. Unfortunately, the best four hits with 
activity against PfNMT in the low micromolar region also showed activity against 
human NMT in the same range. This needs to be addressed in upcoming drug 
development projects. Potentially, modifications at the C6-position of the 
benzothiazole-scaffold could decrease activity againt the human enzyme and further 
investigations into building block A can yield higher potency against malarial NMT. 
A different scaffold as RC should also be examined. Various amines could be 
employed to probe possible AA interactions in the peptide binding pocket; in 
particular interactions with Ser should be investigated (Pfizer, unpublished work). 
A large problem was the solubility of compounds. Sections should be included to 
increase solubility in aqueous assay buffer such as ether, ketones or alcohol moieties.  
Also in future projects, libraries can be produced by solid phase assisted synthesis 
instead of combinatorial solution phase chemistry (II.3.3., pg. 44, (Yamazaki, 
Kaneko et al. 2005)). 
A different series, based on benzofuran scaffolds, is analysed in the Leatherbarrow 
Research Group as previously mentioned. There has been no solubility issue noted 
so far. Zhiyong Yu has reported an inhibitor with an IC50-value of 15 µM; a good 
starting point for optimising the inhibitors further (Yu 2009). 
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VIII APPENDIX 
 
VIII.1 Compound Synthesis and Characterisation 
 
 
cis-N-(Benzo[d]thiazol-2-yl)-4-((naphthalen-2-yl)methylamino)cyclohexane-
carboxamide (35). Compound 38 (102 mg, 0.262 mmol) was dissolved in DCE 
(1.4 mL), with a final concentration of 0.2 M. NEt3 (76 7L, 0.545 mmol), 
2-naphthaldehyde (40 mg, 0.256 mmol), NaBH(OAc)3 (91 mg, 0.429 mmol) were 
added to the reaction mixture. Product precipitation was observed over time. After 
24 h, the precipitate was collected by filtration. The crude product was purified by 
chromatography on silica gel (0–70% EtOAc in Hex) to afford 35 (0.73 g, 67%) as a 
white crystalline solid.  
TFA salt (94). Compound 35 was dissolved in TFA and stirred for 10 min. All 
volatiles were removed in vacuo.  
HCl salt (95).Compound 35 was dissolved in DCM. HCl (conc) was added and stirred 
for 10 min. All volatiles were removed in vacuo. 
35. >98% Purity (tr = 10.8 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.03 (EtOAc–Hexane, 2:1); mp 196–198 °C; max/cm-1 (solid) 2927 
(w, br), 1674 (m, sh), 1544 (m, sh), 1183 (s, br), 1133 (s, br), 721 (s, sh); H/ppm 
(400 MHz, CDCl3) 7.85 (1H, m, PhH), 7.77–7.83 (4H, m, PhH), 7.73 (1H, m, PhH), 
7.42–7.48 (4H, m, PhH), 7.32 (1H, t, J 11.4, PhH), 3.90 (2H, s, NHCH2), 2.78 (1H, 
m, NHCOCH), 2.48 (1H, m, CHNH), 2.04 (2H, m, CH2), 1.73 (2H, m, CH2), 1.59 
(2H, m, CH2), 1.39 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 174.7 (C), 159.8 (C), 
147.7 (C), 137.8 (C), 131.8 (C), 128.1 (PhH), 127.7 (PhH), 126.7 (PhH), 126.5 
(PhH), 126.3 (PhH), 125.6 (PhH), 124.0 (PhH), 121.7 (PhH), 120.4 (PhH), 51.5 
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(CH), 51.2 (NHCH2), 43.5 (CH), 29.1 (2C, CH2), 24.1 (2C, CH2); m/z (FAB) 416 
(40%, [M + H]+), 289 (15%, [M – naphtyl]), 149 (30%, [M –ABT]+), 141 (75%, [M 
– methylnaphtyl]), 136 (75%, [benzothiazole]+); HRMS found 416.1798 
(C25H26N3OS, [M+H]+, requires 416.1797). 
 
 
 
cis-4-N-tert-Butylcarbamatecyclohexylcarboxylic acid (36). rac-cis-4-
Aminocyclohexanecarboxylic acid (2.06 g, 14 mmol) was dissolved in NEt3 
(11.8 mL, 85 mmol) and MeOH (14 mL), with a final concentration of 1.0 M. A 
solution of di-tert-butyl dicarbonate (6.95 g, 32 mmol) in MeOH was added drop 
wise to the cream-coloured suspension. The reaction mixture was refluxed at 60 °C. 
Gas formation was noticed. After 18 h reaction time, the reaction mixture was 
filtered and concentrated in vacuo. The oily, yellow-coloured substance was 
dissolved in 2% NaHCO3 (50 mL) and washed with hexane (3 × 50 mL). The 
aqueous phase was acidified with cold 1 M HCl (aq) to a pH of 2, whereupon 
precipitation was noticed. The product was extracted with EtOAc. The organic phase 
was dried over MgSO4 and filtered. The solid was dried in vacuo to yield 36 (2.37 g, 
70%) as a white amorphous solid. 
>98% Purity; Rf = 0.62 (EtOAc–Hex, 2:1); mp 169–172 °C; max/cm-1 (solid) 3295 
(w, br), 2928 (m, br), 2857 (w, br), 1694 (vs, sh), 1635 (m, sh), 1407 (m, sh), 1367 
(m, sh), 1162 (s, sh), 962 (m, sh), 752 (s, sh); H/ppm (500 MHz, DMSO-d6) 6.15 
(NH-Boc), 3.32 (1H, m, CHCOOH), 2.35 (1H, m, CHNH), 1.82–1.88 (2H, m, CH2), 
1.40–1.55 (6H, m, CH2), 1.36 (9H, s, C(CH3)3), C/ppm (125 MHz, DMSO-d6) 175.8 
(C), 154.7 (C), 77.1 (C(CH3)3), 47.8 (CH), 39.7 (CH), 29.7 (2C, CH2), 28.7 (3C, 
CH2), 25.1 (2C, CH2); m/z (FAB) 244 (10%, [M + H]+), 188 (40%, [M + 
tert-butyl]+), 126 (50%), 57 (100%, [tert-butyl]+); HRMS found 406.1591 
(C23H24N3O2S, [M + H]+, requires 406.1589). 
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cis-tert-Butyl-4-(benzo[d]thiazol-2-ylcarbamoyl)cyclohexylcarbamate (37). 
Compound 36 (2.20 g, 9 mmol) was dissolved in DMF–DCM (1/1, V/V, 18 mL), 
with a final concentration of 0.5 M, at 0 °C. 2-Aminobenzothiazole (1.51 g, 
10 mmol), PyBOP (5.16 g, 10 mmol), DIPEA (3.15 mL, 18 mmol) were added. 
After 10 min the clear, yellow-coloured solution was allowed to warm to RT. After 
19 h, the pink-coloured suspension was filtered. The precipitate was washed with 
H2O (3 × 20 mL), brine (1 × 10 mL), dried over MgSO4 and filtered. The solid was 
dried in vacuo to yield 37 (3.07 g, 90%) as a white amorphous solid.  
>98% Purity (tr = 13.4 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.35 (EtOAc–Hexane, 2:1); mp 239–240 °C; max/cm-1 (solid) 3049 (m, br), 
2932 (m, br), 2863 (w, sh), 1672 (s, sh), 1550 (s, sh), 1441 (m, sh), 1399 (m, sh), 
1362 (m, sh), 1258 (m, sh), 1167 (s, sh), 1071 (m, sh), 962 (m, sh), 753 (s, sh); 
H/ppm (500 MHz, DMSO-d6) 12.10 (1H, s, NHCO), 7.85 (1H, d, J 7.5, PhH), 7.62 
(1H, d, J 7.5, PhH), 7.32 (1H, t, J 7.5, PhH), 7.18 (1H, t, J 7.0, PhH), 6.72 (1H, s, 
NH-Boc), 2.78 (1H, m, NHCOCH), 2.40 (1H, m, CHNH-Boc), 1.78 (2H, m, CH2), 
1.50–1.56 (4H, m, CH2), 1.42 (2H, m, CH2), 1.28 (9H, s, C(CH3)3); C/ppm 
(125 MHz, DMSO-d6) 174.9 (C), 158.2 (C), 155.1 (C), 148.6 (C), 130.5 (C), 126.1 
(PhH), 123.5 (PhH), 121.7 (PhH), 120.4 (PhH), 77.5 (C(CH3)3), 45.9 (CH), 41.7 
(CH), 28.4 (3C, C(CH3)3), 28.9 (CH2), 24.0 (CH2); m/z (FAB) 376 (85%, [M + H]+), 
151 (90%, [ABT + H]+), 57 (85%, [tert-butyl + H]+); HRMS found 376.1711 
(C19H26N3O3S, [M + H]+, requires 376.1695). 
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cis-4-Amino-N-(benzo[d]thiazol-2-yl)cyclohexylcarboxamide (38). Compound 37 
(0.10 g, 0.3 mmol) was dissolved in TFA–H2O–TIPS (90/5/5, V/V/V, 0.50 mL, 
6.5 mmol TFA) and DCM (0.20 mL), with a final concentration of 0.4 M for 37. The 
reaction mixture was stirred for 30 min at RT until gas formation stopped. Cold 
diethyl ether was added until precipitation was observed (~10 mL). The precipitate 
was collected by centrifugation and washed with cold diethyl ether (3 × 10 mL). The 
solid was dried in vacuo to afford 38 (0.06 g, 79%) as a white flocculent solid (TFA 
salt).  
>98% Purity (tr = 5.3 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.02 (EtOAc–Hexane, 2:1); mp 197–199 °C; max/cm-1 (solid) 2926 (w, br), 
1676 (m, sh), 1563 (m, sh), 1134 (s, sh), 720 (s, sh); H/ppm (500 MHz, DMSO-d6) 
12.40 (1H, s, NHCO), 8.03 (2H, br s, NH2), 7.94 (1H, d, J 7.5, PhH), 7.72 (1H, d, 
J 9.0, PhH), 7.41 (1H, t, J 7.5, PhH), 7.28 (1H, t, J 7.5, PhH), 3.19 (1H, m, CHNH2), 
2.76 (1H, m, NHCOCH), 1.98 (2H, m, CH2), 1.73 (4H, m, CH2), 1.67 (2H, m, CH2); 
C/ppm (125 MHz, DMSO-d6) 174.5 (C), 158.1 (C), 148.6 (C), 131.5 (C), 126.2 
(PhH), 123.6 (PhH), 121.7 (PhH), 120.5 (PhH), 47.6 (CH), 25.0 (2C, CH2), 24.0 
(2C, CH2); m/z (ESI) 391 (20%, [M + TFA]+), 276 (20%, [M + H]+), 151 (100%, 
[ABT + H]+); HRMS found 276.1178 (C14H18N3OS, [M + H]+, requires 276.1171). 
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N-(Benzo[d]thiazol-2-yl)cyclohexylcarboxamide (39). 2-Aminobenzothiazole 
(1.49 g, 10 mmol) and 4-pyrrolidinopyridine (1.77 g, 12 mmol) were each dissolved 
in DMF (20 mL), with a final concentration of 0.5 M for 2-aminobenzothiazole, and 
added together, upon which a white precipitate formed. Cyclohexanecarbonyl 
chloride (1.470 mL, 12 mmol) was added drop wise. After 12 h the reaction mixture 
was diluted with DCM (80 mL), washed with 1 M HCl (aq) (3 × 100 mL), H2O 
(3 × 100 mL) and brine (1 × 100 mL), dried over MgSO4, filtered and concentrated 
in vacuo. The crude product was purified by chromatography on silica gel (0–98% 
DCM in MeOH) to afford yellow oil. Re-crystallisation in MeOH resulted in 39 
(2.04g, 78%) as a cream-coloured crystalline solid. 
>98% Purity (tr = 13.6 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.82 (EtOAc–Hexane, 2:1); mp 137.6–138.4 °C; max/cm-1 (solid) 3179 (w, br), 
3056 (w, br), 2928 (m, sh), 1693 (s, sh), 1542 (s, sh), 1443 (s, sh), 1262 (s, sh), 1162 
(s, sh), 1126 (s, sh), 760 (s, sh); H/ppm (400 MHz, CDCl3) 11.63 (1H, s, NHCO), 
7.86 (1H, d, J 8.0, PhH), 7.79 (1H, d, J 8.0, PhH), 7.46 (1H, t, J 7.5, PhH), 7.34 (1H, 
t, J 7.5, PhH), 2.32 (1H, tt, J 12.0, J 3.5, NHCOCH), 1.80 (2H, m, CH2), 1.67 (2H, 
m, CH2), 1.47–1.55 (3H, m, CH2), 1.13 (1H, m, CH2), 0.96 (2H, m, CH2), C/ppm 
(100 MHz, CDCl3) 175.2 (C), 160.2 (C), 147.4 (C), 132.0 (C), 126.4 (PhH), 124.1 
(PhH), 121.7 (PhH), 120.4 (PhH), 45.0 (NHCOCH), 29.2 (2C, CH2), 25.1 (2C, 
CH2); m/z HRMS found 262.1067 (C14H17N2OS, [M + H]+, requires 262.1062). 
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N-(Benzo[d]thiazol-2-yl)-2-cyclohexaneacetamide (40). Cyclohexylacetic acid 
(0.65 g, 5 mmol) was dissolved in DMF–DCM (1/1, V/V, 18 mL), with a final 
concentration of 0.25 M. DIPEA (1.55 mL, 9 mmol), HOBt (0.70 g, 6 mmol), and 
HBTU (2.57 g, 7 mmol) were added sequentially. The clear, yellow-coloured 
solution was stirred for 30 min at RT. 2-Aminobenzothiazole (0.62 g, 4 mmol) was 
added to the reaction mixture. After 20 h the solution was diluted with DCM 
(100 mL), washed with H2O (3 × 100 mL), and dried in vacuo. The crude product 
was purified by chromatography on silica gel (0–95% DCM in MeOH) to afford 40 
(0.024 g, 2%) as a white crystalline solid. 
>98% Purity (tr = 14.9 min, 2–98% MeOH–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.65 (EtOAc–Hexane, 2:1); mp 174–179 °C; max/cm-1 (solid) 3184 
(w, br), 3056 (w, br), 2926 (m, br), 2850 (m, sh), 1657 (m, sh), 1543 (s, br), 1456 (w, 
br), 1116 (m, br),  721 (s, sh); H/ppm (300 MHz, CDCl3) 7.83 (1H, d, J 8.1, PhH), 
7.75 (1H, d, J 8.1, PhH), 7.74 (1H, t, J 7.2, PhH), 7.32 (1H, t, J 7.2, PhH), 2.33 (1H, 
m, CH2), 1.69–1.83 (2H, m, CH2), 1.01–1.37 (6H, m, CH2), 0.86 (3H, m, CH2), 
C/ppm (75 MHz, CDCl3) 172.1 (C), 146.2 (C), 130.4 (PhH), 126.1 (PhH), 120.1 
(PhH), 114.6 (PhH), 64.3 (CH2), 42.9 (CH), 33.1 (CH2), 29.7 (2, CH2), 26.0 (CH2); 
m/z (FAB) 275 (30%, [M + H]+), 151 (25%, [ABT + H]+); HRMS found 275.1229 
(C15H19N2OS, [M + H]+, requires 275.1218). 
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cis-tert-Butyl-3-(benzo[d]thiazol-2-ylcarbamoyl)cyclohexylcarbamate (41). 
3-(rac-cis-N-tert-Butylcarbamate)cyclohexylcarboxylic acid (0.49 g, 2.0 mmol) was 
dissolved in DMF (14 mL), with a final concentration of 0.5 M, at 0 °C. 
2-Aminobenzothiazole (0.34 g, 2.0 mmol), PyBOP (1.19 g, 2.0 mmol), DIPEA 
(0.696 mL, 4.0 mmol) were added. After 10 min the clear, yellow-coloured solution 
was allowed to warm to RT. After 19 h, the clear, brown-coloured reaction mixture 
was diluted with DCM (100 mL), washed 0.1 M HCl (aq) (3 × 100 mL), H2O 
(3 × 100 mL), brine (1 × 100 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was dissolved in a minimal amount of DCM 
(1 mL) and added to cold diethyl ether until precipitation was observed (~10 mL). 
The precipitate was collected by centrifugation and washed with cold diethyl ether 
(1 × 10 mL). The solid was dried in vacuo to yield 41 (0.50 g, 66%) as a white 
flocculent solid.  
>98% Purity (tr = 13.5 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.51 (EtOAc–Hexane, 2:1); mp 190–194 °C; max/cm-1 (solid) 3274 (m, br), 
3141 (vw, br), 2935 (m, br), 2866 (w, br), 1675 (s, sh), 1557 (s, sh), 1441 (s, sh), 
1364 (s, sh), 1315 (s, sh), 1266 (s, sh), 1167 (s, sh), 757 (vs, sh); H/ppm (400 MHz, 
DMSO-d6) 12.31 (1H, s, NHCO), 7.95 (1H, d, J 7.6, PhH), 7.72 (1H, d, J 8.0, PhH), 
7.42 (1H, t, J 8.8, PhH), 7.29 (1H, t, J 7.6, PhH), 6.84 (1H, d, J 8.0, NH-tert-Bu), 
3.28 (1H, m, CHNH-Boc), 2.60 (1H, m, CH), 1.94 (1H, m, CH2), 1.77 (3H, m, CH2), 
1.37 (9H, s, C(CH3)3), 1.29 (3H, m, CH2), 1.10 (1H, m, CH2); C/ppm (100 MHz, 
DMSO-d6) 174.7 (C), 158.3 (C), 155.0 (C), 131.5 (PhH), 126.2 (PhH), 123.6 (PhH), 
121.8 (PhH), 120.6 (PhH), 77.7 (C(CH3)3), 55.0 (CH), 48.6 (CH2), 43.0 (CH), 35.2 
(CH2), 28.4 (3C, C(CH3)3), 27.9 (CH2), 24.0 (CH2); m/z (FAB) 376 (85%, [M + H]+), 
151 (90%, [ABT + H]+), 57 (85%, [tBu + H]+); HRMS found 376.1711 
(C19H26N3O3S, [M + H]+, requires 376.1695). 
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(S)-tert-Butyl 2-(benzo[d]thiazol-2-ylcarbamoyl)pyrrolidine-1-carboxylate (42). 
Boc-L-Pro-OH (1.01 g, 4.7 mmol) was dissolved in DMF (10 mL), with a final 
concentration of 0.5 M, at 0 °C. 2-Aminobenzothiazole (0.79 g, 5.2 mmol), PyBOP 
(2.75 g, 5.3 mmol), DIPEA (1.628 mL, 9.4 mmol) were added sequentially. After 
10 min the clear, yellow-coloured solution was allowed to warm up to RT. After 4 h, 
the brown-coloured reaction mixture was diluted with DCM (100 mL), washed 
0.1 M HCl (aq) (3 × 100 mL), H2O (3 × 100 mL), brine (1 × 100 mL), and dried over 
Na2SO4, filtered and all volatiles removed in vacuo. The crude product was purified 
with flash column chromatography (DCM–MeOH, 0–40%) to yield 42 (1.39 g, 86%) 
as a white amorphous solid.  
>98% Purity (tr = 12.4 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.42 (EtOAc–Hexane, 2:1); mp 199–201 °C; max/cm-1 (solid) 3188 (w, br), 
3058 (w, br), 2967 (m, br), 2880 (w, br), 1720 (m, sh), 1652 (m, sh), 1555 (m, sh), 
1424 (m, sh), 1264 (s, sh), 1164 (m, sh), 755 (s, sh); H/ppm (400 MHz, CDCl3) 
11.39 (1H, s, NHCO),7.78 (2H, m, PhH), 7.35 (1H, m, PhH), 7.24 (1H, m, PhH), 
4.52 (1H, app d, J 4.8, CH), 3.48 (2H, m, CH2N), 1.82–2.29 (4H, m, CH2), 1.39–
1.45 (9H, m, C(CH3)3); H/ppm (400 MHz, CDCl3, 50 °C) 7.77 (2H, d, J 8.0, PhH), 
7.40 (1H, t, J 8.0, PhH), 7.27 (1H, t, J 8.0, PhH), 4.50 (1H, s, CH), 3.48 (2H, m, 
CH2), 2.38 (1H, m, CH2), 2.12 (1H, m, CH2), 1.93 (2H, m, CH2), 1.39 (9H, s, 
C(CH3)3); C/ppm (100 MHz, CDCl3) 172.3 (C), 158.5 (C), 156.2 (C), 148.5 (C), 
132.1 (C), 126.2 (PhH), 124.0 (PhH), 121.4 (PhH), 120.9 (PhH), 81.2 (C(CH3)3), 
60.9 (CH), 46.4 (NHCH2), 28.4 (3C, C(CH3)3), 26.5 (CH2), 24.6 (CH2); m/z (FAB) 
348 (100%, [M + H]+), 292 (15%, [M – tert-butyl]+), 248 (50%, [M – Boc]+, 151 
(95%, [ABT + H]+), 57 (40%, [tert-butyl]+); HRMS found 348.1396 (C17H22N3O3S, 
[M + H]+, requires 348.1382). 
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cis-3-Amino-N-(benzo[d]thiazol-2-yl)cyclohexylcarboxamide (43). Compound 41 
(0.41 g, 1.0 mmol) was dissolved in TFA–H2O–TIPS (90/5/5, V/V/V, 1.67 mL, 
22 mmol TFA), with a final concentration of 0.6 M for 41. The reaction mixture was 
stirred for 30 min at RT until gas formation stopped. Cold diethyl ether was added 
until precipitation was observed (~17 mL). The precipitate was collected by 
centrifugation and washed with cold diethyl ether (3 × 10 mL). The solid was dried 
in vacuo to afford 43 (0.42 g, 99%) as a white flocculent solid (TFA salt).  
>98% Purity (tr = 6.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.02 (EtOAc–Hexane, 2:1); mp 190–194 °C; max/cm-1 (solid) 2962 (w, br), 
2874 (w, br), 1685 (w, sh), 1175 (m, br), 1123 (s, br), 758 (s, sh), 720 (s, sh); H/ppm 
(400 MHz, DMSO-d6) 12.44 (1H, s, NHCO), 8.01 (1H, br s, NH2), 7.95 (1H, d, 
J 8.0, PhH), 7.43 (1H, d, J 8.0, PhH), 7.43 (1H, t, J 8.2, PhH), 7.29 (1H, t, J 8.0, 
PhH), 3.09 (1H, m, CHNH2), 2.67 (1H, m, NHCOCH), 2.09 (1H, m, CH2), 1.93 (2H, 
m, CH2), 1.84 (1H, m, CH2), 1.53 (1H, q, J 12.4, CH2), 1.20-1.41 (3H, m, CH2); 
C/ppm (100 MHz, DMSO-d6) 173.8 (C), 158.0 (C), 148.9 (C), 131.6 (C), 126.3 
(PhH), 123.7 (PhH), 121.8 (PhH), 120.6 (PhH), 48.7 (CH), 42.0 (CH), 32.2 (CH2), 
29.7 (CH2), 28.0 (CH2), 23.2 (CH2); m/z (FAB) 391 (10%, [M + TFA]+), 276 (100%, 
[M + H]+), 151 (90%, [ABT + H]+); HRMS found 276.1174 (C14H18N3OS, [M + 
H]+, requires 276.1171). 
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(S)-N-(Benzo[d]thiazol-2-yl)pyrrolidine-2-carboxamide (44). Compound 42 
(0.83 g, 2.4 mmol) was dissolved in TFA–H2O–TIPS (90/5/5, V/V/V, 4.0 mL, 
47 mmol TFA) and DCM (2.4 mL), with a final concentration of 0.4 M for 42. The 
clear, slightly yellow-coloured reaction mixture was stirred for 30 min at RT until 
gas formation stopped. Cold diethyl ether was added until precipitation was observed 
(~60 mL). The precipitate was collected by centrifugation and washed with cold 
diethyl ether (3 × 10 mL). The solid was dried in vacuo to afford 44 (0.73 g, 84%) as 
a white flocculent solid (TFA salt).  
>98% Purity (tr = 4.9 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.02 (EtOAc–Hexane, 2:1); mp 144–145 °C; max/cm-1 (solid) 2997 (w, br), 
1663 (s, sh), 1180 (s, sh), 1130 (s, sh), 721 (m, sh); H/ppm (400 MHz, DMSO-d6) 
9.45 (1H, br s, NH), 8.00 (1H, d, J 7.6, PhH), 7.78 (1H, d, J 8.0, PhH), 7.47 (1H, t, 
J 7.6, PhH), 7.35 (1H, t, J 7.0, PhH), 4.52 (1H, app dd, J 7.6, CH), 3.30 (2H, m, 
NHCH2), 2.42 (1H, m, CH2CH), 2.04 (1H, m, CH2CH), 1.95 (2H, m, CH2); C/ppm 
(100 MHz, DMSO-d6) 158.6 (C), 131.5 (C), 126.6 (PhH), 124.2 (PhH), 122.0 
(PhH), 59.7 (CH), 46.1 (NHCH2), 29.4 (CH2), 23.7 (CH2); m/z (FAB) 248 (100%, 
[M + H]+), 151 (25%, [ABT + H]+), 70 (50%, [pyrrolidine]+); HRMS found 
248.0869 (C12H14N3OS, [M + H]+, requires 248.0858). 
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(S)-N-(Benzo[d]thiazol-2-yl)-1-((naphtalen-2-yl)methyl)pyrrolidine-2-carbox-
amide (45). Compound 42 (30.5 mg, 0.084 mmol) was dissolved in NEt3 (35 7L, 
0.251 mmol) and DCM (420 µL), with a final concentration of 0.2 M, at 0 °C. 
Bromomethylnaphthalene (21.3 mg, 0.101 mmol) was added after 5 min. Aqueous 
work-up procedure followed after overnight reaction at 4 °C; the reaction mixture 
was diluted with DCM (20 mL), washed 0.1 M HCl (aq) (3 × 20 mL), H2O 
(3 × 20 mL), brine (1 × 20 mL), and dried over Na2SO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–70% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 45 (9 mg, 
28%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 10.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.53 (EtOAc–Hexane, 2:1); mp 74–76 °; max/cm-1 (solid) 2962 (w, br), 1670 (s, 
sh), 1177 (s, br), 1126 (s, sh), 750 (s, sh); H/ppm (400 MHz, CDCl3) 10.74 (1H, m, 
NHCO), 7.81 (3H, m, PhH), 7.75 (3H, m, PhH), 7.52 (1H, m, PhH), 7.38–7.47 (3H, 
m, PhH), 7.30 (1H, m, PhH), 4.04 (1H, d, J 12.4, NCH2), 3.87 (1H, d, J 12.8, NCH2), 
3.50 (1H, app dd, J 4.4, CH), 3.17 (1H, m, NCcyclopentylH2), 2.59 (1H, m, 
NCcyclopentylH2), 2.28–2.38 (1H, m, CH2), 2.01–2.08 (1H, m, CH2), 1.76–1.90 (2H, m, 
CH2); C/ppm (100 MHz, CDCl3) 173.8 (C), 157.4 (C), 148.8 (C), 135.0 (C), 133.5 
(C), 133.0 (C), 132.5 (C), 128.7 (PhH), 128.1 (PhH), 128.0 (PhH), 127.9 (PhH), 
127.2 (PhH), 126.1 (PhH), 124.0 (PhH), 121.6 (PhH), 121.2 (PhH), 66.8 (CH), 54.4 
(NCH2), 29.9 (CH2), 24.6 (CH2); m/z (FAB) 338 (55%, [M + H]+), 210 (55%, [M – 
furan-methylnaphthalene]+), 141 (100%, [methylnaphthalene]+), 83 (25%, 
[methylfuran]+), 69 (45%, [furan]+); HRMS found 388.1414 (C23H22N3OS, [M + 
H]+, requires 388.1414). 
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(S)-N-(Benzo[d]thiazol-2-yl)-1-benzylpyrrolidine-2-carboxamide (46). 
Compound 42 (49.6 mg, 0.137 mmol) was dissolved in NEt3 (58 7L, 0.416 mmol) 
and DCM (1.4 mL), with a final concentration of 0.1 M. Benzylbromide (20 µL, 
0.168 mmol) was added after 10 min. Aqueous work-up procedure followed after 
overnight reaction; the reaction mixture was diluted with DCM (20 mL), washed 
0.1 M HCl (aq) (3 × 20 mL), H2O (3 × 20 mL), brine (1 × 20 mL), and dried over 
Na2SO4, filtered and all volatiles removed in vacuo. The crude product was purified 
by preparative HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and 
lyophilised to yield 46 (13 mg, 14%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 16.0 min, 2–98% MeOH–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.58 (EtOAc–Hexane, 2:1); max/cm-1 (solid) 2976 (w, br), 1664 (m, 
sh), 1180 (s, br), 1130 (s, br), 763 (m, sh); H/ppm (400 MHz, CDCl3) 7.74 (1H, t, 
J 9.4, PhH), 7.46 (3H, m, PhH), 7.31 (5H, m, PhH), 4.32 (1H, d, J 12.8, NCH2), 4.04 
(1H, d, J 12.8, NCH2), 3.69 (1H, m, CH), 2.99 (1H, m, CH2), 2.39 (1H, m, CH2), 
2.25 (1H, m, CH2), 2.03 (2H, m, NCcyclopentylH2), 2.03 (1H, m, CH2); C/ppm 
(100 MHz, CDCl3) 170.3 (C), 162.5 (C), 156.3 (C), 138.7 (C), 129.5 (PhH), 127.7 
(PhH), 125.1 (PhH), 122.3 (PhH), 117.5 (PhH), 58.1 (NCH2), 54.6 (CH), 46.1 
(NCcyclopentylH2), 29.5 (CH2), 23.1 (CH2); m/z (ESI) 338 (100%, [M + H]+), 360 
(100%, [M + Na]+); HRMS found 338.1315 (C19H20N3OS, [M + H]+, requires 
338.1327). 
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(S)-N-(Benzo[d]thiazol-2-yl)-1-((benzofuran-5-yl)methyl)pyrrolidine-2-carbox-
amide (47). Compound 42 (33.1 mg, 0.092 mmol) was dissolved in acetic acid 
(27.6 µL, 0.460 mmol), molecular sieves (~10 mg) and DMF–DCM (0.46 mL), with 
a final concentration of 0.2 M. 1-Benzofuran-5-carbaldehyde (40.3 mg, 0.248 mmol) 
was added after 5 min. After 1 h at RT, NaBH(OAc)3 (118 mg, 0.557 mmol) was 
added to the reaction mixture. Aqueous work-up procedure followed after overnight 
reaction; the reaction mixture was diluted with DCM (20 mL), washed 0.1 M HCl (aq) 
(3 × 20 mL), H2O (3 × 20 mL), brine (1 × 20 mL), and dried over Na2SO4, filtered 
and all volatiles removed in vacuo. The crude product was purified by preparative 
HPLC (30–70% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to 
yield 47 (35.0 mg, 77%) as a white flocculent solid (TFA salt). 
>90% Purity (tr = 8.8 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
H/ppm (400 MHz, MeOH-d4) 7.80 (2H, m, PhH), 7.70 (2H, m, PhH), 7.65 (1H, m, 
PhH), 7.57 (1H, m, PhH), 7.52 (1H, d, J 8.2, PhH), 7.41–7.46 (3H, m, PhH), 7.30 
(2H, m, PhH), 4.67 (2H, s, NCH2), 4.57 (2H, s, NCH2), 4.50 (1H, app dd, J 7.6, CH), 
3.70 (1H, m, NCcyclopentylH2), 3.47 (1H, m, NCcyclopentylH2), 2.68 (1H, m, CH2), 2.25 
(1H, m, CH2), 2.11 (1H, m, CH2), 2.11 (1H, m, CH2); C/ppm (100 MHz, MeOH-d4) 
169.1 (C), 157.1 (C), 148.0 (PhH), 146.9 (PhH), 137.5 (C), 132.8 (C), 129.8 (PhH), 
129.0 (PhH), 128.1 (PhH), 127.6 (PhH), 125.9 (PhH), 123.0 (PhH), 121.0 (PhH), 
113.1 (PhH), 107.8 (PhH), 68.4 (CH), 65.6 (NCH2), 60.0 (NCH2), 56.1 (CH2), 30.4 
(CH2), 23.9 (CH2); m/z (ESI) 378 (100%, [M + H]+); HRMS found 378.1264 
(C21H20N3O2S, [M + H]+, requires 378.1276). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(cyclohexylmethylamino)cyclohexane-
carboxamide (48) and cis-N-(benzo[d]thiazol-2-yl)-4-(cyclohexylmethylamino)-
cyclohexanecarboxamide (50). Compound 38 (33.8 mg, 0.087 mmol) was 
dissolved in NEt3 (24.3 7L, 0.174 mmol), molecular sieves (~10 mg) and DMF 
(0.435 mL), with a final concentration of 0.2 M. Cyclohexanecarbaldehyde (15.7 µL, 
0.130 mmol) was added after 15 min. After 1 h NaBH(OAc)3 (36.1 mg, 0.170 mmol) 
was added to the reaction mixture. After 24 h, the reaction was quenched with 
NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) 
(3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered 
and all volatiles removed in vacuo. The crude product was purified by preparative 
HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to 
yield 48 (11.7 mg, 29%) and by-product 50 (<1 mg) as white flocculent solids (TFA 
salts). 
48. >98% Purity (tr = 10.3 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.01 (EtOAc–Hexane, 2:1); mp 186–188 °C; max/cm-1 (solid) 2930 
(w, br), 1669 (s, sh), 1178 (s, br), 1132 (s, br), 720 (s, sh); H/ppm (400 MHz, 
CDCl3) 7.82 (1H, d, J 8.0, PhH), 7.69 (1H, d, J 8.0, PhH), 7.51 (1H, t, J 7.6, PhH), 
7.41 (1H, t, J 7.6, PhH), 3.11 (1H, m, CHNH), 2.85 (3H, m, NHCH2, NHCOCH), 
2.28 (1H, m, CH2), 2.05 (1H, m, CH2), 1.87 (5H, m, CH2), 1.70 (5H, m, CH2), 1.10–
1.25 (4H, m, CH2), 0.98 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 173.4 (C), 126.9 
(PhH), 125.3 (PhH), 122.3 (PhH), 118.1 (PhH), 66.5 (CHNH), 50.8 (NHCH2), 39.6 
(NHCOCH), 34.9 (CH2), 30.3 (3C, CH2), 25.4 (3H, CH2); m/z (ESI) 372 (100%, [M 
+ H]+), 325 (20%); HRMS found 372.2122 (C21H30N3OS, [M + H]+, requires 
372.2110). 
50. >98% Purity (tr = 14.2 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.52 (EtOAc–Hexane, 2:1); mp 79–82 °C; max/cm-1 (solid) 2933 (w, 
br), 1671 (s, sh), 1544 (s, sh), 1178 (s, br), 1134 (s, br), 719 (s, sh); H/ppm 
(400 MHz, CDCl3) 7.84 (1H, d, J 7.6, PhH), 7.81 (1H, d, J 8.0, PhH), 7.53 (1H, t, 
J 7.2, PhH), 7.41 (1H, t, J 7.6, PhH), 3.53 (1H, m, CHNH), 2.92 (3H, m, NCH2, 
NHCOCH), 2.73 (2H, m, NCH2), 2.29 (2H, m, CH2), 2.12 (2H, m, CH2), 1.93 (4H, 
m, CH2), 1.83 (6H, m, CH2), 1.74 (4H, m, CH2), 1.67 (2H, m, CH2), 1.29 (4H, m, 
CH2), 1.17 (2H, m, CH2), 1.02 (4H, m, CH2); C/ppm (100 MHz, CDCl3) 127.2 
(PhH), 124.9 (PhH), 121.0 (PhH), 119.5 (PhH), 62.6 (CHN), 58.8 (2C, NCH2), 37.7 
(NHCOCH), 31.7 (CH2), 26.4 (CH2), 25.4 (3C, CH2), 22.5 (CH2); m/z (ESI) 468 
(100%, [M + H]+); HRMS found 468.3036 (C28H42N3OS, [M + H]+, requires 
468.3049). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(benzylamino)cyclohexanecarboxamide (49) and 
cis-N-(benzo[d]thiazol-2-yl)-4-(dibenzylamino)cyclohexanecarboxamide (53). 
Compound 38 (55.2 mg, 0.142 mmol) was dissolved in NEt3 (43.5 7L, 0.312 mmol) 
and DMF (0.71 mL), with a final concentration with 0.2 M. Benzaldehyde (28.8 µL, 
0.284 mmol) was added after 15 min. After 1 h NaBH(OAc)3 (119.8 mg, 
0.565 mmol) was added to the reaction mixture. After 24 h, the reaction was 
quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), washed with 0.1 M 
HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, 
filtered and all volatiles removed in vacuo. The crude product was purified by 
preparative HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and 
lyophilised to yield 49 (16 mg, 23%) and by-product 53 (5 mg, 8%) as white 
flocculent solids (TFA salts). 
49. >98% Purity (tr = 8.9 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.04 (EtOAc–Hexane, 2:1); mp 191–192 °C; max/cm-1 (solid) 3545 
(w, br), 2954 (w, br), 1657 (s, sh), 1179 (s, br), 1130 (m, sh), 754 (m, sh); H/ppm 
(400 MHz, CDCl3) 9.63 (1H, s, N+H2 TFA-), 7.82 (1H, d, J 7.5, PhABTH), 7.73 (1H, 
d, J 8.0, PhABTH), 7.52 (1H, t, J 8.0, PhABTH), 7.39–7.44 (3H, m, PhH), 7.32 (3H, m, 
PhH), 4.01 (2H, s, NHCH2), 3.02 (1H, m, CHNH), 2.82 (1H, m, NHCOCH), 2.17–
2.23 (2H, m, CH2), 1.84 (4H, m, CH2), 1.68 (2H, m, CH2); C/ppm (100 MHz, 
CDCl3) 173.4 (C), 130.1 (PhH), 128.9 (PhH), 127.4 (PhH), 125.8 (PhH), 122.1 
(PhH), 117.9 (PhH), 54.8 (CHNH), 48.1 (NHCH2), 40.3 (NHCOCH), 25.0 (2C, 
CH2), 24.0 (2C, CH2); m/z (ESI) 366 (100%, [M + H]+); HRMS found 366.1649 
(C21H24N3OS, [M + H]+, requires 366.1640). 
53. >98% Purity (tr = 11.7 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.67 (EtOAc–Hexane, 2:1); mp 168–170 °C; max/cm-1 (solid) 1669 
(m, sh), 1178 (s, br), 1133 (s, br), 701 (m, sh); H/ppm (400 MHz, CDCl3) 7.82 (1H, 
d, J 7.2, PhABTH), 7.73 (1H, d, J 8.0, PhABTH), 7.50–7.55 (5H, m, PhH), 7.49 (1H, t, 
J 8.0, PhABTH), 7.39 (1H, t, J 8.0, PhABTH), 7.38 (5H, m, PhH), 4.12 (4H, s, NCH2), 
3.26 (1H, m, CHN), 2.86 (1H, m, NHCOCH), 2.26 (2H, m, CH2), 2.12 (2H, m, 
CH2), 1.99 (2H, m, CH2), 1.58 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 174.0 (C), 
130.7 (3C, PhH), 129.0 (3C, PhH), 126.9 (PhH), 121.9 (PhH), 118.5 (PhH), 61.1 
(CHN), 54.2 (2C, NCH2), 38.7 (NHCOCH), 26.2 (2C, CH2), 22.0 (2C, CH2); m/z 
(ESI) 456 (100%, [M + H]+); HRMS found 456.2008 (C28H30N3OS, [M + H]+, 
requires 456.2110). 
 
  
VIII APPENDIX 
208 | P a g e  
 
    
cis-N-(Benzo[d]thiazol-2-yl)-4-((furan-2-yl)methylamino)cyclohexanecarbox-
amide (51) and cis-N-(benzo[d]thiazol-2-yl)-4-(bis(furan-2-yl)methylamino)-
cyclohexanecarboxamide (52). Compound 38 (42.2 mg, 0.108 mmol) was 
dissolved in NEt3 (33.1 7L, 0.237 mmol) and DMF (0.54 mL), with a concentration 
of 0.2 M. Furan-2-carbaldehyde (17.9 µL, 0.216 mmol) was added after 15 min. 
After 1 h NaBH(OAc)3 (81.9 mg, 0.386 mmol) was added to the reaction mixture. 
After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM 
(10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine 
(1 × 10 mL), and dried over MgSO4, filtered and all volatiles removed in vacuo. The 
crude product was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) 
in 30 min, = = 220 nm) and lyophilised to yield 51 (1.3 mg, 3%) and 52 (36.5 mg, 
78%) as white flocculent solids (TFA salts). 
51. >98% Purity (tr = 7.6 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.02 (EtOAc–Hexane, 2:1); mp 64–66 °C; max/cm-1 (solid) 1668 (s, 
sh), 1544 (s, sh), 1179 (m, br), 1133 (m, br), 722 (s, sh); H/ppm (400 MHz, CDCl3) 
7.77 (1H, d, J 8.0, PhABTH), 7.69 (1H, d, J 8.0, PhABTH), 7.49 (1H, t, J 7.6, PhABTH), 
7.38 (1H, t, J 8.0, PhABTH), 7.43 (1H, m, PhH), 6.57 (1H, m, PhH), 6.36 (1H, m, 
PhH), 4.20 (2H, s, NHCH2), 3.12 (1H, m, CHNH), 2.84 (1H, m, NHCOCH), 2.25 
(2H, m, CH2), 1.94 (4H, m, CH2), 1.77 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 
144.5 (PhH), 127.3 (PhABTH), 125.3 (PhABTH), 121.9 (PhABTH), 118.1 (PhABTH), 
112.7 (PhH), 111.3 (PhH), 54.0 (CHNH), 40.4 (NHCH2), 40.8 (NHCOCH), 25.2 
(2C, CH2), 24.2 (2C, CH2); m/z (ESI) 356 (100%, [M + H]+), 206 (30%), 151 (20%, 
[ABT + H]+); HRMS found 356.1429 (C19H22N3O2S, [M + H]+, requires 356.1433). 
52. >98% Purity (tr = 10.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.53 (EtOAc–Hexane, 2:1); mp 70–72 °C; max/cm-1 (solid) 1669 (m, 
br), 1546 (m, br), 1182 (s, br), 1134 (s, br), 720 (s, sh); H/ppm (400 MHz, CDCl3) 
7.86 (1H, d, J 7.6, PhABTH), 7.79 (1H, d, J 8.0, PhABTH), 7.53 (1H, t, J 7.6, PhABTH), 
7.47 (2H, m, PhH), 7.42 (1H, t, J 7.6, PhABTH), 6.67 (2H, m, PhH), 6.42 (2H, m, 
PhH), 4.31 (4H, s, NCH2), 3.15 (1H, m, CHN), 2.86 (1H, m, NHCOCH), 2.28 (2H, 
m, CH2), 1.98 (2H, m, CH2), 1.82 (2H, m, CH2), 1.65 (2H, m, CH2); C/ppm 
(100 MHz, CDCl3) 143.7 (2C, PhH), 126.7 (PhH), 124.9 (PhH), 121.3 (PhH), 118.7 
(PhH), 114.4 (PhH), 111.3 (2C, PhH), 60.3 (CHN), 45.4 (2C, NCH2), 38.8 
(NHCOCH), 26.6 (2C, CH2), 22.3 (2C, CH2); m/z (ESI) 436 (100%, [M + H]+), 151 
(25%, [ABT + H]+); HRMS found 436.1701 (C24H26N3O3S, [M + H]+, requires 
436.1695). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-((benzofuran-5-yl)methylamino)cyclohexane-
carboxamide (54) and cis-N-(benzo[d]thiazol-2-yl)-4-(bis(benzofuran-5-yl-
methyl)amino)cyclohexanecarboxamide (69). Compound 38 (55.4 mg, 
0.142 mmol) was dissolved in NEt3 (43 7L, 0.309 mmol) and DMF (0.71 mL), with 
a concentration of 0.2 M. 5-Benzofurancarbaldehyde (40.8 mg, 0.279 mmol) was 
added after 15 min. After 1 h NaBH(OAc)3 (122.2 mg, 0.577 mmol) was added to 
the reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) 
(1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–70% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 54 (23 mg, 
31%) and by-product 69 (31 mg, 41%) as white flocculent solids (TFA salts). 
54. >98% Purity (tr = 9.8 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.04 (EtOAc–Hexane, 2:1); mp 184–186 °C; max/cm-1 (solid) 3405 
(w, br), 2960 (w, br), 1674 (s, sh), 1533 (m, sh), 1448 (m, sh), 1179 (s, br), 1127 (s, 
br), 721 (s, sh); H/ppm (400 MHz, CDCl3) 9.65 (1H, s, NH), 7.83 (1H, d, J 8.0, 
PhH), 7.69 (1H, d, J 8.0, PhH), 7.64 (1H, m, PhH), 7.58 (1H, m, PhH), 7.48 (1H, t, 
J 8.4, PhH), 7.39 (2H, m, PhH), 7.37 (1H, m, PhH), 6.71 (1H, m, OCH), 4.10 (1H, s, 
NHCH2), 3.64 (1H, s, NHCH2), 2.96 (1H, m, CHNH), 2.72 (1H, m, NHCOCH), 2.14 
(2H, m, CH2), 1.80 (2H, m, CH2), 1.70 (2H, m, CH2), 1.53 (2H, m, CH2); C/ppm 
(100 MHz, CDCl3) 145.8 (PhH), 126.7 (PhH), 126.5 (PhH), 124.8 (PhH), 123.2 
(PhH), 122.7 (PhH), 121.2 (PhH), 118.9 (PhH), 106.8 (OCH), 53.4 (CHNH), 48.8 
(NHCH2), 39.6 (NHCOCH), 25.1 (2C, CH2), 24.4 (2C, CH2); m/z (ESI) 406 (100%, 
[M + H]+), 256 (20%); HRMS found 406.1587 (C23H24N3O2S, [M + H]+, requires 
406.1589). 
69. >98% Purity (tr = 18.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.53 (EtOAc–Hexane, 2:1); mp 221–226 °C; max/cm-1 (solid) 2947 
(w, br), 1665 (m, sh), 1180 (s, br), 1130 (s, br), 762 (m, sh); ); H/ppm (400 MHz, 
CDCl3) 8.05 (2H, m, PhH), 7.97 (1H, d, J 7.6, PhABTH), 7.73 (3H, m, PhH), 7.64 
(2H, m, PhH), 7.44 (1H, t, J 8.0, PhABTH), 7.39 (2H, m, PhH), 7.31 (1H, t, J 8.0, 
PhABTH), 6.98 (2H, m, PhH), 4.56 (2H, s, NCH2), 4.35 (2H, s, NCH2), 3.21 (1H, m, 
CHNH), 2.86 (1H, m, NHCOCH), 2.21 (2H, m, CH2), 2.05 (4H, m, CH2), 1.55 (2H, 
m, CH2); C/ppm (100 MHz, CDCl3) 174.3 (C), 158.0 (C), 154.6 (C), 147.5 (PhH), 
127.6 (PhH), 126.8 (PhH), 124.9 (PhH), 123.7 (PhH), 122.1 (PhH), 120.8 (PhH), 
112.1 (PhH), 107.2 (2C, PhH), 61.9 (CHN), 54.3 (2C, NCH2), 36.8 (NHCOCH), 
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26.6 (2C, CH2), 23.0 (2C, CH2); m/z (ESI) 536 (100%, [M + H]+), 338 (30%), 206 
(20%); HRMS found 536.2016 (C32H29N3O3S, [M + H]+, requires 536.2008). 
 
 
   
cis-N-(Benzo[d]thiazol-2-yl)-4-((benzo[d][1,3]dioxol-5-yl)methylamino)cyclo-
hexanecarboxamide (56) and cis-N-(benzo[d]thiazol-2-yl)-4-(bis(benzo[d][1,3]-
dioxol-5-yl)methylamino)cyclohexanecarboxamide (57). Compound 43 (40.7 mg, 
0.105 mmol) was dissolved in NEt3 (32.2 7L, 0.230 mmol) and DMF (0.525 mL), 
with a final concentration of 0.2 M. Piperonal (32.1 mg, 0.214 mmol) was added 
after 15 min. After 1 h NaBH(OAc)3 (84.1 mg, 0.397 mmol) was added to the 
reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), 
diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–50% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 56 
(13.9 mg, 25%) and the by-product 57 (3.9 mg, 7%) as white flocculent solids (TFA 
salts). 
56. >98% Purity (tr = 9.1 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.25 (EtOAc–Hexane, 2:1); mp 71–72 °C; max/cm-1 (solid) 2962 (w, 
br), 1671 (s, br), 1448 (s, sh), 1181 (s, br), 1135 (s, br), 721 (s, sh); H/ppm 
(400 MHz, CDCl3) 7.83 (1H, d, J 7.2, PhABTH), 7.66 (1H, d, J 8.0, PhABTH), 7.48 
(1H, t, J 7.2, PhABTH), 7.34–7.43 (2H, m, PhH), 6.94 (1H, m, PhH), 6.87 (1H, d, 
J 8.4, PhH), 6.73 (1H, d, J 8.0, PhH), 5.99 (1H, s OCH2O), 6.08 (1H, s OCH2O), 
4.04 (2H, s, NHCH2), 3.02 (1H, m, CHNH), 2.77 (1H, m, NHCOCH), 2.17 (2H, m, 
CH2), 1.88 (2H, m, CH2), 1.75 (2H, m, CH2), 1.63 (2H, m, CH2); C/ppm (100 MHz, 
CDCl3) 126.9 (PhABTH), 124.8 (PhH), 123.9 (PhH), 121.9 (PhABTH), 118.7 
(PhABTH), 110.1 (PhH), 108.5 (PhH), 102.2 (OCH2O), 54.2 (CHNH), 48.3 
(NHCH2), 40.0 (NHCOCH), 25.3 (2C, CH2), 24.7 (2C, CH2); m/z (ESI) 410 (100%, 
[M + H]+), 280 (20%); HRMS found 410.1541 (C22H24N3O3S, [M + H]+, requires 
410.1538). 
57. >98% Purity (tr = 11.8 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); mp 114–121 °C; H/ppm (400 MHz, CDCl3) 7.82 (1H, d, J 7.2, PhABTH), 
7.73 (1H, d, J 8.0, PhABTH), 7.49 (1H, t, J 8.0, PhABTH), 7.39 (1H, t, J 8.0, PhABTH), 
7.05 (2H, m, PhH), 6.93 (2H, m, PhH), 6.78 (2H, m, PhH), 5.97 (4H, s, OCH2O), 
4.08 (4H, s, NCH2), 3.24 (1H, m, CHN), 2.85 (1H, m, NHCOCH), 2.26 (2H, m, 
CH2), 2.09 (2H, m, CH2), 1.98 (2H, m, CH2), 1.60 (2H, m, CH2); C/ppm (100 MHz, 
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CDCl3) 174.3 (C), 148.8 (C), 126.8 (PhH), 124.9 (PhH), 124.7 (PhH), 121.5 (PhH), 
120.0 (PhH), 110.7 (2C, PhH), 108.5 (2C, PhH), 101.4 (2C, OCH2O), 60.3 (CHN), 
54.0 (2C, NCH2), 37.9 (NHCOCH), 25.9 (2C, CH2), 21.9 (2C, CH2); m/z (ESI) 544 
(100%, [M + H]+); HRMS found 544.1896 (C30H30N3O5S, [M + H]+, requires 
544.1906). 
 
 
 
cis-N-(Benzo[d]thiazol-2-yl)-4-(4-methylsulfonyl)benzylamino)cyclohexane-
carboxamide (58). Compound 38 (35.0 mg, 0.090 mmol) was dissolved in NEt3 
(25.1 7L, 0.180 mmol) and DMF (0.45 mL), with a concentration of 0.2 M. 
4-Methylsulfonylbenzaldehyde (28.5 mg, 0.155 mmol) was added after 15 min. 
After 1 h NaBH(OAc)3 (37.7 mg, 0.178 mmol) was added to the reaction mixture. 
After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM 
(10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine 
(1 × 10 mL), and dried over MgSO4, filtered and all volatiles removed in vacuo. The 
crude product was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) 
in 30 min, = = 220 nm) and lyophilised to yield 58 (2.7 mg, 5%) as a white 
flocculent solid (TFA salt). 
>98% Purity (tr = 7.8 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.41 (EtOAc–Hexane, 2:1); mp 135–136 °C; max/cm-1 (solid) 2933 (w, br), 
1656 (m, sh), 1542 (m, sh), 1295 (m, br), 1147 (s, br), 762 (s, sh); H/ppm (400 MHz, 
MeOH-d4) 8.18 (1H, m, PhH), 8.08 (1H, d, J 8.4, PhH), 7.95 (1H, m, PhH), 7.87 
(1H, d, J 7.6, PhH), 7.77 (3H, m, PhH), 7.60 (1H, m, PhH), 7.45 (1H, t, J 8.4, PhH), 
7.32 (1H, t, J 8.4, PhH), 4.40 (2H, s, NHCH2), 3.15 (1H, m, CHNH), 2.94 (1H, m, 
NHCOCH), 2.26 (2H, m, CH2), 2.12 (2H, m, CH2), 2.02 (2H, m, CH2), 1.84 (2H, m, 
CH2); C/ppm (100 MHz, MeOH-d4) 135.2 (PhH), 130.7 (PhH), 127.9 (PhH), 125.0 
(PhH), 120.2 (PhH), 116.0 (PhH), 121.0 (PhH), 47.2 (NHCH2), 44.0 (CHNH), 39.2 
(NHCOCH), 25.0 (4C, CH2); m/z (ESI) 466 (100%, [M + Na]), 444 (50%, [M + 
H]+), 276 (50%), 151 (25%, [ABT + H]+); HRMS found 444.1425 (C22H26N3O3S2, 
[M + H]+, requires 444.1416). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(4-methoxybenzylamino)cyclohexanecarbox-
amide (59) and cis-N-(benzo[d]thiazol-2-yl)-4-(bis(4-methoxybenzyl)amino)-
cyclohexanecarboxamide (60). Compound 38 (39.0 mg, 0.100 mmol) was 
dissolved in NEt3 (31.0 7L, 0.222 mmol) and DMF (0.50 mL), with a concentration 
of 0.2 M. p-Anisaldehyde (24.3 µL, 0.200 mmol) was added after 15 min. After 1 h 
NaBH(OAc)3 (37.5 mg, 0.177 mmol) was added to the reaction mixture. After 24 h, 
the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), 
washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and 
dried over MgSO4, filtered and all volatiles removed in vacuo. The crude product 
was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 59 (3.8 mg, 7%) and 60 (11.6 mg, 23%) as white 
flocculent solids (TFA salts). 
59. >98% Purity (tr = 9.2 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.02 (EtOAc–Hexane, 2:1); mp 86–88 °C; max/cm-1 (solid) 2961 (w, 
br), 2848 (w, br), 1669 (s, sh), 1540 (m, sh), 1178 (s, br), 1131 (s, br), 721 (s, sh); 
H/ppm (400 MHz, CDCl3) 7.84 (1H, m, PhH), 7.69 (1H, d, J 8.0, PhH), 7.48 (1H, t, 
J 8.0, PhH), 7.39 (1H, d, J 7.6, PhH), 7.34 (2H, m, PhH), 7.01 (1H, d, J 8.4, PhH), 
6.84 (1H, d, J 8.4, PhH), 4.02 (2H, s, NHCH2), 2.99 (1H, m, CHNH), 2.77 (1H, m, 
NHCOCH), 3.90 (1H, s, OCH3), 3.73 (2H, s, OCH3), 2.17 (2H, m, CH2), 1.86 (2H, 
m, CH2), 1.75 (2H, m, CH2), 1.60 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 131.3 
(PhH), 124.7 (PhH), 122.0 (PhH), 118.8 (PhH), 114.5 (PhH), 55.5 (OCH3), 54.1 
(CHNH), 47.6 (NHCH2), 40.1 (NHCOCH), 24.6 (2C, CH2), 24.6 (2C, CH2); m/z 
(ESI) 396 (100%, [M + H]+), 246 (30%); HRMS found 396.1751 (C22H26N3O2S, [M 
+ H]+, requires 396.1746). 
60. >98% Purity (tr = 12.1 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.53 (EtOAc–Hexane, 2:1); mp 92–96 °C; max/cm-1 (solid) 2968 (w, 
br), 1669 (m, sh), 1517 (m, sh), 1257 (s, sh), 1179 (s, br), 1130 (s, br), 719 (s, sh); 
H/ppm (400 MHz, CDCl3) 7.83 (1H, d, J 8.0, PhABTH), 7.72 (1H, d, J 8.0, PhABTH), 
7.49 (1H, t, J 7.6, PhABTH), 7.39 (1H, t, J 8.0, PhABTH), 7.43 (4H, d, J 8.8, PhH), 
6.99 (4H, d, J 8.8, PhH), 4.01 (4H, s, NCH2), 3.76 (6H, s, OCH3), 3.22 (1H, m, 
CHN), 2.83 (1H, m, NHCOCH), 2.24 (2H, m, CH2), 2.09 (2H, m, CH2), 1.97 (2H, 
m, CH2), 1.55 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 173.7 (C), 160.8 (C), 132.5 
(4C, PhH), 126.8 (PhH), 125.2 (PhH), 121.5 (PhH), 118.4 (PhH), 114.4 (4C, PhH), 
55.1 (2C, OCH3), 59.8 (CHNH), 53.7 (2C, NCH2), 38.2 (NHCOCH), 26.2 (2C, 
CH2), 22.2 (2C, CH2); m/z (ESI) 516 (100%, [M + H]+); HRMS found 516.2321 
(C30H34N3O3S, [M + H]+, requires 516.2321). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(4-fluorobenzylamino)cyclohexanecarboxamide 
(61) and cis-N-(benzo[d]thiazol-2-yl)-4-(bis(4-fluorobenzyl)amino)cyclohexane-
carboxamide (62). Compound 38 (32.0 mg, 0.082 mmol) was dissolved in NEt3 
(23.0 7L, 0.165 mmol) and DMF (0.41 mL), with a concentration of 0.2 M. 
p-Fluorobenzaldehyde (17.6 µL, 0.164 mmol) was added after 15 min. After 1 h 
NaBH(OAc)3 (70.5 mg, 0.333 mmol) was added to the reaction mixture. After 24 h, 
the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), 
washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and 
dried over MgSO4, filtered and all volatiles removed in vacuo. The crude product 
was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 61 (8.5 mg, 21%) and by-product 62 (6.7 mg, 17%) 
as white flocculent solids (TFA salts). 
61. >98% Purity (tr = 9.2 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.02 (EtOAc–Hexane, 2:1); mp 180–182 °C; max/cm-1 (solid) 2971 
(w, br), 1669 (s, sh), 1545 (m, sh), 1181 (s, br), 1132 (s, br), 721 (s, sh); H/ppm 
(400 MHz, MeOH-d4) 7.86 (1H, d, J 8.0, PhABTH), 7.75 (1H, d, J 8.0, PhABTH), 7.55 
(1H, m, PhH), 7.44 (1H, t, J 7.2, PhABTH), 7.32 (1H, t, J 8.0, PhABTH), 7.22 (2H, m, 
PhH), 4.25 (2H, s, NHCH2), 3.26 (1H, m, CHNH), 2.92 (1H, m, NHCOCH), 2.25 
(2H, m, CH2), 2.10 (2H, m, CH2), 1.99 (2H, m, CH2), 1.84 (2H, m, CH2); C/ppm 
(100 MHz, MeOH-d4) 174.3 (C), 164.7 (C), 162.2 (C), 158.5 (C), 148.6 (C), 132.0 
(PhH), 125.8 (PhH), 123.5 (PhH), 120.9 (PhH), 120.3 (PhH), 115.8 (PhH), 115.5 
(PhH), 55.7 (CHNH), 48.0 (NHCH2), 38.3 (NHCOCH), 25.0 (2C, CH2); m/z (ESI) 
384 (100%, [M + H]+), 276 (20%), 234 (20%), 151 (20%, [M + ABT]+); HRMS 
found 384.1554 (C21H23N3OSF, [M + H]+, requires 384.1546). 
62. >98% Purity (tr = 12.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.64 (EtOAc–Hexane, 2:1); mp 102–106 °C; max/cm-1 (solid) 2976 
(w, br), 1669 (s, sh), 1542 (m, sh), 1515 (m, sh), 1181 (s, br), 1131 (s, br), 759 (s, sh), 
720 (s, sh); H/ppm (400 MHz, CDCl3) 7.84 (1H, d, J 8.0, PhABTH), 7.79 (1H, d, 
J 8.0, PhABTH), 7.52 (1H, t, J 7.6, PhABTH), 7.39–7.46 (5H, m, PhH), 7.05 (4H, m, 
PhH), 4.03 (4H, s, NCH2), 3.08 (1H, m, CHN), 2.82 (1H, m, NHCOCH), 2.27 (2H, 
m, CH2), 2.02 (2H, m, CH2), 1.94 (2H, m, CH2), 1.73 (2H, m, CH2); C/ppm 
(100 MHz, CDCl3) 132.1 (PhH), 126.9 (PhH), 125.0 (PhH), 121.7 (PhH), 119.1 
(PhH), 116.1 (PhH), 53.4 (2C, NCH2), 38.4 (NHCOCH), 26.9 (2C, CH2), 23.0 
(CH2); m/z (ESI) 492 (100%, [M + H]+); HRMS found 492.1921 (C28H28N3OSF2, [M 
+ H]+, requires 492.1921). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(perfluorobenzylamino)cyclohexanecarboxamide 
(63). Compound 38 (40.1 mg, 0.103 mmol) was dissolved in NEt3 (31.6 7L, 
0.227 mmol) and DMF (0.515 mL), with a concentration of 0.2 M. 2,3,4,5,6-Penta-
fluorobenzaldehyde (25.4 mg, 0.206 mmol) was added after 15 min. After 1 h 
NaBH(OAc)3 (92.8 mg, 0.438 mmol) was added to the reaction mixture. After 24 h, 
the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), 
washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and 
dried over MgSO4, filtered and all volatiles removed in vacuo. The crude product 
was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 63 (6.2 mg, 11%) as a white flocculent solid (TFA 
salt). 
>98% Purity (tr = 9.9 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.42 (EtOAc–Hexane, 2:1); mp 183–185 °C; max/cm-1 (solid) 3266 (w, br), 
2868 (w, br), 1681 (s, sh), 1521 (s, sh), 1128 (s, br), 954 (m, br), 755 (s, sh); H/ppm 
(400 MHz, MeOH-d4) 7.87 (1H, d, J 7.6, PhABTH), 7.76 (1H, d, J 8.0, PhABTH), 7.45 
(1H, t, J 8.4, PhABTH), 7.32 (1H, t, J 8.4, PhABTH), 4.44 (2H, s, NHCH2), 3.41 (1H, 
m, CHNH), 2.94 (1H, m, NHCOCH), 2.27 (2H, m, CH2), 2.13 (2H, m, CH2), 2.02 
(2H, m, CH2), 1.87 (2H, m, CH2); C/ppm (100 MHz, MeOH-d4) 174.1 (C), 131.4 
(C), 125.7 (PhABTH), 123.6 (PhABTH), 120.9 (PhABTH), 120.3 (PhABTH), 48.5 
(CHNH), 37.9 (NHCOCH), 35.1 (NHCH2), 24.9 (4C, CH2); m/z (ESI) 456 (100%, 
[M + H]+), 222 (20%), 151 (20%, [M + ABT]+); HRMS found 456.1177 
(C21H19N3OSF5, [M + H]+, requires 456.1169).  
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cis-N-(Benzo[d]thiazol-2-yl)-4-(3-nitrobenzylamino)cyclohexanecarboxamide 
(64). Compound 38 (39.8 mg, 0.102 mmol) was dissolved in NEt3 (31.0 7L, 
0.222 mmol) and DMF (0.51 mL), with a concentration of 0.2 M. 
o-Nitrobenzaldehyde (30.2 mg, 0.200 mmol) was added after 15 min. After 1 h 
NaBH(OAc)3 (83.0 mg, 0.392 mmol) was added to the reaction mixture. After 24 h, 
the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), 
washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and 
dried over MgSO4, filtered and all volatiles removed in vacuo. The crude product 
was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 64 (25.8 mg, 48%) as a white flocculent solid (TFA 
salt). 
>98% Purity (tr = 9.1 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.02 (EtOAc–Hexane, 2:1); mp 87–89 °C; max/cm-1 (solid) 3266 (w, br), 2868 
(w, br), 1681 (s, sh), 1512 (s, sh), 1128 (s, br), 954 (m, br), 755 (s, sh); H/ppm 
(400 MHz, CDCl3) 8.17 (1H, d, J 9.6, PhH), 7.87 (1H, d, J 7.2, PhABTH), 7.81 (1H, 
d, J 7.6, PhH), 7.76 (1H, d, J 8.4, PhABTH), 7.71 (1H, t, J 6.4, PhH), 7.63 (1H, t, 
J 7.2, PhH), 7.54 (1H, t, J 7.2, PhABTH), 7.44 (1H, t, J 8.0, PhABTH), 4.30 (2H, s, 
NHCH2), 3.50 (1H, m, CHNH), 2.88 (1H, m, NHCOCH), 2.27 (2H, m, CH2), 2.09 
(4H, m, CH2), 1.87 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 174.2 (C), 163.2 (C), 
148.6 (C), 135.2 (PhH), 134.7 (PhH), 131.4 (PhH), 128.4 (PhH), 126.0 (PhH), 125.6 
(PhH), 122.3 (PhH), 117.1 (PhH), 57.2 (CHNH), 47.2 (NHCH2), 40.0 (NHCOCH), 
25.0 (2C, CH2), 23.5 (2C, CH2); m/z (ESI) 411 (100%, [M + H]+), 261 (25%); 
HRMS found 411.1504 (C21H23N3O3S2, [M + H]+, requires 411.1491). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-((thiophene-2-yl)methylamino)cyclohexane-
carboxamide (65) and cis-N-(benzo[d]thiazol-2-yl)-4-(bis(thiophene-2-yl)-
methylamino)cyclohexanecarboxamide (66). Compound 38 (42.3 mg, 
0.109 mmol) was dissolved in NEt3 (33.4 7L, 0.240 mmol) and DMF (0.545 mL), 
with a concentration of 0.2 M. Thiophene-2-carbaldehyde (20.4 µL, 0.218 mmol) 
was added after 15 min. After 1 h NaBH(OAc)3 (92.5 mg, 0.436 mmol) was added to 
the reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) 
(1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–70% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 65 (5.4 mg, 
10%) and 66 (6.4 mg, 13%) as white flocculent solids (TFA salts). 
65. >98% Purity (tr = 8.3 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.01 (EtOAc–Hexane, 2:1); mp 178–181 °C; max/cm-1 (solid) 2952 
(w, br), 1666 (m, br), 1540 (m, sh), 1443 (m, sh), 1267 (s, br), 1134 (s, br), 718 (s, 
sh); H/ppm (400 MHz, MeOD-d4) 7.87 (1H, d, J 7.6, PhABTH), 7.65 (1H, d, J 8.0, 
PhABTH), 7.59 (1H, m, PhH), 7.47 (1H, t, J 7.2, PhABTH), 7.32 (2H, m, PhH), 7.14 
(1H, m, PhH), 4.51 (2H, s, NHCH2), 3.28 (1H, m, CHNH), 2.91 (1H, m, NHCOCH), 
2.24 (2H, m, CH2), 2.01 (2H, m, CH2), 1.99 (2H, m, CH2), 1.84 (2H, m, CH2); 
C/ppm (100 MHz, MeOD-d4) 130.2 (PhH), 128.1 (PhH), 127.4 (PhH), 125.9 
(PhABTH), 123.5 (PhH), 120.8 (PhABTH), 120.4 (PhABTH), 47.7 (CHNH), 41.9 
(NHCH2), 38.5 (NHCOCH), 25.1 (4C, CH2); m/z (ESI) 372 (100%, [M + H]+), 222 
(40%), 151 (30%, [ABT + H]+); HRMS found 372.1206 (C19H22N3OS2, [M + H]+, 
requires 372.1204). 
66. >98% Purity (tr = 11.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.70 (EtOAc–Hexane, 2:1); mp 82–87 °C; max/cm-1 (solid) 2966 (w, 
br), 1668 (s, sh), 1543 (s, sh), 1182 (s, br), 1135 (s, br), 720 (s, sh); H/ppm 
(400 MHz, CDCl3) 7.87 (1H, d, J 7.6, PhABTH), 7.83 (1H, d, J 8.0, PhABTH), 7.56 
(1H, t, J 8.0, PhABTH), 7.44 (1H, t, J 8.0, PhABTH), 7.33 (2H, m, PhH), 7.18 (2H, m, 
PhH), 7.02 (2H, m, PhH), 4.26 (2H, s, NHCH2), 3.67 (2H, s, NHCH2), 3.06 (1H, m, 
CHNH), 2.86 (1H, m, NHCOCH), 2.30 (2H, m, CH2), 1.96 (2H, m, CH2), 1.68 (2H, 
m, CH2); C/ppm (100 MHz, CDCl3) 174.1 (C), 130.3 (PhH), 127.4 (PhH), 125.1 
(PhH), 121.9 (PhH), 118.4 (PhH), 58.9 (CHNH), 47.1 (2C, NHCH2), 38.7 
(NHCOCH), 26.0 (2C, CH2), 23.7 (CH2); m/z (ESI) 468 (100%, [M + H]+); HRMS 
found 468.1228 (C24H26N3OS3, [M + H]+, requires 468.1238). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(3,4-dihydroxybenzylamino)cyclohexane-
carboxamide (67). Compound 38 (35.8 mg, 0.103 mmol) was dissolved in NEt3 
(25.6 7L, 0.184 mmol) and DMF (0.46 mL), with a concentration of 0.2 M. 
3,4-Dihydroxybenzaldehyde (19.0 mg, 0.138 mmol) was added after 15 min. After 
1 h NaBH(OAc)3 (37.5 mg, 0.177 mmol) was added to the reaction mixture. After 
24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM 
(10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine 
(1 × 10 mL), and dried over MgSO4, filtered and all volatiles removed in vacuo. The 
crude product was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) 
in 30 min, = = 220 nm) and lyophilised to yield 67 (1.0 mg, 2%) as a white 
flocculent solid (TFA salt). 
>98% Purity (tr = 7.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.01 (EtOAc–Hexane, 2:1); mp 135–137 °C; max/cm-1 (solid) 1672 (w, sh), 
1573 (w, sh), 1183 (m, br), 1132 (m, br), 721 (w, sh); H/ppm (400 MHz, MeOH-d4) 
7.86 (1H, d, J 8.4, PhABTH), 7.74 (1H, d, J 8.4, PhABTH), 7.44 (1H, d, J 8.4, PhABTH), 
7.31 (1H, t, J 7.2, PhABTH), 6.91 (1H, m, PhH), 6.81 (2H, m, PhH), 4.01 (2H, s, 
NHCH2), 3.22 (1H, m, CHNH), 2.90 (1H, m, NHCOCH), 2.22 (2H, m, CH2), 2.05 
(2H, m, CH2), 1.95 (2H, m, CH2), 1.83 (2H, m, CH2); C/ppm (100 MHz, MeOH-d4) 
127.2 (PhABTH), 124.7 (PhABTH), 122.1 (PhABTH), 122.7 (PhH), 121.6 (PhABTH), 
117.4 (PhH), 116.3 (PhH), 56.2 (CHNH), 49.2 (NHCH2), 39.4 (NHCOCH), 26.2 
(4C, CH2); m/z (ESI) 396 (100%, [M + H]+), 276 (80%); HRMS found 396.1525 
(C21H24N3O3S, [M + H]+, requires 396.1538).  
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cis-N-(Benzo[d]thiazol-2-yl)-4-((anthracen-3-yl)methylamino)cyclohexane-
carboxamide (68). Compound 38 (35.1 mg, 0.090 mmol) was dissolved in NEt3 
(25.1 7L, 0.180 mmol), molecular sieves (~10 mg) and DMF (0.45 mL), with a final 
concentration of 0.2 M. 9-Anthraldehyde (25.5 mg, 0.124 mmol) was added after 
15 min. After 1 h NaBH(OAc)3 (35.5 mg, 0.168 mmol) was added to the reaction 
mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), diluted 
with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), 
brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles removed in 
vacuo. The crude product was purified by preparative HPLC (30–70% ACN–H2O 
(+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 68 (1.7 mg, 3%) as a 
white flocculent solid (TFA salt). 
>98% Purity (tr = 12.3 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.71 (EtOAc–Hexane, 2:1); max/cm-1 (solid) 2917 (w, br), 2359 (w, br), 1677 (s, 
sh), 1286 (s, sh), 1171 (m, sh), 938 (m, sh), 695 (s, sh); m/z (ESI) 466 (100%, [M + 
H]+), 316 (30%), 276 (25%), 191 (30%); HRMS found 466.1947 (C29H28N3OS, [M + 
H]+, requires 466.1953). 
 
 
  
VIII APPENDIX 
219 | P a g e  
 
 
cis-N-(Benzo[d]thiazol-2-yl)-4-((dibenzo[b,d]furan-2-yl)methylamino)cyclo-
hexanecarboxamide (69). Compound 38 (35.1 mg, 0.090 mmol) was dissolved in 
NEt3 (25.1 7L, 0.180 mmol), molecular sieves (~10 mg) and DMF (0.450 mL), with 
a final concentration of 0.2 M. Dibenzo[b,d]furan-2-carbaldehyde (26.3 mg, 
0.134 mmol) was added after 15 min. After 1 h NaBH(OAc)3 (44.6 mg, 0.210 mmol) 
was added to the reaction mixture. After 24 h, the reaction was quenched with 
NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) 
(3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered 
and all volatiles removed in vacuo. The crude product was purified by preparative 
HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to 
yield 69 (9.2 mg, 17%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 11.7 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.57 (EtOAc–Hexane, 2:1); mp 110–112 °C; max/cm-1 (solid) 1671 (s, sh), 1540 
(m, sh), 1450 (m, sh), 1267 (s, br), 1196 (s, br), 1130 (s, br), 720 (s, sh); H/ppm 
(400 MHz, MeOH-d4) 8.22 (1H, m, PhH), 8.08 (1H, d, J 8.4, PhH), 8.04 (1H, m, 
PhH), 7.87 (1H, d, J 8.4, PhH), 7.70 (1H, m, PhH), 7.64 (2H, m, PhH), 7.58 (2H, m, 
PhH), 7.45 (2H, m, PhH), 7.45 (1H, t, J 8.0, PhH), 7.37 (1H, t, J 7.6, PhH), 7.32 (1H, 
t, J 8.0, PhH), 4.78 (1H, s, NHCH2), 4.44 (1H, s, NHCH2), 3.34 (1H, m, CHNH), 
2.94 (1H, m, NHCOCH), 2.26 (2H, m, CH2), 2.14 (2H, m, CH2), 2.04 (2H, m, CH2), 
1.84 (2H, m, CH2); C/ppm (100 MHz, MeOH-d4) 174.6 (C), 156.7 (C), 148.6 (C), 
128.8 (PhH), 127.8 (PhH), 125.8 (PhH), 122.2 (PhH), 120.9 (PhH), 120.5 (PhH), 
120.3 (PhH), 111.8 (PhH), 111.4 (PhH), 111.2 (PhH), 110.8 (PhH), 55.9 (CHNH), 
47.8 (NHCH2), 38.0 (NHCOCH), 24.9 (4C, CH2); m/z (ESI) 456 (100%, [M + H]+), 
306 (40%); HRMS found 456.1758 (C27H26N3O2S, [M + H]+, requires 456.1746). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(phenethylamino)cyclohexanecarboxamide (70). 
Compound 38 (34.8 mg, 0.059 mmol) was dissolved in NEt3 (24.8 7L, 0.178 mmol), 
molecular sieves (~10 mg) and DMF (0.45 mL), with a final concentration of 0.2 M. 
Phenylacetaldehyde (14.9 µL, 0.133 mmol) was added after 15 min. After 1 h 
NaBH(OAc)3 (54.6 mg, 0.258 mmol) was added to the reaction mixture. After 24 h, 
the reaction was quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), 
washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and 
dried over MgSO4, filtered and all volatiles removed in vacuo. The crude product 
was purified by preparative HPLC (30–70% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 70 (1.3 mg, 3%) as a white flocculent solid (TFA 
salt). 
>98% Purity (tr = 9.8 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.01 (EtOAc–Hexane, 2:1); mp 135–138 °C; max/cm-1 (solid) 2948 (w, br), 
1541 (s, sh), 1187 (s, br), 1136 (s, br), 756 (m, sh); H/ppm (500 MHz, CDCl3) 9.69 
(NH), 7.85 (1H, m, PhH), 7.71 (1H, m, PhH), 7.61 (1H, m, PhH), 7.50 (1H, m, PhH), 
7.35 (1H, t, J 11.5, PhH), 7.18–7.24 (4H, m, PhH), 4.20 (2H, s, CH2), 3.26 (1H, m, 
CHNH), 2.84 (1H, m, NHCOCH), 2.42 (2H, m, CH2), 1.80 (2H, m, CH2), 1.70 (2H, 
m, CH2), 1.53 (2H, m, CH2), 1.27 (2H, s, CH2); C/ppm (125 MHz, CDCl3) 136.4 
(C), 128.1 (PhH), 128.0 (PhH), 127.0 (PhH), 124.7 (PhH), 122.2 (PhH), 121.9 
(PhH), 117.8 (PhH), 117.4 (PhH); m/z (ESI) 380 (100%, [M + H]+), 230 (20%); 
HRMS found 380.1801 (C22H26N3OS, [M + H]+, requires 380.1797). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-((2,3-dihydrobenzofuran-5-yl)methylamino)-
cyclohexanecarboxamide (71). Compound 38 (35.0 mg, 0.090 mmol) was 
dissolved in NEt3 (25.1 7L, 0.180 mmol), molecular sieves (~10 mg) and DMF 
(0.450 mL), with a final concentration of 0.2 M. 2,3-Dihydrobenzofuran-5-
carbaldehyde (17 µL, 0.135 mmol) was added after 15 min. After 1 h NaBH(OAc)3 
(43.7 mg, 0.206 mmol) was added to the reaction mixture. After 24 h, the reaction 
was quenched with NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), washed with 
0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and dried over 
MgSO4, filtered and all volatiles removed in vacuo. The crude product was purified 
by preparative HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and 
lyophilised to yield 71 (12.4 mg, 26%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 9.2 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.01 (EtOAc–Hexane, 2:1); mp 88–100 °C; max/cm-1 (solid) 2966 (w, br), 1671 
(s, sh), 1543 (m, sh), 1179 (s, br), 1131 (s, br), 721 (s, sh); H/ppm (400 MHz, 
CDCl3) 9.53 (1H, s, NH), 7.81 (1H, d, J 8.0, PhH), 7.75 (1H, m, PhH), 7.68 (1H, m, 
PhH), 7.48 (1H, t, J 8.0, PhH), 7.38 (1H, t, J 7.6, PhH), 7.12 (1H, d, J 7.6, PhH), 
6.88 (1H, d, J 8.0, PhH), 6.68 (1H, d, J 8.0, PhH), 4.69 (1H, t, J 8.8, CH2), 4.51 (1H, 
t, J 8.8, CH2), 3.99 (2H, s, NHCH2), 3.28 (1H, t, J 8.8, CH2), 3.14 (1H, t, J 8.8, CH2), 
3.04 (1H, m, CHNH), 2.79 (1H, m, NHCOCH), 2.19 (2H, m, CH2), 1.85 (4H, m, 
CH2), 1.66 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 173.5 (C), 164.4 (C), 160.9 
(C), 130.2 (PhH), 127.0 (PhH), 124.9 (PhH), 121.9 (PhH), 118.6 (PhH), 113.4 
(PhH), 109.3 (PhH), 71.4 (OCH2), 53.5 (CHNH), 47.6 (NHCH2), 40.5 (NHCOCH), 
28.8 (CH2), 25.3 (2C, CH2), 24.2 (2C, CH2); m/z (ESI) 408 (100%, [M + H]+), 258 
(50%); HRMS found 408.1739 (C23H26N3O2S, [M + H]+, requires 408.1746). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-(benzo[b]thiophen-5-ylmethylamino)cyclo-
hexanecarboxamide (72). Compound 38 (36.3 mg, 0.093 mmol) was dissolved in 
NEt3 (25.9 7L, 0.186 mmol), molecular sieves (~10 mg) and DMF (0.450 mL), with 
a concentration of 0.2 M. 1-Benzothiophene-5-carbaldehyde (22.2 mg, 0.137 mmol) 
was added after 15 min. After 1 h NaBH(OAc)3 (44.9 mg, 0.212 mmol) was added to 
the reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) 
(1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–50% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 72 (9.5 mg, 
19%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 10.4 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.01 (EtOAc–Hexane, 2:1); mp 163–166 °C; max/cm-1 (solid) 1671 (s, sh), 1540 
(m, sh), 1450 (m, sh), 1196 (s, br), 1130 (s, br), 720 (s, sh); H/ppm (400 MHz, 
CDCl3) 9.64 (1H, s, NH), 7.89 (1H, m, PhH), 7.81 (1H, m, PhH), 7.75 (2H, m, PhH), 
7.57 (1H, t, J 8.4, PhH), 7.39–7.44 (3H, m, PhH), 7.28 (1H, m, PhH), 4.05 (2H, s, 
NHCH2), 3.00 (1H, m, CHNH), 2.79 (1H, m, NHCOCH), 2.18 (2H, m, CH2), 1.96 
(2H, m, CH2), 1.84 (2H, m, CH2), 1.67 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 
174.0 (C), 163.1 (C), 162.3 (C), 140.8 (C), 139.6 (C), 128.0 (PhH), 127.7 (PhH), 
125.7 (PhH), 125.5 (PhH), 123.4 (PhH), 123.1 (PhH), 121.5 (PhH), 117.8 (PhH), 
53.7 (CHNH), 48.0 (NHCH2), 40.3 (NHCOCH), 24.5 (2C, CH2), 23.9 (2C, CH2); 
m/z (ESI) 422 (100%, [M + H]+), 272 (60%), 151 (25%, [ABT + H]+); HRMS found 
422.1351 (C23H24N3OS2, [M + H]+, requires 422.1361). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-((1H-indole-5-yl)methylamino)cyclohexane-
carboxamide (73). Compound 38 (31.3 mg, 0.080 mmol) was dissolved in NEt3 
(22.4 7L, 0.160 mmol), molecular sieves (~10 mg) and DMF (0.450 mL), with a 
final concentration of 0.2 M. Indole-5-carbaldehyde (10.4 mg, 0.172 mmol) was 
added after 15 min. After 1 h NaBH(OAc)3 (33.7 mg, 0.159 mmol) was added to the 
reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), 
diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–50% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 73 
(21.3 mg, 51%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 16.3 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.53 (EtOAc–Hexane, 2:1); mp 123–128 °C; max/cm-1 (solid) 1674 (s, sh), 1199 
(s, br), 1135 (s, br), 724 (s, sh); H/ppm (400 MHz, CDCl3) 9.23 (1H, s, NH), 7.81 
(1H, m, PhH), 7.61 (1H, m, PhH), 7.50 (2H, m, PhH), 7.34 (2H, m, PhH), 7.23 (2H, 
m, PhH), 6.74 (1H, m, PhH), 4.12 (2H, s, NHCH2), 3.01 (1H, m, CHNH), 2.82 (1H, 
m, NHCOCH), 2.09 (2H, m, CH2), 1.82 (2H, m, CH2), 1.75 (2H, m, CH2), 1.60 (2H, 
m, CH2); C/ppm (100 MHz, CDCl3) 192.3 (C), 126.4 (PhH), 125.9 (PhH), 124.4 
(PhH), 121.9 (PhH), 112.2 (PhH), 104.8 (PhH), 48.8 (NHCH2), 34.0 (CH2), 24.0 
(CH2); m/z (ESI) 405 (100%, [M + H]+), 151 (25%, [ABT + H]+); HRMS found 
405.1754 (C23H25N4OS, [M + H]+, requires 405.1745). 
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cis-N-(Benzo[d]thiazol-2-yl)-3-((naphthalen-2-yl)methylamino)cyclohexane-
carboxamide (74) and cis-N-(benzo[d]thiazol-2-yl)-3-(bis(naphthalen-2-yl)-
methylamino) cyclohexanecarboxamide (75). Compound 43 (49.7 mg, 
0.128 mmol) was dissolved in NEt3 (39 7L, 0.280 mmol) and DMF (0.64 mL), with 
a final concentration of 0.2 M. 2-Naphthaldehyde (40.1 mg, 0.257 mmol) was added 
after 15 min. After 1 h NaBH(OAc)3 (92.0 mg, 0.434 mmol) was added to the 
reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), 
diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–70% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 74 (7 mg, 
10%) and by-product 75 (10 mg, 14%) as white flocculent solids (TFA salts). 
74. >98% Purity (tr = 10.9 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.02 (EtOAc–Hexane, 2:1); mp 138–139 °C; max/cm-1 (solid) 2958 
(w, br), 1674 (m, sh), 1547 (m, sh), 1179 (m, br), 1131 (m, br), 721 (m, sh); H/ppm 
(400 MHz, CDCl3) 9.72 (1H, s, NH), 7.73–7.81 (5H, m, PhH), 7.42–7.50 (3H, m, 
PhH), 7.36–7.42 (2H, m, PhH), 4.11 (1H, d, J 13.2, NHCH2), 4.03 (1H, d, J 13.2, 
NHCH2), 2.94 (1H, m, NHCOCH), 2.46 (1H, m, CHNH), 1.85 (3H, m, CH2), 1.56 
(1H, m, CH2), 1.30 (1H, m, CH2), 1.13 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 
130.0 (PhH), 128.2 (PhH), 127.8 (PhH), 127.1 (PhH), 126.5 (PhH), 125.2 (PhH), 
48.1 (NHCH2), 43.3 (NHCOCH), 30.2 (CH2), 27.3 (CH2), 22.3 (CH2); m/z (ESI) 438 
(30%, [M + Na]+), 416 (60%, [M + H]+), 155 (100%); HRMS found 416.1811 
(C25H26N3OS, [M+H]+, requires 416.1797). 
75. >98% Purity (tr = 14.5 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.78 (EtOAc–Hexane, 2:1); mp 137–139 °C; max/cm-1 (solid) 2957 
(w, br), 1668 (m, sh), 1545 (m, sh), 1179 (s, br), 1128 (m, br), 719 (s, sh); H/ppm 
(400 MHz, CDCl3) 7.95 (2H, s, PhH), 7.78–7.84 (7H, m, PhH), 7.76 (1H, d, J 12.0, 
PhH), 7.59 (2H, d, J 8.0, PhH), 7.46–7.52 (4H, m, PhH), 7.42 (1H, t, J 8.0, PhH), 
7.35 (1H, t, J 8.0, PhH), 4.37 (2H, d, J 12.0, NCH2), 4.26 (2H, d, J 12.0, NCH2), 
3.32 (1H, m, CHNH), 2.84 (1H, m, CH2), 2.54 (1H, m, NHCOCH), 2.31 (1H, m, 
CHCH2), 1.94–2.03 (3H, m, CH2), 1.42–1.62 (2H, m, CH2), 1.24 (1H, m, CH2); 
C/ppm (100 MHz, CDCl3) 173.3 (C), 133.5 (PhH), 133.2 (PhH), 130.6 (PhH), 
129.2 (PhH), 128.2 (PhH), 127.6 (PhH), 127.4 (PhH), 127.1 (PhH), 126.8 (PhH), 
125.5(PhH), 121.8 (PhH), 119.0 (PhH), 60.2 (CHN), 54.5 (2C, NCH2), 43.7 
(NHCOCH), 29.2 (CH2), 27.9 (CH2), 26.1 (CH2), 23.9 (CH2); m/z (ESI) 556 (60%, 
[M + H]+); HRMS found 556.2399 (C36H34N3OS, [M + H]+, requires 556.2423). 
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cis-N-(Benzo[d]thiazol-2-yl)-3-(benzylamino)cyclohexanecarboxamide (76) and 
cis-N-(benzo[d]thiazol-2-yl)-3-(dibenzylamino)cyclohexanecarboxamide (77). 
Compound 43 (48.4 mg, 0.142 mmol) was dissolved in NEt3 (38 7L, 0.273 mmol) 
and DMF (0.62 mL), with a final concentration with 0.2 M. Benzaldehyde (25 µL, 
0.246 mmol) was added after 15 min. After 1 h NaBH(OAc)3 (105.3 mg, 0.45 mmol) 
was added to the reaction mixture. After 24 h, the reaction was quenched with 
NaHCO3 (sat) (1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) 
(3 × 10 mL), H2O (3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered 
and all volatiles removed in vacuo. The crude product was purified by preparative 
HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to 
yield 76 (27 mg, 45%) and by-product 77 (18 mg, 32%) as white flocculent solids 
(TFA salts). 
76. >98% Purity (tr = 9.1 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.09 (EtOAc–Hexane, 2:1); mp 130–132 °C; max/cm-1 (solid) 2956 
(w, br), 1670 (s, sh), 1547 (s, sh), 1179 (s, br), 1130 (s, sh), 721 (m, sh); H/ppm 
(400 MHz, CDCl3) 9.72 (1H, br s, NH), 7.78 (1H, d, J 8.0, PhH), 7.61 (1H, d, J 8.0, 
PhH), 7.39 (1H, d, J 7.8, PhH), 7.31 (3H, m, PhH), 7.28 (3H, m, PhH), 3.98 (2H, s, 
NHCH2), 3.02 (1H, m, CHNH), 2.54 (1H, m, NHCOCH), 2.40 (1H, m, CH2), 2.02 
(1H, m, CH2), 1.83 (3H, m, CH2), 1.42 (2H, m, CH2), 1.23 (1H, m, CH2); C/ppm 
(100 MHz, CDCl3) 130.5 (PhH), 130.1 (PhH), 129.6 (PhH), 129.3 (PhH), 126.8 
(PhH), 124.5 (PhH), 121.9 (PhH), 55.5 (CHNH), 48.2 (NHCH2), 43.2 (NHCOCH), 
30.9 (CH2), 28.0 (CH2), 23.3 (CH2); m/z (ESI) 366 (60%, [M + H]+); HRMS found 
366.1631 (C21H24N3OS, [M + H]+, requires 366.1640). 
77. >98% Purity (tr = 12.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.82 (EtOAc–Hexane, 2:1); mp 118–120 °C; max/cm-1 (solid) 2962 
(w, br), 1667 (s, sh), 1546 (m, sh), 1164 (s, br), 1128 (s, br), 750 (s, sh); H/ppm (400 
MHz, CDCl3) 7.85 (1H, d, J 7.2, PhH), 7.77 (1H, d, J 8.4, PhH), 7.50–7.55 (5H, m, 
PhH), 7.43 (1H, t, J 7.2, PhH), 7.38 (6H, m, PhH), 4.21 (4H, s, NCH2), 3.26 (1H, m, 
CHN), 2.86 (1H, NHCOCH), 2.26 (1H, m, CH2), 2.12 (1H, m, CH2), 2.00 (2H, m, 
CH2), 1.58 (2H, m, CH2); C/ppm (100 MHz, CDCl3) 173.9 (C), 131.2 (PhH), 130.8 
(4C, PhH), 129.1 (4C, PhH), 126.9 (PhH), 122.2 (PhH), 118.5 (PhH), 60.7 (CHN), 
53.9 (2C, NCH2), 38.1 (NHCOCH), 26.2 (2C, CH2), 22.3 (2C, CH2); m/z (FAB) 456 
(100%, [M + H]+); HRMS found 456.2068 (C28H30N3OS, [M + H]+, requires 
456.2110). 
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cis-N-(Benzo[d]thiazol-2-yl)-3-((benzofuran-5-yl)methylamino)cyclohexane-
carboxamide (78) and cis-N-(benzo[d]thiazol-2-yl)-3-(bis(benzofuran-5-
ylmethyl)amino)cyclohexanecarboxamide (79). Compound 43 (56.3 mg, 
0.145 mmol) was dissolved in NEt3 (44 7L, 0.316 mmol) and DMF (0.723 mL), with 
a concentration of 0.2 M. 5-Benzofurancarbaldehyde (40.9 mg, 0.280 mmol) was 
added after 15 min. After 1 h NaBH(OAc)3 (120.3 mg, 0.568 mmol) was added to 
the reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) 
(1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–70% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 78 (2.5 mg, 
3%) and by-product 79 (28 mg, 36%) as white flocculent solids (TFA salts). 
78. >98% Purity (tr = 10.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.09 (EtOAc–Hexane, 2:1); mp 134–135 °C; max/cm-1 (solid) 2955 
(w, br), 1670 (s, sh), 1547 (m, sh), 1200 (s, br), 1129 (s, br), 721 (m, sh); H/ppm 
(400 MHz, CDCl3) 9.62 (1H, br s, NH), 7.82 (1H, d, J 8.0, PhH), 7.74 (1H, d, J 8.0, 
PhH), 7.61 (2H, m, PhH), 7.53 (1H, t, J 8.0, PhH), 7.43 (2H, m, PhH), 7.28 (1H, m, 
PhH), 6.73 (1H, m, OCHCH), 4.12 (1H, d, J 12.8, NHCH2), 4.03 (1H, d, J 12.8, 
NHCH2), 2.98 (1H, m, CHNH), 2.53 (1H, m, NHCOCH), 2.53 (1H, m, CH2), 1.98 
(1H, m, CH2), 1.88–1.73 (3H, m, CH2), 1.40 (1H, m, CH2), 1.21 (2H, m, CH2); 
H/ppm (400 MHz, DMSO-d6) 8.87 (1H, br s, NH), 8.08 (1H, m, PhH), 7.98 (1H, d, 
J 7.6, PhH), 7.80 (1H, m, PhH), 7.74 (1H, d, J 8.0, PhH), 7.69 (1H, d, J 8.4, PhH), 
7.45 (2H, m, PhH), 7.31 (1H, t, PhH), 7.05 (1H, m, OCHCH), 4.32 (2H, m, NHCH2), 
3.18 (1H, m, CHNH), 2.67 (1H, m, NHCOCH), 2.37 (1H, m, CH2), 2.17 (1H, m, 
CH2), 1.92 (2H, m, CH2), 1.62 (1H, m, CH2), 1.35 (3H, m, CH2); C/ppm (100 MHz, 
CDCl3) 128.4 (PhH), 126.5 (PhH), 125.0 (PhH), 123.6 (PhH), 122.5 (PhH), 117.7 
(PhH), 112.1 (PhH), 106.9 (PhH), 55.0 (CHNH), 48.4 (NHCH2), 43.3 (NHCOCH), 
31.2 (CH2), 28.3 (CH2), 27.6 (CH2), 23.3 (CH2); C/ppm (100 MHz, DMSO-d6) 
136.0 (PhH), 131.3 (PhH), 127.6 (PhH), 126.6 (PhH), 123.1 (PhH), 121.7 (PhH), 
120.6 (PhH), 111.5 (PhH), 106.7 (PhH), 55.1 (CHNH), 47.0 (NHCH2), 41.9 
(NHCOCH), 30.3 (CH2), 28.1 (CH2), 23.1 (CH2); m/z (ESI) 406 (100%, [M + H]+); 
HRMS found 406.1591 (C23H24N3O2S, [M + H]+, requires 406.1589). 
79. >98% Purity (tr = 13.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm); Rf = 0.78 (EtOAc–Hexane, 2:1); mp 113–115 °C; max/cm-1 (solid) 3468 
(w, br), 3018 (w, br), 2971 (m, sh), 1741 (s, sh), 1366 (s, sh), 1217 (s, sh); H/ppm 
(400 MHz, CDCl3) 7.81 (4H, m, PhH), 7.66 (2H, m, PhH), 7.50 (3H, m, PhH), 7.41 
(3H, m, PhH), 6.77 (2H, m, PhH), 4.35 (2H, m, NCH2), 4.24 (2H, m, NCH2), 3.35 
(1H, m, CHN), 2.57 (1H, NHCOCH), 2.86 (1H, m, CH2), 2.32 (1H, m, CH2), 2.00 
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(3H, m, CH2), 1.34–1.64 (2H, m, CH2), 1.22 (1H, m, CH2); C/ppm (100 MHz, 
CDCl3) 146.1 (2C, PhH), 126.7 (PhH), 124.2 (PhH), 121.7 (PhH), 118.7 (PhH), 
112.0 (2C, PhH), 106.7 (2C, PhH), 59.9 (CHN), 54.3 (2C, NCH2), 43.3 (NHCOCH), 
29.2 (CH2), 27.8 (CH2), 25.6 (CH2), 23.9 (CH2); m/z (ESI) 536 (100%, [M + H]+), 
155 (15%); HRMS found 536.2008 (C32H29N3O3S, [M + H]+, requires 536.2008). 
 
 
 
cis-N-(Benzo[d]thiazol-2-yl)-3-((1H-indole-5-yl)methylamino)cyclohexane-
carboxamide (80). Compound 43 (35.0 mg, 0.090 mmol) was dissolved in NEt3 
(25.1 7L, 0.180 mmol), molecular sieves (~10 mg) and DMF (0.450 mL), with a 
final concentration of 0.2 M. Indole-5-carbaldehyde (20.6 mg, 0.142 mmol) was 
added after 15 min. After 1 h NaBH(OAc)3 (37.0 mg, 0.175 mmol) was added to the 
reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), 
diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–50% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 80 (7.0 mg, 
15%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 9.6 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.58 (EtOAc–Hexane, 2:1); mp 116–121 °C; max/cm-1 (solid) 2953 (w, br), 
2863 (w, br), 1673 (s, sh), 1201 (s, br), 1182 (s, br), 702 (m, sh); H/ppm (400 MHz, 
MeOH-d4) 7.86 (1H, d, J 8.0, PhH), 7.74 (1H, d, J 8.0, PhH), 7.71 (1H, m, PhH), 
7.48 (1H, t, J 8.4, PhH), 7.44 (1H, m, PhH), 7.32 (2H, m, PhH), 7.22 (1H, m, PhH), 
4.33 (2H, s, NHCH2), 3.26 (1H, m, NHCOCH), 2.70 (1H, m, CHNH), 2.41 (1H, m, 
CH2), 2.28 (1H, m, CH2), 2.05 (2H, m, CH2), 1.78 (1H, m, CH2), 1.51 (3H, m, CH2); 
C/ppm (100 MHz, MeOH-d4) 127.4 (PhH), 125.2 (PhH), 123.7 (PhH), 123.3 (PhH), 
122.5 (PhH), 122.0 (PhH), 113.2 (PhH), 102.9 (PhH), 57.0 (CHNH), 50.8 (2H, s, 
NHCH2), 44.1 (NHCOCH), 32.2 (CH2), 29.9 (CH2), 24.8 (CH2); m/z (ESI) 405 
(100%, [M + H]+); HRMS found 405.1747 (C23H25N4OS, [M + H]+, requires 
405.1745). 
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cis-N-(Benzo[d]thiazol-2-yl)-3-(benzo[b]thiophen-5-ylmethylamino)cyclo-
hexanecarboxamide (81). Compound 43 (34.3 mg, 0.088 mmol) was dissolved in 
NEt3 (24.5 7L, 0.176 mmol), molecular sieves (~10 mg) and DMF (0.440 mL), with 
a concentration of 0.2 M. 1-Benzothiophene-5-carbaldehyde (22.4 mg, 0.138 mmol) 
was added after 15 min. After 1 h NaBH(OAc)3 (35.0 mg, 0.165 mmol) was added to 
the reaction mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) 
(1 mL), diluted with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O 
(3 × 10 mL), brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles 
removed in vacuo. The crude product was purified by preparative HPLC (30–50% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 81 (5.9 mg, 
13%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 10.6 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.01 (EtOAc–Hexane, 2:1); mp 124–126 °C; max/cm-1 (solid) 2965 (w, br), 
1670 (s, sh), 1547 (m, sh), 1184 (s, br), 1133 (s, br), 722 (m, sh); H/ppm (400 MHz, 
CDCl3) 8.04 (1H, d, J 8.4, PhH), 8.01 (1H, m, PhH), 7.87 (1H, d, J 8.0, PhH), 7.71 
(1H, t, J 5.6, PhH), 7.49–7.42 (3H, m, PhH), 7.32 (1H, t, J 7.0, PhH), 4.41 (2H, s, 
NHCH2), 3.36 (1H, m, CHNH), 2.72 (1H, m, NHCOCH), 2.45 (1H, m, CH2), 2.30 
(1H, m, CH2), 2.06 (2H, m, CH2), 1.78 (1H, m, CH2), 1.53 (3H, m, CH2); C/ppm 
(100 MHz, CDCl3) 173.53 (C), 140.8 (C), 140.2 (C), 128.0 (PhH), 126.3 (PhH), 
126.6 (PhH), 126.0 (PhH), 124.1 (PhH), 123.3 (PhH), 122.4 (PhH), 117.8 (PhH), 
55.2 (CHNH), 48.1 (NHCH2), 43.2 (NHCOCH), 30.2 (CH2), 28.2 (CH2), 27.7 (CH2), 
23.3 (CH2); m/z (ESI) 422 (100%, [M + H]+); HRMS found 422.1367 (C23H24N3OS2, 
[M + H]+, requires 422.1361). 
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cis-N-(Benzo[d]thiazol-2-yl)-3-(benzo[d][1,3]dioxol-5-yl)methylamino)cyclo-
hexanecarboxamide (82). Compound 43 (30.7 mg, 0.079 mmol) was dissolved in 
NEt3 (22.0 7L, 0.158 mmol), molecular sieves (~10 mg) and DMF (0.395 mL), with 
a final concentration of 0.2 M. Piperonal (18.0 mg, 0.120 mmol) was added after 
15 min. After 1 h NaBH(OAc)3 (30.0 mg, 0.142 mmol) was added to the reaction 
mixture. After 24 h, the reaction was quenched with NaHCO3 (sat) (1 mL), diluted 
with DCM (10 mL), washed with 0.1 M HCl (aq) (3 × 10 mL), H2O (3 × 10 mL), 
brine (1 × 10 mL), and dried over MgSO4, filtered and all volatiles removed in 
vacuo. The crude product was purified by preparative HPLC (30–50% ACN–H2O 
(+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 82 (11.2 mg, 28%) as 
a white flocculent solid (TFA salt). 
>98% Purity (tr = 9.4 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.62 (EtOAc–Hexane, 2:1); mp 89–96 °C; max/cm-1 (solid) 2970 (w, br), 2870 
(w, br), 1670 (s, sh), 1549 (m, sh), 1448 (s, sh), 1256 (m, sh), 1180 (s, br), 1128 (s, 
br), 1038 (m, sh), 721 (m, sh); H/ppm (400 MHz, CDCl3) 7.82 (1H, d, J 8.0, PhH), 
7.75 (1H, d, J 8.0, PhH), 7.54 (1H, m, PhH), 7.43 (1H, m, PhH), 6.98 (1H, m, PhH), 
6.94 (1H, m, PhH), 6.79 (1H, m, PhH), 6.08 (1H, s, OCH2O), 5.93 (1H, s, OCH2O), 
4.04 (2H, s, NHCH2), 3.07 (1H, m, NHCOCH), 2.62 (1H, m, CHNH), 2.15–1.90 
(5H, m, CH2), 1.58 (2H, m, CH2), 1.42 (1H, m, CH2); C/ppm (100 MHz, CDCl3) 
190.5 (C), 173.3 (C), 148.7 (C), 126.9 (PhH), 124.3 (PhH), 121.9 (PhH), 119.2 
(PhH), 110.1 (PhH), 108.8 (PhH), 101.5 (OCH2O), 55.0 (NHCOCH), 48.2 
(NHCH2), 43.0 (CHNH), 30.8 (CH2), 28.2 (CH2), 23.4 (CH2); m/z (ESI) 410 (100%, 
[M + H]+); HRMS found 410.1533 (C22H24N3O3S, [M + H]+, requires 410.1538). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-((N-(naphthalene-3-yl)methyl)acetamido)cyclo-
hexanecarboxamide (83). Compound 35 (49.1 mg, 0.118 mmol) was dissolved in 
Ac2O (0.500 mL, 5.29 mmol), with a final concentration of 0.2 M. After 1 h, all 
volatiles were removed in vacuo. The crude product was purified by preparative 
HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to 
yield 83 (33 mg, 61%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 14.7 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.04 (EtOAc–Hexane, 2:1); mp 216–218 °C; max/cm-1 (solid) 3538 (w, br), 
3373 (w, br), 3183 (w, br), 3061 (w, br), 2921 (m, sh), 1600 (m, sh), 1548 (m, sh), 
1440 (m, sh), 1267 (s, sh), 758 (s, sh); m/z (ESI) 480 (100%, [M + Na]),458 (60%, 
[M + H]+), 276 (30%); HRMS found 458.1917 (C27H27N3O2S, [M + H]+, requires 
458.1902). 
 
 
 
cis-N-(Benzo[d]thiazol-2-yl)-4-(N-benzylacetamido)cyclohexanecarboxamide 
(84). Compound 49 (6.2 mg, 0.013 mmol) was dissolved in Ac2O (0.250 mL, 
2.64 mmol), with a final concentration of 0.04 M. After 1 h, all volatiles were 
removed in vacuo. The crude product was purified by preparative HPLC (30–70% 
ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm) and lyophilised to yield 84 (3.5 mg, 
66%) as a white flocculent solid (TFA salt). 
>98% Purity (tr = 13.0 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.01 (EtOAc–Hexane, 2:1); mp 135–137 °C; m/z (ESI) 430 (80%, [M + 
Na]),408 (100%, [M + H]+); HRMS found 408.1751 (C23H26N3O2S, [M + H]+, 
requires 408.1756). 
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cis-N-(Benzo[d]thiazol-2-yl)-4-((N-(benzofuran-5-yl)methyl)acetamido)cyclo-
hexanecarboxamide (85). Compound 54 (5.0 mg, 0.010 mmol) was dissolved in 
NEt3 (13.2 µL, 0.100 mmol) and Ac2O (3.0 mL, 32 mmol) in a final concentration of 
3 mM for 54. After 1 h, all volatiles were removed in vacuo. The crude product was 
purified by preparative HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 85 (0.6 mg, 14%) as a white flocculent solid (TFA 
salt). 
>98% Purity (tr = 13.3 min, 2–98% ACN–H2O (+0.1% TFA) in 30 min, = = 220 nm); 
Rf = 0.09 (EtOAc–Hexane, 2:1); mp 216–218 °C; max/cm-1 (solid) 3538 (w, br), 
3373 (w, br), 3183 (w, br), 3061 (w, br), 2921 (m, sh), 1600 (m, sh), 1548 (m, sh), 
1440 (m, sh), 1267 (s, sh), 758 (s, sh); H/ppm (400 MHz, MeOH-d4) 7.88 (2H, m, 
PhH), 7.83 (1H, m, PhH), 7.76 (1H, d, J 8.0, PhABTH), 7.66 (1H, d, J 8.4, PhABTH), 
7.45 (1H, m, PhH), 7.33 (1H, t, J 8.0, PhABTH), 6.95 (1H, m, OCH), 4.62 (1H, d, 
J 13.2, NCH2), 4.39 (1H, d, J 13.6, NCH2), 2.96 (1H, m, NHCOCH), 3.48 (1H, m, 
CHN), 2.34 (2H, m, CH2), 2.22 (2H, m, CH2), 1.84 (2H, m, CH2), 1.34 (3H, t, J 7.5, 
COCH3); C/ppm (100 MHz, MeOH-d4) 174.6 (C), 146.2 (PhH), 126.8 (PhH), 125.6 
(PhH), 124.1 (PhH), 123.5 (PhH), 121.1 (PhH), 120.3 (PhH), 111.8 (PhH), 106.4 
(PhH), 61.2 (CHN), 53.1 (NCH2), 36.9 (NHCOCH), 26.1 (2C, CH2), 21.9 (CH2); m/z 
(ESI) 480 (100%, [M + Na]),458 (60%, [M + H]+), 276 (30%); HRMS found 
448.1712 (C25H26N3O3S, [M + H]+, requires 448.1695). 
 
 
 
cis-N-(Benzo[d]thiazol-2-yl)-4-((N-(naphthalene-3-yl)methyl)amino)-N-methyl-
cyclohexanecarboxamide (86). Compound 35 (7.9 mg, 0.015 mmol) was dissolved 
in DMF (0.150 mL), with a final concentration of 0.1 M. K2CO3 (6.2 mg, 
0.045 mmol) and MeI (1.87 µL, 0.030 mmol) were added, the round bottom flask 
wrapped in aluminium foil and left to stir at RT for 18 h. The reaction mixture was 
diluted with DCM (10 mL), washed with H2O (3 × 10 mL), brine (1 × 10 mL), dried 
over MgSO4, filtered and all volatiles removed in vacuo. The crude product was 
purified by preparative HPLC (30–50% ACN–H2O (+0.1% TFA) in 30 min, = = 
220 nm) and lyophilised to yield 86 (1.0 mg, 15%) as a white flocculent solid (TFA 
salt). 
Rf = 0.09 (EtOAc–Hexane, 2:1); m/z (ESI) 444 (100%, [M + H]+), 276 (30%); 
HRMS found 444.2126 (C27H30N3OS, [M + H]+, requires 444.2110).  
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VIII.2 Miscellaneous Information 
 
Table VIII-1: Bacterial strains 
The table references E. coli strains used during enzyme expressions. The legend defines the 
abbreviations. (Source: Novagen, E. coli genotypes www.openwetware.org 14.07.2008) 
E. coli Strain Genotype 
BL21(DE3)  
(Studier and Moffatt 1986) 
F– ompT hsdSB(rB–mB–) gal dcm (DE3) 
DH5™ 
(Grant, Jessee et al. 1990) 
F– >80lacZ?M15 ?(lacZYA–argF) U169 recA1 endA1 hsdR17 
(rK–, mK+) phoA supE44 =– thi-1 gyrA96 relA1  
 
Legend: F- = does not carry the F plasmid which is a self-transmissible, low-copy plasmid used for 
generation of single-stranded DNA when infected with M13 phage, often carries lacI and lacZ@M15 
genotypes; lacl = encodes the lac repressor that controls expression from promoters that carry lac 
operator, IPTG binds lac repressor and derepresses promoter; lacZ = -D-galactosidase gene, 
lacZ?M15 = required for -galactosidase complementation, carried on lambdoid prophage A80; 
ompT = mutation in outer membrane protein protease VII, reduces proteolysis of expressed proteins; 
hsdS = both restriction and methylation of certain sequences is deleted from strain; rB/K–mB/K– = B/K 
defines the strain lineage, r+/– indicates that it has/has not got the restriction system, m+/– indicates 
that it has/has not got the modification (methylation) system; dcm = cytosine methylation at second C 
of CCWGG sites abolished; DE3 = = prophage carrying the T7 RNA polymerase gene and lacI, used 
to induce expression in T7 driven expression systems; argF = ornithine carbamoyl transferase 
mutation blocks ability to use arginine; recA = mutation in a gene responsible for general 
recombination of DNA; endA = mutation in non-specific endonuclease endonuclease I, eliminates 
non-specific endonuclease activity, resulting in improved plasmid preps; hsd = mutations in the 
system of methylation and restriction that allow E. coli to recognize DNA as foreign, hsd genotype 
allows efficient transformation of DNA generated from PCR reactions; supE = tRNA glutamine 
suppressor of amber; thi-1 = requires thiamine for growth on minimal media; gyrA96 = DNA gyrase 
mutant produces resistance to nalidixic acid; relA = regulates the coupling between transcription and 
translation. 
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(B)
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(C)
 
 
(D)
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(E)
 
Figure VIII-1: Sequence alignments of NMT proteins 
(A) HsNMT1, HsNMT2; (B) ScNMT, HsNMT1, HsNMT2; (C) PfNMT, HsNMT1, HsNMT2;  
(D) ScNMT, CaNMT, PfNMT; (E) PfNMT, CaNMT.  
FASTA sequences are: PfNMT (AAF18461), CaNMT (P30418), HsNMT1 (P30419), HsNMT2 
(O60551), ScNMT (P14743). They have been aligned with the program MultAlign (Version 5.4.1. 
(Corpet 1988)). The colour code is as follows: Red = exact match, blue = AA of similar properties, 
black = no match, with a consensus level of 90% high and 50% low. The consensus symbols are as 
follows: ! = any of IV, $ = any of LM, % = any of FY and # = any of NDQEBZ.  
 
Table VIII-2: PfNMT construct 
PfNMT was sequenced by Dr R S Gunaratne (Gunaratne, Sajid et al. 2000; Bowyer 2006). 
PfNMT Construct      
10 
MGGSHHHHHH 
20 
GMASMTGGQQ 
30 
MGRDLYDDDD 
40 
KDRWGSNDDK 
50 
KDFVGRDLYQ 
60 
LIRNAKDKIK 
70 
IDYKFWYTQP 
80 
VPKINDEFDE 
90 
NVNEPFISDN 
100 
KVEDVRKEEY 
110 
KLPSGYAWCV 
120 
CDITKENDRS 
130 
DIYNLLTDNY 
140 
VEDDDNVFRF 
150 
NYSSEFLLWA 
160 
LSSPNYVKNW 
170 
HIGVKYESTN 
180 
KLVGFISAIP 
190 
IDMCVNKNII 
200 
KMAEVNFLCV 
210 
HKSLRSKRLA 
220 
PVLIKEITRR 
230 
INLESIWQAI 
240 
YTAGVYLPKP 
250 
ISTARYFHRS 
260 
INVKKLIEIG 
270 
FSCLNTRLTM 
280 
SRAIKLYRID 
290 
DTLNIKNLRL 
300 
MKKKDIDGLQ 
310 
KLLNEHLKQY 
320 
NLHAIFSKED 
330 
VAHWFTPIDQ 
340 
VIYTYVNEEN 
350 
GEIKDLISFY 
360 
SLPSKVLGNN 
370 
KYNILNAAFS 
380 
FYNITTTTTF 
390 
KNLIQDAICL 
400 
AKRNNFDVFN 
410 
ALEVMDNYSV 
420 
FQDLKFGEGD 
430 
GSLKYYLYNW 
440 
KCASCHPSKI 
 
     GIVLL 
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